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 Summary 
 
The Effect of Statins on Bone and Mineral Metabolism 
Both statins and amino-bisphosphonates reduce the prenylation of proteins which 
are involved in cytoskeletal organization and activation of polarized and motile cells. 
Consequently statins have been postulated to affect bone metabolism. We investigated 
the effects of different doses of simvastatin (1,5,10 and 20mg/Kg/day), administered orally 
over 12 weeks to intact female Sprague-Dawley rats, and the effect of simvastatin 
20mg/Kg/day in sham and ovariectomised rats, on femoral bone mineral density (BMD) 
and quantitative bone histomorphometry (QBH), compared to controls. Similarly, the affect 
of atorvastatin (2,5mg/Kg/day) and pravastatin (10mg/Kg/day) on BMD was investigated 
and compared to controls. BMD was decreased by simvastatin 1mg/Kg/day (p = 0.042), 
atorvastatin (p = 0,0002) and pravastatin (p = 0.002). The effect on QBH parameters 
differed with different doses of simvastatin (ANOVA; p = 0.00012). QBH parameters of 
both bone formation and resorption were equivalently and markedly increased by 
simvastatin 20mg/Kg/day in two independent groups of intact rats, and reflected by a 
relatively unchanged BMD. At lower doses, simvastatin 1mg/Kg/day decreased bone 
formation while increasing bone resorption as reflected by a marked decrease in BMD. 
Ovariectomised animals receiving simvastatin 20mg/Kg/day showed no change in BMD 
relative to the untreated ovariectomised controls, their increase in bone formation was 
smaller than in sham-operated rats receiving simvastatin and there was no change in 
bone resorption. The dose response curves of simvastatin for bone formation and 
resorption differed from each other.  
From these studies it is concluded that:-  
a) low-dose simvastatin (1mg/Kg/day), atorvastatin 2.5mg/Kg/day) and pravastatin 
10mg/Kg/day) decrease BMD in rodents;  
 b) 1mg/Kg/day simvastatin decreases bone formation and increases bone 
resorption and is reflected by a reduced BMD;  
c) 20mg/Kg/day simvastatin increases bone formation and resorption and results 
in an unchanged BMD;  
d) the effects of simvastatin on QBH differ at different dosages;  
e) the dose-response curves for QBH parameters of bone resorption and bone 
formation differ from each other;  
f) the effects of simvastatin seen in intact rats are not observed in ovariectomised 
rats;  
g) simvastatin is unable to prevent the bone loss caused by ovariectomy. 
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Opsomming 
 
Die Effek van Statiene op Been en Mineraal Metabolisme 
Beide statiene en aminobisfosfonate verminder die prenelasie van proteïene wat 
betrokke is in die sitoskeletale organisasie en aktivering van gepolariseerde en 
beweeglike selle. Gevolglik is dit gepostuleer dat statiene ‘n invloed sal hê op been 
metabolisme. Ons het die effekte van verskillende dossisse van simvastatien (1, 5, 10 en 
20mg/Kg/dag), mondelings toegedien oor 12 weke aan intakte vroulike Sprague-Dawley 
rotte, en die effek van simvastatien 20mg/Kg/dag op skyn- en ge-ovariektomeerde rotte, 
op femorale been mineral digtheid (BMD) en kwantitatiewe been histomorfometrie (KBH), 
vergeleke met kontroles, ondersoek. Op ‘n soortgelyke manier is die effek van 
atorvastatien (2,5mg/Kg/day) en pravastatien (10mgKg/dag) op BMD ondersoek en 
vergelyk met kontroles. BMD is verminder deur simvastatien 1mg/Kg/dag (p = 0.042), 
atorvastatien (p = 0.0002) en pravastatien (p = 0.002). Die effekte op KBH parameters het 
verskil met verskillende dossisse van simvastatien (ANOVA; p = 0.00012). KBH 
parameters van beide been vormasie en resorpsie is vergelykend en merkbaar verhoog 
deur simvastatien 20mg/Kg/dag in twee onafhanklike groepe van intakte rotte en is 
vergesel deur ‘n relatiewe onveranderde BMD. Met laer dossisse het simvastatien 
1mg/Kg/dag been vormasie verminder terwyl been resorpsie verhoog is en is weerspieël 
deur ‘n merkbaar verminderde BMD. Ge-ovariektomeerde diere wat simvastatien 
20mg/Kg/dag ontvang het, het geen verandering in BMD relatief tot die onbehandelde ge-
ovariektomeerde kontroles getoon nie, en die toename in been vormasie was kleiner as in 
die skyngeopereerde rotte wat simvastatien ontvang het en daar was geen verandering in 
been resorpsie nie. Die dosis-respons kurwes vir simvastatien vir been vormasie en 
resorpsie het van mekaar verskil.  
Uit hierdie studies word die volgende gevolgtrekkings gamaak:-   
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a) lae-dosis simvastatien (1mg/Kg/dag), atorvastatien 2.5mg/Kg/dag en 
pravastatien 10mg/Kg/dag verminder BMD in knaagdiere;  
b) 1mg/Kg/dag simvastatien verminder been vormasie en verhoog been resorpsie 
en veroorsaak gevolglik ‘n velaging in die BMD;  
c) 20mg/Kg/dag simvastatien verhoog been vormasie en resorpsie met ‘n 
gevolglike onveranderde BMD;  
d) die effekte van simvastatien op KBH verskil met verskillende dossisse;  
e) die dosis-repons kurwes van been resorpsie en been vormasie veskil van 
mekaar 
f) die effekte van simvastatien wat waargeneem in intakte rotte word nie gesien in 
ge-ovariektomeerde rotte nie;  
g) simvastatien kannie die verlies van been wat veroorsaak word deur 
ovariektomie voorkom nie.  
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 Chapter 1: Background and Literature review. 
1.1. Introduction. 
Osteoporosis affects a sizable proportion of Westernised societies, particularly 
females. The lifetime risk of a fracture in Caucasian women is thought to be in the region 
of 30 – 40%. [1993]   Accurate figures for South Africa are hard to come by. It is estimated 
that the incidence of osteoporosis in the White, Asian and Coloured  (peoples with an 
ethnic admixture) populations is similar to that of Caucasians in developed countries, 
whereas the disease is less common in the South African Black populations. [Daniels ED, 
Pettifor JM et al., 1997]   The incidence of osteoporosis increases with advancing age in a 
similar fashion to cardiovascular disease and it is not uncommon to find these two 
conditions occurring together. [Solomon L, 1979] 
Cardiovascular diseases, including coronary artery disease and strokes, are the 
leading causes of mortality and morbidity in the United States of America (USA) followed 
by lung and colon cancer, diabetes and chronic obstructive pulmonary disease. [Doyle R, 
2001]   The incidence of coronary artery disease and associated risk factors, including 
dyslipidaemia, are similarly high in the South African White, Asian and Coloured ethnic 
groups, exceeding the prevalence of most Westernised societies in Europe and the North 
Americas. [Steyn K, Jooste PL et al., 1985]  Co-incidentally, the prevalence of coronary 
artery disease, and the associated dyslipidaemia, is much lower in the South African 
Black peoples than in the other ethnic groups. [Steyn K, Jooste PL et al., 1991]   There is 
anecdotal evidence that these figures on the incidence of coronary artery disease in South 
African Blacks may be on the rise due to the adoption of a Westernised lifestyle.  
However, there are no data to support this supposition and indeed, there is evidence in 
favour of the contrary. [Walker AR, Adam A, and Küstner HG, 1993]   Nonetheless, 
atherosclerosis and strokes are not uncommon in the Black populations despite the 
relatively low incidence of dyslipidaemia. [Fourie J and Steyn K, 1995]   
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The associated risk factors for atherosclerosis are increasingly being targeted for 
aggressive management, and dyslipidaemia has found itself most amenable to this attack. 
[Nass CM, Wiviott SD et al., 2000]   The advent of the newer and highly effective lipid-
lowering agents such as the hydroxymethylglutaryl-CoA (HMG-CoA) Reductase Inhibitors 
(statins), has introduced a potent tool for the reduction of cholesterol which effectively 
reduces the risk of cardiac events. [Farnier M and Davignon J, 1998; Farnier M, 1999]   
The increasingly lenient and broadened guidelines for the use of statins has meant that 
more people with, or at risk of, osteoporosis are exposed to these agents. Indeed, the 
statins are among the most commonly used drugs, with more than 3 million Americans 
taking a statin every day. [Gotto AMJ, 1997; Mundy GR, 2001] 
The statins are potent lipid-lowering agents that inhibit the rate-limiting enzyme of 
the cholesterol synthetic pathway, namely HMG-CoA reductase.  [Farnier M and Davignon 
J, 1998]    Consequently they reduce the intracellular free cholesterol pool. The reduction 
of this cholesterol pool may, with the more potent and longer acting statins, reduce 
lipoprotein production by the liver and especially the production of the very low-density 
lipoproteins (VLDL). [Farnier M and Davignon J, 1998; Mundy GR, 2001; Stein EA, Lane 
M, and Laskarzewski P, 1998]   However, this is not the primary mode of action by which 
they lower serum low-density lipoprotein (LDL)-cholesterol. By reducing the intracellular 
cholesterol pool, the statins induce the synthesis of LDL-receptor protein and increase the 
cell surface expression of these receptors. This consequently leads to an increased 
uptake of LDL from the serum, which in turn reduces the serum LDL-cholesterol 
concentration.  
The statins have different pharmacokinetic properties based on their lipid solubility 
and metabolism. [Beaird SL, 2000; Corsini A, Bellosta S et al., 1999b]   In addition they 
differ in their duration of action and their potency. [Dansette PM, Jaoen M, and Pons C, 
2000; Corsini A, Bellosta S et al., 1999b; Wolffenbuttel BH, Mahla G et al., 1998]   The 
statins have been classified into the synthetic and the natural statins, according to which 
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they supposedly have effects on conventional non-lipid cardiovascular risk factors that 
distinguish them from each other. [Mundy GR, 2001; Rosenson RS and Tangney CC, 
1998]   In addition the statins have been found to have other non-lipid-lowering effects 
which may reduce cardiovascular risk. Amongst these are antithrombotic, vasodilative, 
antioxidant, anti-inflammatory and anti-proliferative effects that may participate in 
stabilisation of the endothelium. Other organs systems may also be involved in these 
mechanisms. [Bellosta S, Bernini F et al., 1998; Corsini A, Bellosta S et al., 1999a; Laufs 
U and Liao JK, 2000; Farnier M and Davignon J, 1998; Mundy GR, 2001; Wheeler DC, 
1998]   These non-lipid-lowering effects are referred to as the pleiotropic effects of the 
statins.     
Included in these pleiotropic effects is a postulated effect of statins on bone and 
mineral metabolism. Given the number of elderly persons who are taking statins it would 
be important to delineate the effect of statins in this age group that is particularly at risk for 
osteoporosis. It is this effect on bone health that is the theme of this thesis.  
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1.2. The mevalonate and cholesterol synthetic pathway and protein prenylation. 
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Figure 1.1. The mevalonate/cholesterol synthetic metabolic pathway.  
Important products of this pathway include the prenylated proteins – the 
farnesylated and geranylgeranylated proteins to which farnesylpyrophosphate 
and geranylgeranylpyrophosphate have been added. 
 
Cholesterol and other sterols such as steroid hormones, bile salts and vitamin D 
are widely known derivatives of the mevalonate metabolic pathway (Fig. 1.1). There are 
however, less well known products of this pathway that have important physiological roles; 
dolichol in glycoprotein biosynthesis; the side chain of ubiquinone, an important 
component of the mitochondrial electron transport chain; isopentanyl adenosine, a 
component of isopentanyl transfer-RNA; the farnesylpyrophosphate side chain of haem-a, 
the iron-binding nucleus of haemoglobin; and the important and only relatively recently 
discovered prenylated proteins. It has also become evident that other intermediates of the 
cholesterol synthetic pathway play an important role in signal transduction and other 
cellular processes. Farnesylpyrophosphate and geranylgeranylpyrophosphate are added 
to the carboxy-terminal of numerous cytosolic proteins to form prenylated proteins, which 
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have diverse cellular functions (Fig. 1.2). The discovery of these prenylated proteins has 
provided many new insights into cellular biology and opened up novel therapeutic 
possibilities. 
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Figure 1.2. The prenylation of proteins. 
 Farnesylpyrophosphate or geranylgeranylpyrophosphate are added by one of 
three prenyl-transferases, followed by removal of the three terminal amino acids, 
and the addition of a methyl and palmitoyl molecule. Abbreviations: GGTase I = 
geranylgeraniol transferase type I; GGTase II = geranylgeraniol transferase type 
II; FTase = farnesol transferase; Methyl Tase = methyl transferase; Pal Tase = 
palmitoyl transferse. 
 
It became evident early on that the inhibition of mevalonate synthesis by the 
statins, and the subsequent depletion of the endogenous mevalonate pool, resulted in a 
cessation of cell cycling and DNA synthesis that is associated with pronounced changes 
in cell morphology. Even suppression of tumor growth was noted. [Brown MS and 
Goldstein JL, 1980]   These changes could be reversed by supplying exogenous 
mevalonate to the arrested cells or by removing the inhibitor. This restoration of cell 
growth and morphology could not be reproduced by adding cholesterol, dolichol, 
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ubiquinone or isopentanyl adenosine, suggesting that some other metabolite of 
mevalonate was responsible for these changes. Subsequently it was demonstrated that 
when radiolabeled mevalonate was added to the medium, radioactivity was incorporated 
into a wide range of cytosolic and membrane-bound proteins. This occurred via the 
covalent attachment of the isoprene products of mevalonate, farnesol and 
geranylgeraniol, to these proteins, a process thereafter referred to as prenylation, and the 
modified proteins as prenylated proteins. [Maltese WA, 1990]  
The proteins destined to be prenylated are characterised by a carboxy-terminal 
CAAX box of amino acids where C represents cysteine, A an aliphatic amino acid and X 
any amino acid (Fig. 1.2). These terminal amino acid motifs, and in some cases certain 
additional upstream sequences, act as recognition sites for prenyl transferase enzymes. 
[Moores SL, Schaber MD et al., 1991]   The prenyl transferase attaches the respective 
prenyl group, farnesylpyrophosphate or geranylgeranylpyrophosphate, to a carboxy-
terminal cysteine of the protein. At least 3 prenyl transferases are known to exist and have 
been characterised. Farnesol transferase (FTase) and geranylgeraniol transferase I 
(GGTase I) recognise a CAAX box and the terminal X of the CAAX box determines 
whether farnesol or geranylgeraniol is added to the protein. Geranylgeraniol transferase II 
(GGTase II) recognises CC, CXC and CCXX motifs and is active on a distinct group of 
Rab proteins. [Zhang FL and Casey PJ, 1996]   FTase and GGTase I are heterodimeric 
enzymes which share a common α-subunit that binds to the relevant prenyl group. They 
have different but homologous β-subunits, which recognise the different CAAX sequences 
of the target protein. GGTase II is somewhat different and has two subunits analogous to 
the other transferases but with an additional third subunit required for enzymatic activity. 
These differences from the other prenyl transferases may have therapeutic implications 
particularly for bone metabolism. A bisphosphonate which specifically inhibits this enzyme 
has been developed. [Coxon FP, Helfrich MH et al., 2001; Coxon FP, Dunford JE et al., 
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2001]   This is but one example of a drug that interferes with the cholesterol synthetic 
pathway and is also used to manipulate bone metabolism. 
Prenylation is the first of 3 sequential steps that render these prenylated 
proteins active (Fig. 1.2). These modifications primarily confer lipid solubility and 
consequently membrane binding to the prenylated protein. Prenylation is followed by the 
proteolytic cleavage of the terminal 3 amino acids by a microsomal carboxypeptidase, 
which is then followed by the addition of a methyl group to the remaining terminal cysteine 
by a microsomal aminotransferase. Some prenylated proteins undergo further 
modification by the addition of a palmitoyl molecule to a more proximal cysteine. [Hancock 
JF, Magee AI et al., 1989]  
In all cases prenylation is essential for the activity of all these proteins. If the 
terminal CAAX box is removed or blocked, if the relevant prenyl transferase is inhibited, or 
if the availability of the prenyl substrate is diminished as is found with the inhibition of the 
cholesterol synthetic pathway by statins, then these proteins are inactive. [Kato K, Cox AD 
et al., 1992]   The additional modifications of amino acid cleavage and methylation are 
also required, and sometimes essential, but mostly serve to complement prenylation in the 
activation of these proteins. [Zhang FL and Casey PJ, 1996]   Although the bulk of the 
prenylated proteins are cytosolic in location, they are active only in their membrane bound 
form and both prenylation and palmitoylation render these proteins lipid soluble thus 
allowing them to bind to membranes. In addition to their role in membrane binding these 
post translational modifications are also important for interactions with other regulatory 
proteins of the small GTP-binding proteins. [Cox AD and Der CJ, 1992] 
The prenylated proteins have diverse functions and include the nuclear lamins, the 
γ-subunit of the heterotrimeric receptor-associated G proteins, various retinal proteins and 
by far the largest group, the family of Ras-related small GTP-binding proteins that play an 
essential role in the normal function of cells. [Cox AD and Der CJ, 1992]  
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1.3. Small GTP-binding proteins 
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Figure 1.3. The Ras related GTP-binding proteins act as molecular switches.  
This scheme applies to all the other small Ras-related GTP-binding proteins as 
well as the heterotrimeric receptor-associated G proteins. These proteins are only 
active in their GTP-bound membrane-associated form, which is modulated by 
other regulatory proteins. Active GTP-bound Ras has an intrinsic GTPase activity 
that is further enhanced by GTPase Activating Proteins (GAP) resulting in the 
formation of GDP-bound inactive Ras. The subsequent exchange of GDP for 
GTP is regulated by GTP Exchange Factors (GEF) (also known by other names 
such as GDP Dissociation Inhibitor GDI). These GEFs (or GDI's) generally inhibit 
the exchange of GDP for GTP but also cover the prenylation site on Ras making 
it less lipid soluble and unbinding it from the membrane, with the result that 
inactive GDP-bound Ras is cytosolic in position. With the removal of GEF (or 
GDI), the prenylation site is uncovered, GDP is exchanged for GTP and the 
active GTP-bound Ras becomes membrane bound at its active site. Defects in 
this switching mechanism gives rise to disease. Some mutations of Ras lack 
intrinsic GTPase activity and are consequently continuously active, a situation 
seen in numerous common cancers. [Takai Y, Kaibuchi K et al., 1993] 
 
The small GTP-binding proteins comprise a large super-family of Ras-related 
proteins of which the Ras, Rab, Rho, and Rac, families are amongst those which are 
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prenylated. Prenylation serves to make these proteins more lipid-soluble and able to bind 
to the lipid cell membranes. These proteins cycle between the active GTP-bound and the 
inactive GDP-bound forms (Fig. 1.3). This cycle is modulated by their interaction with a 
large group of regulatory proteins. This interaction with the regulatory proteins is further 
influenced by the prenylation state of the small GTP-binding proteins. [Bokoch GM and 
Der CJ, 1993]  
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The Ras family of small GTP-binding proteins 
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Figure 1.4. Ras proteins in signal transduction.  
Ras is a pivotal link between Tyrosine Kinase 
Receptors and the activation of nuclear 
transcription factors leading to, amongst other 
activities, cell differentiation and growth. It is via 
this pathway that constitutionally active forms of 
Ras result in cancer. Without prenylation Ras 
cannot participate in this pathway. 
 
The Ras family of small GTP-binding proteins acts as an important component of 
the cell’s signal transduction pathway between tyrosine kinase receptors on the one hand 
and the cell nucleus and other effectors on the other hand, leading to, amongst others, 
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cell growth, cell differentiation and metabolic processes (Fig. 1.4). Unlike the other 
members of the small GTP-binding family of proteins, which are geranylgeranylated, the 
Ras proteins are farnesylated. The function of Ras is critically dependent on its 
prenylation state and without farnesylation these Ras proteins are inactive and cannot 
perform their function. [Kato K, Cox AD et al., 1992]  Certain mutant and oncogenic forms 
of Ras lack intrinsic GTPase activity and are consequently unable to switch to the inactive 
GDP-bound form. They are therefore constituitively active and are associated with, and 
lead to, the formation of a variety of human cancers. [Rao KN, 1995]   When the 
prenylation of these oncogenic Ras mutations is prevented, including via the use of 
statins, they lose their oncogenic capacity. [Kawata S, Nagase T et al., 1994]  The 
realisation that prenylation plays a pivotal role in cell growth and differentiation raised the 
possibility that prenylation might play a role in carcinogenesis [Rao KN, 1995]  and that 
inhibition of this process could have therapeutic possibilities. [Gibbs JB and Oliff A, 1997]  
Inhibitors of prenylation have since been used as important adjuvants to cancer 
chemotherapy. [Lerner EC, Hamilton AD, and Sebti SM, 1997; Mundy GR, 1997]  
Statins inhibit the cholesterol synthetic pathway and thereby reduce the availability 
of the substrates for prenylation, namely farnesylpyrophosphate and 
geranylgeranylpyrophosphate. Via their reduction of prenyl group availability, and 
consequently via their inhibition of prenylation, it is supposed that statins might have 
effects other than just the reduction of plasma LDL-cholesterol. These effects include an 
inhibition of cell growth and differentiation possibly via an inhibition of Ras. [Bellosta S, 
Ferri N et al., 2000b; Kawata S, Nagase T et al., 1994]  Cross-sectional studies initially 
suggested an association between low cholesterol levels and malignancy, and there was 
a concern that statins might promote cancer. However, it was subsequently found that 
persons who already had a malignancy or other advanced disease at the time of the 
observations caused these observed low serum cholesterol levels. It is reassuring to note 
that users of statins are less likely to develop a cancer and this observation may well be 
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related to the effects that statins have on prenylation. [Blais L, Desgagne A, and LeLorier 
J, 2000] 
The Rab family of small GTP-binding proteins 
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Figure 1.5. The Rab proteins.  
These are members of the small GTP-binding proteins and play an important 
role in endocytosis, exocytosis and trafficking of vesicles between different 
compartments. This is crucial not only for the function of the endocrine 
pancreas and other endocrine organs but also for most other cells including 
osteoclasts. 
 
Further targets of prenylation inhibiting drugs are the Rab proteins. The Rab family 
of small GTP-binding proteins is intimately involved in the regulation of intracellular 
vesicular transport, exocytosis and endocytosis, as well as targeting of vesicles between 
different organelles and the cell surface membrane (Fig. 1.5). [Kinsella BT and Maltese 
WA, 1991]  It is therefore to be expected that the Rab proteins will play an important role 
in all cells, but particularly in those involved with the cycling of intracellular organelles. The 
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isoprenylation of these Rab proteins is critical for their association with specific 
intracellular compartments and regulation of vesicular transport processes. Prenylation 
also plays an important role by modulating the interaction between Rab and the regulatory 
proteins that determine their ATP or ADP binding, and consequently membrane binding. 
[Takai Y, Kaibuchi K et al., 1993]  GDP Dissociation Inhibitor (GDI) is one such regulatory 
protein, which regulates the GDP and GTP binding of Rab and helps to shuttle Rab 
between donor and acceptor membranes (Fig. 1.6). [Alexandrov K, Horiuchi H et al., 
1994] 
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Figure 1.6. The interaction between Rab and GDI proteins.  
These proteins help to shuttle organelles between donor and acceptor 
membranes. 
 
The Rab family is geranylgeranylated by GGTase II. The geranylgeranylation of 
these proteins therefore means that, experimentally, the effects of prenylation inhibitors on 
these Rab proteins can be expected to be reversed by the addition of 
geranylgeranylpyrophosphate instead of farnesylpyrophosphate. GGTase II is also 
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somewhat different from the other prenyl transferases in that it recognises carboxy-
terminal sequences other than the CAAX. This raises the possibility that there may be a 
large family of these transferases. Furthermore, GGTase II requires another protein for 
activity, namely Rab Exchange Protein (REP). REP is homologous to GDI and is required 
in all cells. [Alexandrov K, Horiuchi H et al., 1994]  A mutation of this protein was found to 
be responsible for choroideremia, an inherited X-linked disease that results in a slow 
degeneration of the retina ultimately leading to blindness.  There are no other systemic 
features in this disease suggesting that there might be other isoforms of REP. [Cremers 
FP, Armstrong SA et al., 1994]   A further search has led to the discovery of a closely 
related protein which is active in cells other than the retina, now named REP2, and the 
retinal protein REP1. [Zhang FL and Casey PJ, 1996] 
Extensive intracellular vesicular trafficking is essential for the polarisation and 
bone resorbing activities of osteoclasts and it is to be expected that the Rab proteins will 
play an important role in the function of these cells. Rab 3 isoforms are expressed in bone 
marrow macrophages and their expression is increased by cytokines that promote the 
osteoclastic differentiation of these cells. Of note is that the Rab-3 co-localises with the 
H+ATPase or the vacuolar proton pump of osteoclasts. [Abu-Amer Y, Teitelbaum SL et al., 
1999]  
It is clear that Rab proteins play an important role in osteoclast function. Their 
inhibition might be an important method by which certain drugs exert their antiresorptive 
properties. 
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The Rho family of small GTP-binding proteins. 
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Figure 1.7. The Rho proteins.  
Rho members of the small GTP-binding proteins play a pivotal role in the 
cytoskeleton via focal adhesion complex and stress fibre assembly. This 
explains the morphological changes observed when statins are added to cell 
cultures and which can be reversed by the addition of mevalonate. 
Abbreviations: Tsn = tensin; Vcln = vinculin; Tin = talin; Fbn = fibrinin; Act = 
actin. 
 
The Rho family of small GTPase proteins, comprising Rho, Rac and CDC42, plays 
a central role in the cytoskeletal organisation of polymerised actin (Fig. 1.7). [Craig SW 
and Johnson RP, 1996].  These changes are pivotal to the activation and function of 
motile and polarised cells such as macrophages and osteoclasts. 
Rho is geranylgeranylated by GGTase I. However, under certain circumstances 
RhoB can also be farnesylated by the same GGTase I. The determinants of this 
differential prenylation and its function still remains unclear. [Armstrong SA, Hannah VC et 
al., 1995; Adamson P, Marshall CJ et al., 1992]   The addition of lovastatin and other 
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statins to cell cultures results in marked changes in cell morphology, which correlate with 
the disassembly of actin microfilaments, and that are reversed by the addition of 
mevalonate. Rho activity is essential for the cytoskeletal changes that occur on the 
activation of polarised cells and can be inhibited by various prenylation inhibitors including 
statins, indicating that prenylation is also indispensable for the cytoskeletal effects of Rho. 
[Garret IR, Chen D et al., 2001]    
Rho is also involved in the regulation of calcium sensitivity of smooth muscle, and 
probably of other cells, that can also be inhibited by statins. [Grönroos E, Andersson T et 
al., 1996; Alvarez DS and Andriantsitohaina R, 2001]   The Rho proteins act as efficient 
substrates for the Clostridium botulinum C3 ADP-ribosyltransferase exoenzyme which 
ADP-ribosylates and inactivate Rho. This toxin and enzyme is used as an additional tool 
in the investigation of cytoskeletal assembly and, experimentally, it is applied as an 
inhibitor to Rho. The effect of this Clostridium botulinum exotoxin produces the same 
cellular morphological changes as those observed with the addition of statins. [Aktories K, 
1997]   It would also indicate that the pathways affected by statins and Clostridium 
botulinum exotoxin which disrupt the cytoskeleton, are the same. Indeed this supposition 
is now routinely made when studying these effects. 
The Rac family of the Rho proteins is involved with actin filament organisation, 
which leads to the formation of lamellipodia and membrane ruffling induced by growth 
factors.  It is involved at a relatively early stage in the sequence of events during the 
cytoskeletal organisation that occurs in concert with Rho. This process can be inhibited by 
the microinjection of inactive Rac mutants and prenylation inhibitors, including statins. 
[Craig SW and Johnson RP, 1996]   Rac also has an influence on the assembly of stress 
fibres indicating a communication with Rho and Rac. Rac additionally plays an essential 
role in the NADPH oxidase system of phagocytic leukocytes (neutrophils, macrophages, 
and eosinophils) which is dependent on prenylation and which can also be prevented by 
inhibitors of prenylation. [Kreck ML, Freeman JL et al., 1996]  
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The Rho family of proteins therefore has a profound effect on the cytoskeleton and 
its dynamics. It can therefore be expected that Rho proteins play an important role in 
polarised and motile cells such as macrophages. Osteoclasts are another example of 
such cells, and it is to be anticipated that Rho proteins will play an important role in bone 
remodeling. Drugs modulating these effects can also be postulated to influence the 
function of the Rho proteins. 
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1.4. The involvement of prenylation in bone metabolism. 
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Figure 1.8. CDC42,  Rac and Rho.  
A schematic representation of the signal transduction pathways from the cell 
surface to the cytoskeleton. The binding of ligands to the serpentine receptors,  
tyrosine kinase receptors and integrins result in signal cascades for which 
CDC42, Rac and Rho are pivotal, and which lead to cytoskeletal reorganisation 
and activation of polarised and motile cells. Note that nuclear transcription 
factors are also activated. 
 
Motile and polarised cells can be activated by a variety of stimuli; via the ligand 
binding of the serpentine and tyrosine kinase receptors, and via integrins after contact 
with components of the extracellular matrix and other cell adhesion molecules (Fig. 1.8). 
[Denhardt DT, 1996]   The activation of cells, and in particular polarised and motile cells 
such as osteoclasts and monocyte-derived macrophages, by growth factors, cytokines 
and integrins, requires the transmission of a signal from the cell surface to the 
cytoskeleton. [Clark EA, King WG et al., 1998]   This leads to activation of these cells, 
changes in the cytoskeletal organisation and results in the formation of filopodia, 
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lamellipodia (cell ruffling), and focal adhesion complexes and stress fibres. This in turn 
results in alterations in cell morphology, and confers mobility to these cells. In parallel with 
these morphologic changes, certain growth characteristics of the cell are altered – some 
cells start proliferating or dividing while other cells undergo programmed cell death or 
apoptosis. The signal transduction pathways from the cell surface to the cytoskeleton can 
follow different paths and a complex system of cross-talk exists between these different 
signal transduction pathways (Fig 1.9). [Gauthier RC, Vignal E et al., 1998; Denhardt DT, 
1996; Laufs U and Liao JK, 1998; Lim L, Manser E et al., 1996; Reszka AA, Wesolowski 
G et al., 1998]   Consequently, and important to realize that the response to growth 
factors, cytokines or integrins differs in different cell types. Contact with a particular 
extracellular matrix protein will cause proliferation in one cell type but may cause 
apoptosis or death in another cell. [Ghosh PM, Mott GE et al., 1997]   This may have 
important implications for the effects of prenylation inhibitors in bone and mineral 
metabolism.  [Gómez J, Martínez AC et al., 1998] 
It is clear that CDC42, Rac and Rho play a central and critical role in cytoskeletal 
reorganisation. In addition, Rac and Rho, and other elements related to the cytoskeleton, 
also play a role in transmitting signals to the cell nucleus, leading to transcription and 
translation (Fig. 1.9). Of note is the important role that PI3 kinase and other 
phosphatidylinositol kinases play in these pathways, acting as an important link between 
the receptors and cytoskeletal elements (Fig. 1.9). [Carpenter CL, Tolias KF et al., 1997; 
Gómez J, Martínez AC et al., 1998; Martin SS, Rose DW et al., 1996] 
Signals which affect the cytoskeleton for the most part involve the Rho family of 
small GTPases, namely Rho, Rac and CDC42. [Hall A, 1998; Burridge K and 
Chrzanowska WM, 1996; Tapon N and Hall A, 1997]   As indicated, CDC 42 is involved 
with the formation of filopodia, Rac to lamellipodia and membrane ruffling, and Rho 
regulates the formation of focal adhesion and stress fibres. [Craig SW and Johnson RP, 
1996]   After contact with the appropriate ligand, the Rho proteins are activated which, 
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amongst other processes, involves prenylation and specifically geranylgeranylation, 
resulting in a translocation of Rho from the cytosol to membranes. The degree of 
activation and the duration of the signal are further determined by associated modulating 
proteins which determine the GTPase activity and membrane association. [Ando S, 
Kaibuchi K et al., 1992; Sasaki T and Takai Y, 1998] 
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Figure 1.9. Signaling pathways between the cell surface and cytoskeletal elements. 
Adapted from an extensive literature search. 
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A predominant overall downstream effect after ligand binding to the serpentine 
receptors, some of the tyrosine kinase receptors and the integrins is cytoskeletal 
reorganisation.  Prenylation inhibitors including statins block the cholesterol synthetic 
pathway and reduce the availability of the substrates for prenylation, namely 
farnesylpyrophosphate and geranylgeranylpyrophosphate. Prenylation inhibitors can block 
the cytoskeletal effects seen after ligand binding. These blocking effects produced by the 
prenylation inhibitors can be reversed by the addition of mevalonate and 
geranylgeranylpyrophosphate but not by farnesylpyrophosphate - this implies involvement 
of Rho, which is geranylgeranylated, and not Ras, which is farnesylated.  Importantly, 
other downstream products of the cholesterol synthetic pathway, including the addition of 
LDL-cholesterol, are unable to reverse the effects of the statin prenylation inhibitors. The 
statins therefore induce their effect on the cytoskeleton via an inhibition of 
geranylgeranylation.  
The Rho proteins are geranylgeranylated and it is logical to assume that they are a 
target of the statins when the statins affect the cytoskeleton. The inhibitory cytoskeletal 
effects of the statins can be mimicked by Clostridium botulinum C3 transferase exotoxin 
and Clostridium difficile Toxin B, which are inhibitors of Rho, and can also be mimicked by 
the expression of dominant negative mutations of Rho in the cells. [Laufs U and Liao JK, 
1998]   Clostridium botulinum C3 transferase also prevents the reversal by 
geranylgeranylpyrophosphate of the cytoskeletal effects produced by the treatment with 
statins. The cytoskeletal effects of statins can be counteracted by the addition of 
Escherichia coli nectrotising exotoxin, an activator of Rho proteins. [Kreck ML, Uhlinger 
DJ et al., 1994]   It is clear therefore, that geranylgeranylation, and as a result Rho, plays 
a critical role in the downstream events following on signalling which leads to cytoskeletal 
reorganization. These events can be profoundly affected by prenylation inhibitors such as 
the statins. 
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However, there are other downstream effects and effectors of activated Rho that 
may play an important role in various processes and organs. Nuclear transcription of 
various proteins may be directly or indirectly affected. [Lim L, Manser E et al., 1996; 
Denhardt DT, 1996]   Furthermore nitric oxide synthase (NOS) is regulated by Rho 
proteins which act as negative regulators [Laufs U and Liao JK, 1998] , either by 
increased transcription and/or by prolonged half-life and stability of the NOS mRNA or of 
the enzyme itself. [Lim L, Manser E et al., 1996]    
Osteoclasts are amongst the cells that undergo cytoskeletal organisation and 
membrane ruffling prior to activation. It has been demonstrated that Cdc42, Rho and Rac 
proteins are pivotal intermediaries in the signal transduction between the integrins and 
receptors on the cell surface and actin filament organisation (Fig. 1.8; 1.9). [Craig SW and 
Johnson RP, 1996]   Given the above, there is every reason to believe that inhibition of 
prenylation should have some effect on osteoclasts and that this effect may be inhibitory. 
There is evidence that the ultimate target for bisphosphonates is the osteoclast 
and that they cause inhibition and apoptosis of osteoclasts, and also inhibit 
osteoclastogenesis. [Rodan GA, 1998; Luckman SP, Coxon FP et al., 1998a]   It has been 
demonstrated that the nitrogen containing bisphosphonates, including alendronate, inhibit 
prenylation via the inhibition of farnesyl pyrophosphate synthase. [Luckman SP, Hughes 
DE et al., 1998; van Beek ER, Pieterman E et al., 1999]   This evidence linking 
osteoclasts, the inhibition of prenylation, and alendronate therefore make it very likely that 
statins, which have a similar mode of action, would also have an important inhibiting effect 
on osteoclasts and therefore bone and mineral metabolism. [van Beek ER, Löwik C et al., 
1999]
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At the time of the start of our studies in August 1998, no data were available on the 
effect of prenylation and statins on bone metabolism and little on the effect of statins on 
the cytoskeleton. Furthermore, important additional data only became available after the 
completion of our first animal studies. At the time of the formulation of our hypotheses, the 
available data seemed to favour a major negative effect of statins on osteoclast function 
and bone resorption.  
2.1. Hypotheses 
There is evidence to support the notion that osteoporosis and atherosclerosis are 
linked. On this basis lipid lowering therapy could therefore be expected to also impinge on 
processes in bone. There is also a large amount of data available that indicates that 
prenylation plays an important role in osteoclast function and bone metabolism. 
Alendronate inhibits osteoclast function and alendronate has also been shown to inhibit 
prenylation. It would therefore be reasonable to assume that the inhibition of prenylation 
by statins might have a similar effect on bone resorption and/or formation and ultimately 
bone health. Data from lipid metabolism and from the pharmacokinetics of various statins 
seemed to indicate that the effects of different statins are not the same. There was also 
some evidence to suggest that the pleiotropic effects of the different statins are not the 
same. 
It was therefore hypothesized that statins would have some effect on bone 
metabolism and that this should be investigated. It was also imperative to formulate sound 
hypotheses based on information existing at the time, and to design studies to prove or 
disprove these hypotheses.   
The following generalised hypotheses were therefore postulated:- 
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• Statins will have an influence on bone and mineral metabolism 
• Similar to alendronate, statins will inhibit osteoclast function 
• Statins will increase bone mineral density 
• The effect of statins on bone will be the greatest in experimental models of 
high bone turnover e.g. oestrogen-deprived animals.  
• The effect on bone may differ between different statins 
2.2. Aims of the studies. 
The aims of the studies were the following:- 
• To investigate the effect of simvastatin on bone mineral density (BMD) in intact 
and ovariectomised rats 
• To investigate the effect of simvastatin on quantitative bone histomorphometry 
(QBH) including parameters of bone resorption and formation, in intact and 
ovariectomised rats 
• To investigate the effect of different dosages of simvastatin on BMD and QBH 
in intact rats 
• To investigate the effect of other statins (pravastatien, atorvastatien) on BMD 
in intact rats. 
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2.3. Methodology for the studies in rats 
The studies on the rats utilised a uniform methodology to be described in this 
chapter. Slight variations in procedure between experiments are described where 
relevant. 
2.3.1. Sites of the studies 
The rats were in the Animal Research Unit of the Faculty of Health Sciences of the 
University of Stellenbosch located at Tygerberg in the Western Cape Province. 
The surgical procedures on the rats were performed in the Animal Research Unit 
of the Department of Anatomy of the Faculty of Health Sciences, University of 
Stellenbosch, Tygerberg. 
BMD measurements on the rat bones were performed in the Endocrinology and 
Metabolism Unit, Department of Internal Medicine, Ward A10, Tygerberg Hospital, 
Tygerberg and confirmed by a blinded investigator at the University of Pretoria. 
QBH was performed in the Bone Histology Laboratory of the above Endocrinology 
and Metabolism Unit, Department of Internal Medicine, Ward A10, Tygerberg Hospital, 
Tygerberg. 
The biochemical measurements of the rat follicle stimulating hormone (rFSH) were 
performed in the Department of Chemical Pathology, Faculty of Health Sciences, 
Tygerberg Hospital, Tygerberg. 
The measurements of serum oestradiol were preformed in the Department of 
Chemical Pathology, University of Pretoria, Pretoria. 
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2.3.2.. Ethical approvals, registrations and time schedules 
The Research C Subcommittee of the Ethics Committee, and the Animal Research 
Committee, Faculty of Health Sciences, University of Stellenbosch, approved the 
treatment and study protocols:- 
• Study and approval number: 98/131 
• Approval date: 30 October 1998. 
The studies were registered for a Doctoral thesis for Dr Frans J Maritz with the 
Registrar of the University of Stellenbosch:- 
• Approval date: 22 October 1999. 
The studies were started in May 1998. The first results of Study 3.1 were available 
in August 1998. Further studies were undertaken in April 1999 and the first preliminary 
results were published in abstract form in the S Afr Med J 1999; 879: 478. 
2.3.3. Materials 
Simvastatin (Zocor; Merck, Sharpe & Dohme), atorvastatin (Lipitor; Parke-Davis) 
and pravastatin (Prava; Bristol-Myers Squib) were obtained commercially.  
The serum rat FSH (rFSH) assay system (Biotrak; rFSH [125I], code RPA550, 
Amersham Life Science Ltd, Buckinghamshire) was obtained from AEC Amersham, South 
Africa.   
Diagnostic Product Corporation, South Africa supplied the oestradiol kit (Estradiol 
double antibody).  
The rat feeds (Rat and Mouse Breeder Feed; Animal Specialties (PTY) Ltd; 
Phosphorus (min) 8g/Kg, calcium (max) 18g/Kg.) were provided by the Animal Research 
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Unit, Faculty of Health Sciences, University of Stellenbosch. Oxytetracycline hydrochloride 
(Terramycin 100; Pfizer Animal Health) was obtained commercially. 
2.3.4. The general rat model 
The female Sprague-Dawley rats were all acquired from the Animal Research Unit, 
Faculty of Health Sciences, University of Stellenbosch. For all the studies, three-month-
old female rats weighing approximately 250gm were obtained from similarly raised and 
weaned litters, and housed, 5 rats per cage, in a light (14h) and temperature (23-250C) 
controlled environment in a pathogen free room. The rats were allowed free access to 
water, were pair-fed and weighed bi-weekly and feeds adjusted to keep the weights 
constant.  
Rats were randomly allocated to groups of ten rats each. Rats receiving active 
medication were compared to a control, placebo-treated group. The rats on active 
medication received their respective statin, dissolved in vegetable oil as vehicle and mixed 
in their feeds, while the control groups received only the vehicle vegetable oil as placebo. 
In all other respects the actively treated rats and the rats in the control groups were 
treated and managed identically.  
The duration of treatment before sacrifice was 8 weeks in the ovariectomy/sham 
model and 12 weeks in all the other rat studies. 
In all the groups of rats, 13 days and 3 days before sacrifice, all animals received 
oxytetracycline hydrochloride (25mg/Kg, intramuscularly). At the end of the study periods 
the rats were sacrificed using thiopental, and the tibias and femurs were harvested for 
quantitative bone histomorphometry and bone mineral density measurements 
respectively. 
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2.3.5. Bone mineral density 
For the BMD measurements the femurs were preserved in 70% alcohol. BMD of 
the right femur of each rat was measured employing dual energy x-ray absorptiometry 
(Hologic QDR 1000), utilising the software and methodology provided by Hologic Inc.  
The BMD measurements performed on the femurs of the ovariectomy model were 
repeated on a separate Hologic QDR1000 densitometer at a different center (University of 
Pretoria), using the same methodology and software, and the results were then 
compared. 
2.3.6. Quantitative bone histomorphometry 
For the QBH estimations, one tibia from each rat was removed, fixed in a modified 
Millonig’s solution (3.7% formaldehyde, 93mm NaH2PO4, 105mm NaOH and 14.6mm 
sucrose) for 24 hours only, embedded in methylmethacrylate, sectioned at 5μm and 
stained by the Goldner technique.  [Jones R and McClung A, 1990]   QBH analyses were 
performed, using a Merz-Schenk integrating eyepiece, [Merz WA and Schenk RK, 1970]   
by a single, experienced technician blinded to the treatment group of the rats.   
Trabecular bone only was analysed, by not including sections within 2 fields (x 250 
magnification) from either the growth plate or the cortices. Particular care was taken to 
analyze this same, standardized site in every animal. At least 120 fields per animal were 
counted. Time-spaced tetracycline labeling was assessed on unstained, 50μm thick 
sections. Histomorphometry terminology and calculations used are those described in the 
Report of the American Society for Bone and Mineral Research Committee on 
Histomorphometry Nomenclature. [Parfitt AM, Drezner MK et al., 1987] 
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2.3.7. Data. 
For each study the raw data for that particular study will be presented as an 
appendix. Data pertinent to the discussion of any particular study will be presented as a 
table in the relevant chapter. For illustrative purposes data will, where possible, be 
presented in graphic format..  
2.3.8. Statistics 
For the statistical analysis, and for all the studies, the BMD measurements and 
QBH parameters were compared to their respective controls. Further between-group 
analyses were done where appropriate. 
Traditionally the differences between groups are examined by means of a 
Student's t-test. A Student’s t-test assumes that the data has a normal distribution and 
was designed specifically to examine small sample sizes of biological data.  
Much of the data on bone mineral density and quantitative bone histomorphometry 
in our studies followed a normal distribution and initially differences between groups were 
examined using the Student’s t-test. However, with sample sizes of 10 or less, even when 
the data appears to have a normal distribution, a normal distribution cannot automatically 
be inferred and a non-parametric method of examining the difference between samples 
must be used. The use of the Mann-Whitney U-test is advised under these circumstances.  
[Dineen LC and Blakesley LC, 1973; Siegel S, 1956]   The Mann-Whitney U test assumes 
that the variable under consideration was measured on at least an ordinal (rank order) 
scale.  The interpretation of the test is essentially identical to the interpretation of the 
result of a Student's t-test for independent samples, except that the computation of the U 
test is based on rank sums rather than means of the samples.  The U test is the most 
powerful (or sensitive) non-parametric alternative to the t-test for independent samples; in 
fact, in some instances it may offer even greater power to reject the null hypothesis than 
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the t-test. Therefore in these studies, a Mann-Whitney U-test for independent samples 
was used to examine the differences between the groups.  
Where multiple parameters are analysed and are compared with each other it is 
not correct to analyse each parameter individually and in isolation. Consideration should 
be given to the influence of other parameters on the findings of any individual parameter. 
For this reason, an overall comparison of all the groups must be made and the results 
must be analysed by ANOVA. Accordingly, between groups analyses should also be 
performed using some form of post hoc analysis within ANOVA. However, it may also be 
argued that ANOVA is not appropriate for the analysis of the small biological samples as 
presented here. 
In view of these considerations, additional statistical analyses of the BMD and 
QBH data were made utilising ANOVA. Differences between groups and comparisons 
with controls were analysed with a post hoc analysis with Fisher's protected least 
significance difference (PLSD) test.  
Since there were no differences between results obtained with ANOVA plus 
Fisher's PLSD Mann-Whitney U-test, the statistical figures quoted in the text will be from 
results obtained from the analyses using the Mann-Whitney U-test. The results of the 
ANOVA and other statistical analyses will be available in the Appendices that contain the 
descriptive statistics for the different groups used in the different studies. These 
appendices are numbered and labelled with numbers that correspond with the numbers of 
the individual studies.  
A correlation between the different doses of simvastatin and the QBH parameters 
of bone formation and resorption was examined by Pearson's test. All statistical analyses 
were performed by computer utilising Statistica software, Kernel release 5.5 A. 
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The results of statistical analyses performed in each group will presented in the 
appendix section. Other statistical data will be quoted in the text or in tables where 
applicable. 
 
2.3.9. Financial support. 
The research was funded from the following sources: - 
• A Research Grant from the Harry Crossley Trust, University of Stellenbosch. 
Approval for this grant was given on 2 December 1998 and a further grant was 
given in 1999. The monies and funds were managed by the Faculty of Health 
Sciences of the University of Stellenbosch. 
• Personal funds of Dr Frans Maritz 
No financial support or otherwise was received from the pharmaceutical industry 
for the completion of these studies. No financial support of kind was received or accepted 
from the Pharmaceutical Industry for the presentation of this data at National Congresses. 
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The following studies were performed in rats utilising sham-operated and 
ovariectomised rats, and also different doses of statins, as well as different statins, in 
intact rats:- 
• The effect of simvastatin 20mg/Kg/day administered for 8 weeks on bone 
mineral density and quantitative bone histomorphometry, in sham-operated 
and ovariectomised female Sprague-Dawley rats. 
• The effect of simvastatin 20mg/Kg/day administered for 12 weeks on bone 
mineral density and quantitative bone histomorphometry, in intact female 
Sprague-Dawley rats. 
• The effect of different dosages of simvastatin (20mg/Kg/day, 10mg/Kg/day, 
5mg/Kg/day and 1mg/Kg/day) administered for 12 weeks on bone mineral 
density and quantitative bone histomorphometry in intact female Sprague-
Dawley rats. 
• The effect of atorvastatin 2.5mg/Kg/day and pravastatien 10mg/Kg/day 
administered for 12 weeks on bone mineral density in intact female Sprague-
Dawley rats. 
The studies were performed to answer specific questions based on a pre-existing 
formulated hypothesis. The hypotheses were based on sound data available at the time of 
the planning of these studies. The studies are presented separately in sub-chapters of this 
chapter. The data for each study are presented in the form of summary tables and in 
figures. The tables and figures are grouped into the separate sub-chapters of the relevant 
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studies. The tables and figures are labeled according to the relevant sub-chapter number 
for ease of reference. 
For sake of brevity and to avoid unnecessary repetition, in the introductory 
background section of each study on which the hypotheses were based, reference will be 
made to background information presented in Chapter 1. 
The complete data with the relevant descriptive statistics and the statistical 
analyses are presented and available in the Appendices section. The appendices are 
numbered according to the study concerned. 
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3.1.  The effect of simvastatin 20mg/Kg/day administered for 8 weeks, on bone 
mineral density and quantitative bone histomorphometry, in sham-operated 
and ovariectomised female Sprague-Dawley rats. 
3.1.1. Background 
At the start of these studies little was known regarding the effect of prenylation or 
statins on bone and mineral metabolism.  
As described in Chapter 1, there is sufficient information to suggest that more than 
a casual link exists between osteoporosis and atherosclerosis. [Parhami F, 2000]   This 
suggests that the treatment of dyslipidaemia might have an effect on the associated 
osteoporosis, or at least have some effect on bone metabolism.  
As early as 1995 there was an indication that lipid lowering agents might have an 
effect on maintaining bone mass. [Wang GJ, Chung KC, and Shen WJ, 1995]   Three 
groups of rabbits were treated with glucocorticoids, two of which also received lovastatin 
or bezafibrate. After 13 weeks the histologic trabecular bone area was higher in the 
groups that had lipid-lowering agents compared to the group that receive steroid only. It 
was therefore concluded that lipid-lowering agents could prevent steroid-induced 
osteoporosis and that this might be an additional use of these agents. The use of 
lovastatin in these studies was the first indication that statins might have an effect on bone 
metabolism. Further work by these researchers supported their earlier findings. They 
showed that lovastatin could prevent the effect of steroids on adipogenesis in cultured 
cells; lovastatin inhibited steroid induced fat-specific gene expression in cultured marrow 
cells and counteracted the inhibitory effects of steroids on osteoblastic gene expression. 
[Cui Q, Wang GJ et al., 1997]   They also showed that lovastatin was able to prevent 
steroid-induced osteonecrosis in chickens. The authors therefore concluded that 
lovastatin might have a role in the prevention of osteonecrosis. 
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The critical and indispensable link between ligand binding to integrins and certain 
cell receptors, and cytoskeletal activation with the involvement of Rac and Rho on the one 
hand and the activation of polarised and motile cells such as osteoclasts on the other 
hand, has been established and alluded to. [Craig SW and Johnson RP, 1996; Giancotti 
FG, 1997; Zigmond SH, 1996; Hall A, 1998; Symons M, 1996]   There is ample evidence 
that prenylation inhibitors including statins can inhibit the function of Rac and Rho. This 
evidence is, on the one hand, direct, where the inhibition of Rac or Rho by a statin has 
been primarily demonstrated. [Hughes AD, 1996; Lebowitz PF, Casey PJ et al., 1997]   
On the other hand the evidence is indirect, where statins have been used in numerous 
experiments as a control to inhibit the effect of Rho function and cytoskeletal organisation. 
[Kranenburg O, Poland M et al., 1997]   This evidence alone suggests that the use of 
statins will have some effect on cells involved in bone turnover, such as osteoclasts.  
The evidence linking protein prenylation and osteoclast function only became 
apparent in an indirect fashion. It was demonstrated that bisphosphonates including 
alendronate inhibited osteoclast function by suppressing osteoclastogenesis, inhibiting 
osteoclast function and causing apoptosis of osteoclasts. [Rogers MJ, Chilton KM et al., 
1996; Sato M, Grasser W et al., 1991; van Beek ER, Löwik CW, and Papapoulos SE, 
1997]   Subsequently it was demonstrated that alendronate inhibits the mevalonate 
pathway and that it inhibits prenylation. This inhibition of prenylation was accordingly 
demonstrated to be the mode of action of alendronate. [Luckman SP, Hughes DE et al., 
1998; Luckman SP, Coxon FP et al., 1998a; Luckman SP, Coxon FP et al., 1998b]   
Indeed it was later shown by the Dutch group that alendronate inhibits isopentenyl 
pyrophosphate isomerase/farnesol pyrophosphate synthase activity. [van Beek ER, 
Pieterman E et al., 1999; van Beek ER, Löwik C et al., 1999]   In some of these initial 
experiments mevastatin was used as a control and produced an effect similar to that seen 
with alendronate and could inhibit osteoclast function. [Luckman SP, Hughes DE et al., 
1998]    
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Further suggestive evidence came from the effect of statins on certain cell lines. 
Statins were able to inhibit certain aspects of macrophage function in blood vessels. 
[Bellosta S, Bernini F et al., 1998]   It was shown that lovastatin was able to induce 
apoptosis in mesangial cells. [Ghosh PM, Mott GE et al., 1997]   Macrophages, mesangial 
cells and osteoclasts are all motile cells that are derived from the same lineage. It 
therefore seemed reasonable to assume that the effects of statins on macrophages and 
mesangial cells would extend also to osteoclasts. 
The above suggested that statins will have an effect on bone turnover and in 
particular on osteoclast function. This prompted us to pursue this line of enquiry further. 
Oestrogen deprived animals are known to have a high bone turnover state. The 
existing evidence seemed to suggest that the inhibition of prenylation via alendronate and 
also via statins would inhibit osteoclast function. [Woo JT, Kasai S et al., 2000]   These 
factors led credence to the suggestion that statins, via their inhibition of prenylation, would 
have a greater effect on ovariectomised rats with their high-turnover state than their sham-
operated counterparts.   
3.1.2. Hypothesis 
Based on the above information, the following hypotheses were formulated: - 
• Simvastatin 20mg/Kg/day administered for 8 weeks will affect bone and 
mineral metabolism 
• Simvastatin 20mg/Kg/day administered for 8 weeks will decrease osteoclast 
function and consequently reduce bone resorption  
• Simvastatin 20mg/Kg/day administered for 8 weeks will increase BMD 
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• The effect of simvastatin 20mg/Kg/day, administered for 8 weeks, on QBH 
parameters of bone resorption and formation, as well as BMD, will be greater 
in ovariectomised rats than in their sham-operated controls 
3.1.3. Aims of the study 
The study was aimed to investigate the following:- 
• To investigate the effect of simvastatin 20mg/Kg/day for 8 weeks on BMD and 
on QBH parameters of bone resorption and formation in sham-operated and 
ovariectomised female Sprague-Dawley rats.  
• To compare the effects of simvastatin 20mg/Kg/day on BMD and parameters 
of QBH between sham-operated intact rats and ovariectomised rats. 
3.1.4. Methodology 
The general rat model, with the associated handling of the rats, feeding, weighing, 
method of drug and placebo administration, time-spaced tetracycline marking, sacrifice 
and harvesting of bones was utilised as described in chapter 2.3.4. 
Forty rats were randomly allocated to four groups of ten rats each. Two weeks 
prior to the administration of the study drugs, an ovariectomy was performed under ether 
anesthesia on two groups.  One of these groups received simvastatin 20mg/Kg/day 
dissolved in vegetable oil as vehicle (OVX-S), while an equivalent amount of vehicle was 
administered to the other group as placebo (OVX). A sham operation was performed 
under ether anesthesia on the remaining two groups of which one group received 
simvastatin 20mg/Kg/day (Sh-S) and the other placebo as above (Sh). The treatment was 
continued for 8 weeks in all the groups. The dosages of simvastatin were based on earlier 
safety and efficacy studies in rats [Gerson RJ, MacDonald JS et al., 1989]   and were 
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similar to those used to assess the effect of statins on bone. [Mundy G, Gutierrez G et al., 
1998; Mundy G, Garrett R et al., 1999] 
The methodology for quantitative bone histomorphometry and bone mineral 
density measurements as described in chapter 2.3.5 was utilised. In addition the bone 
mineral density measurements were repeated at another centre located at the University 
of Pretoria. 
At the time of sacrifice, blood was taken for measurement of rFSH and oestradiol 
to assess the efficacy of the ovariectomies. rFSH was determined using a competitive 
[125I] assay system with magnetic separation as described by Amersham Life Sciences 
Ltd. for the assay system (Biotrak; rFSH [125I]. Oestradiol was measured by a double 
antibody method on an Immuno1 analyser. 
The results of the BMD and the QBH in the sham-operated group (Sh) were 
compared to the ovariectomised group (OVX). The results of the actively treated groups 
(Sh-S, OVX-S) were compared to the placebo treated controls (Sh, OVX) respectively. 
The delta values for the BMD and the different parameters of bone formation and 
resorption in the sham-operated group were compared to the BMD and corresponding 
parameters in the ovariectomised rats. 
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3.1.5. Results  
The descriptive statistics of the hard data and the results of the statistical analyses 
are presented in Appendix A 3.1. 
The BMD, employing DEXA, was decreased in the ovariectomised rats (OVX) 
when compared to the sham-operated animals (Sh) (Fig. 3.1.1; Table 3.1.1). Similarly, 
bone volume, when employing QBH was decreased in the ovariectomised rats (OVX) 
when compared to the sham-operated group (Sh) (p = 0.00037) (Table 3.1.1). In addition, 
the QBH parameters of bone resorption were increased in the ovariectomised rats (OVX) 
(Figs. 3.1.2; 3.1.4; Table 3.1.1) and there was an increase in QBH parameters of bone 
formation (Figs. 3.1.3; 3.1.4; Table 3.1.1), including the bone formation rate (Table 3.1.1), 
in the ovariectomised animals when compared to their sham-operated controls (Sh). 
These expected effects of ovariectomy on BMD and QBH tend to validate the rat model 
used in this study. 
In the sham-operated rats that received simvastatin (Sh-S), the BMD showed a 
tendency to be lower when compared to their untreated controls (Sh) but this never 
reached statistical significance (Table 3.1.1; Fig 3.1.5). The addition of simvastatin to the 
ovariectomised animals (OVX-S) produced no change in the BMD when compared to their 
untreated controls (OVX) (Table 3.1.1; Fig 3.1.5). However, simvastatin produced a 
significantly greater effect and decline (delta) in the BMD of the sham-operated group (Sh-
St) than in the ovariectomised group (p = 0.003) (Fig. 3.1.6). It is also evident that 
treatment  with simvastatin 20mg/Kg/day was unable to prevent the decline in BMD seen 
in the ovariectomised group (OVX-S) (Fig. 3.1.5). 
The static parameters of bone formation (osteoid volumes, surfaces, osteoblasts) 
were significantly increased in the sham-operated animals which received simvastatien 
(Sh-S) supporting previous reports that statins increase bone formation (Fig. 3.1.7.). 
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[Mundy G, Gutierrez G et al., 1998]   This was, however, not supported by dynamic, 
tetracycline-based data and the calculated bone formation rate was similar in the sham-
operated animals which did and did not receive simvastatin (Sh-S and Sh) (Fig. 3.1.7.). 
Reasons for this discrepancy are unclear. Hyperosteoidosis could not be ascribed to a 
mineralisation defect and the mineralization lag time was unaffected statin administration 
(Table 3.1.1.). Surprisingly, parameters of bone resorption (eroded surfaces, osteoclasts) 
were also significantly increased in the statin treated sham-operated rats (Sh-S) (Fig. 
3.1.8.).  [Mundy G, Garrett R et al., 1999] 
In the ovariectomised rats that received simvastatin (OVX-S), the effects of 
simvastatin on QBH parameters when compared to their untreated controls (OVX) differed 
from those seen in the sham-operated rats (Sh-S) (Table 3.1.1). The effect of simvastatin 
20mg/Kg/day on the formative parameters in the ovariectomised rats (OVX-S) was 
smaller than that seen in the sham-operated rats (Sh-S), and were not significant (Table 
3.1.1). Simvastatin had no effect on the on the parameters of bone resorption in the 
ovariectomised rats (Sh-S) (Table 3.1.1). There were no associated changes in bone 
volume and the changes in bone formation rate were negligible (Table 3.1.1). The 
differences in QBH parameters of bone turnover in the simvastatin-treated animals (Sh-S 
and OVX-S) when compared to their respective untreated controls (Sh and OVX), the 
delta value, differed significantly between the Sh-S and OVX-S groups (Fig. 3.1.9; 3.1.10)  
The descriptive statistics and statistical analyses of the data on bone mineral 
density the descriptive statistics of the data on bone histomorphometry, and the statistical 
analyses on the bone histomorphometry data are presented in Appendices section 
(Append. A 3.1.). 
The results of the bone mineral density measurements performed at Pretoria 
University showed no significant differences from those performed at the University of 
Stellenbosch.  
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The oestradiol levels were significantly decreased and the rFSH levels were 
significantly increased in the ovariectomised (OVX, OVX-S) animals when compared to 
their sham-operated controls (Sh, SH-S) (Table 3.1.2) indicating that the ovariectomy had 
been successful.  
The rats had a variable weight over the duration of the study and there was a 
mean weight gain of 22.2 g over the duration of the study (Fig. 3.1.11; Append. A 3.1). 
However, the weight gain in all the groups was similar and moved in parallel and the 
weight gain did not differ statistically between groups (Append. A 3.1). 
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3.1.6. Tables 
Table 3.1.1. Bone Mineral Density and Histomorphometry: Ovariectomy and Sham-
operated Groups. 
 Animal group 
 Sh Sh-S OVX OVX-S 
Bone Mineral Density 0.104(0.001) 0.099(0.002) 0.094(0.001) 0.094(0.002) 
Histomorphometric parameter     
Bone volume (BV/TV) (%) 18.02 (1.05) 17.29 (1.29) 10.54 (0.88) 9.53 (1.17) 
Osteoid volume (OV/BV) (%) 0.8 (0.26) 1.55 (0.3) 2.32 ( 0.41) 2.63 (0.57) 
Osteoid volume (OV/TV) (%) 0.13 (0.03) 0.26 (0.05) 0.23 (0.03) 0.22 (0.04) 
Osteoid surface (OS/BS) (%) 4.41 (1.12) 9.53 (1.38) 11.54 (1.7) 13.59 (1.91) 
Osteoblast surface (Ob.S/BS) (%) 0.49 (0.11) 1.12 ( 0.16) 0.77 (0.19) 1.38 (0.39) 
Osteoid thickness (O.Th) (mcm) 7.66 (0.98) 7.05 (0.61) 9.61 (1.18) 8.15 (0.83) 
Eroded surface (ES/BS) (%) 6.05 (0.94) 8.11 (0.68) 7.94 (1.23) 8.15 ( 0.83) 
Osteoclast surface (Oc.S/BS) (%) 0.74 (0.12) 1.21 ( 0.14) 1.67 (0.31) 1.69 (0.25) 
Osteoclast number (N.Oc/TA) (/mm2) 0.06 (0.01) 0,11 (0.01) 0.16 (0.03) 0.16 (0.02) 
Mineralizing surface (MS/BS) (%) 5.1 (0.78) 5.18 (0.72) 9.28 (0.83) 8.83 (1.01) 
Mineralisation lag time (mlt) (days) 0.59 (0.12) 0.54 (0.08) 0.32 (0.04) 0.27 (0.04) 
Bone formation rate (BFR/BS) (mcm3/mcm2/yr)  15.45 (2.52) 15.65 ( 2.22) 33.37 (4.47) 31.93 (3.5) 
  
 Animal groups compared 
 Sh vs. OVX Sh vs. Sh-S OVX vs. OVX-S 
 * %  p ** %  p *** %  p 
Bone Mineral Density -9.5 0.0065 -4.1 0.1986 -0.06 1.0295 
Histomorphometric parameter       
Bone volume (BV/TV) (%) -41 0.0003 -4 0.8421 -10 0.1128 
Osteoid volume (OV/BV) (%) 190 0.0019 94 0.0279 13 0.9048 
Osteoid volume (OV/TV) (%) 75 0.0244 103 0.0220 -2 0.9048 
Osteoid surface (OS/BS) (%) 162 0.0012 116 0.0133 18 0.3562 
Osteoblast surface (Ob.S/BS) (%) 57 0.3401 127 0.0133 78 0.4967 
Osteoid thickness (O.Th) (mcm) 25 0.2973 -8 0.6038 -15 0.6607 
Eroded surface (ES/BS) (%) 31 0.2224 34 0.0435 3 1.0318 
Osteoclast surface (Oc.S/BS) (%) 126 0.0315 64 0.0435 2 0.9682 
Osteoclast number (N.Oc/TA) (/mm2) 178 0.0078 92 0.0030 0 0.8421 
Mineralizing surface (MS/BS) (%) 82 0.0040 2 0.9682 -5 0.6607 
Mineralisation lag time (mlt) (days) -46 0.0244 -9 0.9048 -15 0.4002 
Bone formation rate (BFR/BS) (mcm3/mcm2/yr)  116 0.0040 1 0.7802 -4 0.9048 
Data expressed as mean (SEM); Sh = Sham; Sh-S = Sham + simvastatin 20mg/Kg/dy; OVX = ovariectomy; OVX-S 
= ovariectomy + simvastatin 20mg/Kg/dy; * = % change of OVX from Sh; ** = % change of Sh-S from Sh; *** = % 
change of OVX-S from OVX. P value = post hoc ANOVA, Fisher's test. 
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Table 3.1.2. Serum rFSH and oestradiol. 
rFSH (ng/ml) Oestradiol (pmol/L) 
Sh 0.6 (0.07) 63 (17.22) 
Sh-S 0.51 (0.05) 52.3 (14.41) 
OVX 6.5 (0.44) † 15.4 (2.36) † 
OVX-S 5.46 (0.25) † 11.81 (1.68) † 
* Data expressed as mean (SE) 
† p = <0.001 compared to Sham group. 
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 3.1.7. Figures 
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Figure 3.1.1. BMD of untreated ovariectomised (OVX) and sham-operated rats 
(Sh). 
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Figure 3.1.2. Quantitative bone histomorphometric parameters of bone resorption 
in untreated ovariectomised rats (OVX) vs. sham-operated controls (Sh). 
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Figure 3.1.3. Quantitative bone histomorphometric parameters of bone formation 
in untreated ovariectomised rats (OVX) vs. sham-operated controls (Sh). 
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Figure 3.1.4. Changes in quantitative histomorphometric parameters of bone 
formation and resorption in the untreated ovariectomised rats (OVX) expressed as 
a percent change from their untreated sham-operated controls (Sh). 
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Figure 3.1.5. BMD in the sham-operated and ovariectomised rats (Sh and OVX) 
and in those receiving simvastatin 20mg/Kg/day (Sh-S and OVX-S). 
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Figure 3.1.6. The delta BMD: the change in BMD induced by simvastatin in the Sh 
and OVX groups.  
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Figure 3.1.7. Quantitative histomorphometric parameters of bone formation in the 
untreated sham-operated rats (Sh) vs. those receiving simvastatin 20mg/Kg/day 
(Sh-S) 
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Figure 3.1.8. Quantitative histomorphometric parameters of bone resorption in the 
untreated sham-operated rats (Sh) vs. those receiving simvastatin 20mg/Kg/day 
(Sh-S). 
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Figure 3.1.9. The delta value of histomorphometric parameters of bone formation 
in the sham-operated and ovariectomised groups. 
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Figure 3.1.10. The delta value of histomorphometric parameters of bone resorption 
in the sham-operated and ovariectomised groups. 
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Figure 3.1.11. Changes in the weights of the sham operated (Sh, SH-S) and 
ovariectomised (OVX, OVX-S) rats over the duration of the study. 
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3.1.8. Discussion 
When compared to the sham-operated group (Sh), ovariectomy (OVX) resulted in 
a significant increase in bone formation and bone resorption. BMD was significantly 
decreased and this was associated with a decrease in histomorphometric bone volume.   
These effects of ovariectomy are expected and tend to validate the rat model used in 
these studies. The accuracy of our bone mineral density measurements were validated by 
similar results obtained at an independent center (University of Pretoria). 
The average weights of the animal groups at the start of the study were 
comparable and the weight gain for any particular group was not significantly different 
from the others. Differences in body and skeletal size could not therefore explain any 
differences in bone mineral density. There is also no reason to believe from the histology 
that the statin used in this study, simvastatin, caused osteomalacia or an increase in bone 
marrow fat, known to result in an under-estimation of bone mineral density.  
In non-ovariectomised rats (Sh, Sh-S) simvastatin had a significant effect on 
quantitative bone histomorphometric parameters of bone turnover. Although we had 
hypothesised that bone resorption would be suppressed by statins, this study surprisingly 
showed an increase in QBH parameters of bone resorption. Although we had anticipated 
that bone resorption would be primarily affected, this study also showed an increase in 
bone formationAlthough there was a decrease in bone mineral density this did not reach 
statistical significance. These differences in the effect of simvastatin on ovariectomised 
and non-ovariectomised rats are further highlighted by the significant differences in the 
delta values of the parameters of bone turnover and bone mineral density in the two 
groups. These significant effects of simvastatin on the bone of the sham-operated rats 
supports the first hypothesis stated for this study. However, the finding that simvastatin 
increased osteoclast numbers and resorption does not support the second and third 
hypotheses that statins will inhibit osteoclast function and increase bone mineral density. 
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This seems to indicate that a mechanism other than the inhibition of prenylation may be 
responsible for the effect produced by simvastatin on the osteoclast.  
The finding that simvastatin 20mg/Kg/day increases bone formation supports the 
findings of other researchers that bone formation is increased. [Mundy G, Gutierrez G et 
al., 1998]   However, our finding that simvastatin 20mg/Kg/day increases the parameters 
of bone resorption is somewhat at variance with the brief report of other workers. [Mundy 
G, Gutierrez G et al., 1998; Mundy G, Garrett R et al., 1999]   These researchers primarily 
looked at bone formation and did not elaborate on parameters of bone resorption. Brief 
mention is made of a decrease in parameters of bone resorption. Later publications by the 
same workers also fail to report the effects of different doses of simvastatin on bone 
resorption.  [Mundy G, Garrett R et al., 1999] 
Simvastatin had no significant effect, on the QBH parameters of bone formation or 
resorption in the ovariectomised (OVX, OVX-S) rats of this study. Similarly the treatment 
with simvastatin had no effect on the bone mineral density in the ovariectomised group. 
This tends to disprove the last hypothesis of this study, that statins will have a greater 
effect in ovariectomised animals. The reasons for this are uncertain but would indicate 
that oestrogen could play some kind of permissive role for the effect that statins have on 
bone. It is also clear that simvastatin, as used in this study, was unable to prevent the 
decrease in bone mineral density and the increase in bone turnover produced by 
ovariectomy. This argues strongly against suppositions and statements that statins may 
be important drugs in the treatment or prevention of osteoporosis. 
Although oestradiol and rFSH levels were measured to confirm the success of the 
ovariectomy, these levels also serve to confirm that the statins themselves did not induce 
a hypogonadal state. The changes induced by statins are reminiscent of oestrogen 
deprivation and because heterotrimeric G-protein-coupled receptors are also prenylated, 
there is reason to suspect that the action of trophic hormones may be interfered with. It is 
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therefore unlikely simvastatin exerts its influence on bone by interfering with the action of 
rFSH. 
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3.1.9. Conclusions 
Although some of the findings in this study were unexpected, the following 
conclusions could be made:- 
1. The rat model employed showed the expected densitometric and histologic 
changes expected following ovariectomy 
2. Simvastatin increases quantitative histomorphometric parameters of both bone 
formation and bone resorption in non-ovariectomised rats 
3. BMD was not significantly altered by simvastatin treatment although it tended to 
decrease (and not increase) BMD 
4. There is a difference in the effect of simvastatin on histomorphometric parameters 
of bone turnover and bone mineral density in the presence or absence of 
oestrogen. Simvastatin does not have an effect on histomorphometric parameters 
of bone turnover or bone mineral density when oestrogen is not present 
5. Simvastatin is not able to prevent the effects and consequences of ovariectomy on 
quantitative histomorphometric parameters of bone turnover and bone mineral 
density 
Further studies are needed to define the role and effect of statins on bone and 
mineral metabolism. 
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3.2. The effect of simvastatin 20mg/Kg/day administered for 12 weeks, on bone 
mineral density and quantitative bone histomorphometry, in intact female 
Sprague-Dawley rats. 
3.2.1. Background 
The results of the Study 3.1 indicated that simvastatin increases bone formation 
but simultaneously also stimulates osteoclastic bone resorption in sham-operated female 
rats but not in ovariectomised rats. This is at variance with one of the initial hypotheses, 
which stated that, due to the inhibitory effect of statins on protein prenylation, osteoclast 
function would be inhibited, and bone resorption would be suppressed, with a resultant 
increase in bone mineral density. Because these findings were surprising it was important 
to confirm these results in another study mimicking the sham-operated group but utilising 
intact female rats. 
3.2.2. Hypotheses 
The following hypothesis was made:- 
• Simvastatin 20mg/Kg/day administered to intact Sprague-Dawley rats over 12 
weeks will increase QBH parameters of both bone formation and resorption 
• Simvastatin 20mg/Kg/day administered to intact Sprague-Dawley rats over 12 
weeks will decrease BMD 
3.2.3. Aims of the study 
The aims of the study were therefore the following:- 
1. To study the effects of simvastatin 20mg/Kg/day on BMD and QBH in intact 
Sprague-Dawley rats. 
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2. To compare the effects of simvastatin 20mg/Kg/day on BMD and QBH found in 
this study with those found in the sham-operated (Sh-S) group of Study 3.1 
3.2.4. Methodology 
The general rat model with the associated handling of the rats, feeding, weighing, 
method of drug and placebo administration, time-spaced tetracycline marking, sacrifice 
and harvesting of bones as described in Chapter 2.3 was utilised. 
Twenty rats were randomly allocated to two groups. One group received 
simvastatin 20mg/Kg/day (S20) dissolved in vegetable oil as vehicle and mixed with their 
feeds while the remaining group received only vegetable oil as a placebo and acted as 
control (C).  The treatment was continued for 12 weeks. The longer duration of treatment 
in this study was partly justified by attempt to find out whether this would make any 
difference to the results. 
The methodology for BMD measurements as described in chapter 2.3.5 and 2.3.6 
were utilised.  
For the statistical analysis the results of the BMD and QBH parameters of bone 
formation and resorption of the S20 group were compared with those of the C group 
utilising the Mann-Whitney U-test. Comparisons of the effect of simvastatin on the intact 
rats in the present study with those of the non-ovariectomised rats in Study 3.1 were 
made by analysing the changes induced in the simvastatin-treated groups after treatment 
compared to their respective controls, the delta value. The delta values were then 
compared between the two studies using the Mann-Whitney U-test.  
3.2.5. Results  
Similar to our findings in Study 3.1, simvastatin 20mg/Kg/day produced a 
decreasing trend in BMD in the treated rats (S20) when compared to the untreated control 
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group (C) (Table 3.2.1; Fig. 3.2.1). However, this decrease in BMD did not reach statistical 
significance, is in agreement with the results of Study 3.1. 
 The static parameters of bone formation increased in the simvastatin 
20mg/Kg/day treated rats (S20) compared to the untreated control group (C) (Table 3.2.1; 
Fig. 3.2.2). Although these increases in the formative parameters were substantial (48-
110%), they did not achieve statistical significance (Table 3.2.1). Bone Formation  Rate 
increased by 20%, but this also failed reach statistical significance (p = 0.15). Treatment 
with simvastatin 20mg/Kg/day (S20) however, resulted in statistically significant increases 
in parameters of bone resorption when compared to the untreated control (C) (Table 
3.2.1; Fig. 3.2.3.). These percent changes are qualitatively similar to those seen in the 
sham-operated animals (SH-S) in Study 3.1 (Fig. 3.1.4; 3.2.4).  
The weights of the rats did not differ statistically between the simvastatin-treated 
(S20) and control (C) groups of the present study  (Fig 3.2.9) (Append B 3.2). There was 
an average weight gain of 17.2 g between the groups over the duration of the study and 
the weight gain by each group, the delta value, did not differ statistically. 
The descriptive statistics and statistical analyses of the data on the BMD, the 
descriptive statistics of the data on bone histomorphometry and the statistical analyses on 
the QBR data are presented in Appendices section (Append. B 3.2). 
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3.2.6. Tables 
Table 3.2.1. Bone Mineral Density and Histomorphometry: 
Simvastatin 20mg/Kg/day vs. Control. 
  Animal Group 
 C S20 
   * % ** p 
Bone Mineral Density 0.105(0.002) 0.103(0.002) -2.04 0.4 
Histomorphometric parameter     
Bone volume (BV/TV) (%) 23.97(1.48) 22.66(1.01) -5 0.406 
Osteoid volume (OV/BV) (%) 0.56(0.05) 0.92(0.24) 66 0.226 
Osteoid volume (OV/TV) (%) 0.13(0.01) 0.20(0.04) 54 0.326 
Osteoid surface (OS/BS) (%) 4.66(0.41) 6.91(1.49) 48 0.174 
Osteoblast surface (Ob.S/BS) (%) 0.84(0.15) 1.75(0.42) 110 0.070 
Osteoid thickness (O.Th) (mcm) 6.06(0.58) 6.57(0.79) 8 0.545 
Eroded surface (ES/BS) (%) 7.39(0.34) 9.35(0.66) 27 0.041 
Osteoclast surface (Oc.S/BS) (%) 0.80(0.06) 1.36(0.15) 70 0.008 
Osteoclast number (N.Oc/TA) (/mm2) 0.07(0.01) 0.11(0.01) 75 0.016 
Mineralizing surface (MS/BS) (%) 7.05(0.5) 7.92(0.48) 12 0.290 
Mineralisation lag time (mlt) (days) 0.37(0.048) 0.33(0.04) -10 0.705 
Bone formation rate (BFR/BS) (mcm3/mcm2/yr)  17.28(1.44) 20.56(1.41) 19 0.151 
Data expressed as mean (SE); C = Control; S20 = simvastatin 20mg/Kg/dy;  * = % change from 
Control; ** = vs. C. 
 
 
Study 3.2. The effect of simvastatin 20mg/Kg/day administered for 12 weeks, on bone mineral density and quantitative bone 
histomorphometry, in intact female Sprague-Dawley rats. 
 
 82
3.2.7. Figures 
Mean+SE
Mean-SE
Mean
BMD: Simvastatin 20mg/Kg/day vs. Control
G
m
/c
m
2
0.101
0.102
0.102
0.104
0.105
0.106
0.106
0.108
C S20
 
Figure 3.2.1. The effect of simvastatin 20mg/Kg/day on bone mineral density 
compared to a control group. 
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Figure 3.2.2. Changes induced by simvastatin 20mg/Kg/day in histomorphometric 
parameters of bone formation (S20) vs. the control group. 
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Resorptive parameters: S20 vs. C
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Figure 3.2.3. Changes induced by simvastatin 20mg/Kg/day in histomorphometric 
parameters of bone resorption (S20) vs. the control group.  
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Figure 3.2.4. Changes in quantitative parameters of bone formation and resorption in 
the simvastatin-treated rats (S20) expressed as a percent change from their untreated 
controls (C). 
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Figure 3.2.5. BMD in the sham-operated groups and the intact rats receiving 
simvastatin 20mg/Kg/day - a comparison of study 3.1 and 3.2. 
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Figure 3.2.6. Changes in the weights of the Control (C) and simvastatin 20mg/Kg/day-
treated rats (S20) rats over the duration of the study. 
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3.2.8. Discussion 
The results of Study 3.1 indicated that osteoclast function and parameters of bone 
resorption were significantly increased by simvastatin 20mg/Kg/day. This was rather 
surprising as this was contrary to one of the hypotheses of that study which stated that 
osteoclast function and bone resorption would be decreased by statins - it was therefore 
imperative that these findings should be confirmed. The finding of study 3.1were 
duplicated in this present Study 3.2 which again showed that simvastatin 20mg/Kg/day 
administered to non-ovariectomised rats clearly increased osteoclastic bone resorption. 
The fact that this has been demonstrated in two studies makes it highly likely that this is 
an effect of simvastatin at these doses and under these experimental conditions in non-
ovariectomised rats. This study, similar to Study 3.1, also suggested that simvastatin 
20mg/Kg/day increases osteoblastic bone formation, although data were less convincing. 
There has been little published data on the in vivo effects of statins in experimental 
animals. Mundy and co-workers have shown that simvastatin significantly increases bone 
formation in rats – results not dissimilar from our own.  {Mundy, Gutierrez, et al. 1998 ID: 
1700}{Mundy, Garrett, et al. 1999 ID: 2629}   Our finding that simvastatin 20mg/Kg/day 
increases bone resorption is, however, novel and unexpected. Mundy et al. [Mundy G, 
Garrett R et al., 1999]primarily looked at bone formation and scant detail regarding their 
findings on bone resorption appear in the literature. [Mundy G, Gutierrez G et al., 1998] 
Other researchers have also found an increase in indices of bone formation with 
cerivastatin. [Miller SC, Bowman BM, and Bagi C, 2001]   However the magnitude and 
significance of these changes are not clear and it appears that the increases in 
parameters of bone formation were less than anticipated. Of note is that ovariectomised 
Sprague Dawley rats were used in these studies which contrasts with our study 3.1 where 
the QBH parameters of bone formation were barely affected by simvastatin 20mg/Kg/day 
in ovariectomised rats, changes being confined to the intact sham-operated animals. No 
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other in vivo work has been published regarding the effects of statins on bone formation or 
resorption in any experimental animals.. 
In this study the BMD showed a decreasing trend but this was not statistically 
significant. These findings are similar to those found in the previous Study 3.1. This might 
imply that bone resorption is increased in excess of bone formation; at best the BMD 
imndicates that bone resorption and bone formation are increased to an equal degree 
resulting in a BMD that is unchanges. These two studies provided no data to suggest that 
simvastatin increases BMD or that it prevents the deleterious effects of OVX on bone loss. 
There has been no published data to indicate that any other studies have been done in 
experimental animals to measure the effect of statins on BMD. Our studies are therefore 
the first which have attempted to look at this aspect of the effect of statins on bone.  
3.2.9. Conclusions 
From the results of this study the following conclusion can be made:- 
1. Simvastatin 20mg/Kg/day significantly increases QBH parameters of 
osteoclastic bone resorption in intact rats female rats 
2. Simvastatin 20mg/Kg/day appeared to have a modest stimulatory effect on 
osteoblastic bone formation. 
3. These effects on QBH parameters of bone turnover and BMD confirm the 
findings of Study 3.1. 
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3.3 The effect of different dosages of simvastatin (20mg/Kg/day, 10mg/Kg/day, 
5mg/Kg/day and 1mg/Kg/day) administered for 12 weeks, on bone mineral 
density and quantitative bone histomorphometry in intact female Sprague-
Dawley rats.  
3.3.1. Background 
Statins primarily reduce serum Total Cholesterol (TC) and low-density lipoprotein-
cholesterol (LDL-C) and to a lesser degree triglycerides. Simultaneously they also 
increase high-density lipoprotein-cholesterol (HDL-C). For all the statins there seems to 
be a dose response curve for the reduction in TC and LDL-C.[Cobos A, Jovell AJ et al., 
1999]    This dose response relationship is not linear but rather curvilinear and plateau-
shaped.  There is a lesser decrease in cholesterol for each incremental increase in the 
dose of the statin. If simvastatin had an effect on bone, it would therefore not be 
inconceivable that there would be a similar dose response curve for BMD and different 
QBH parameters of bone turnover.  
Our own previous work only investigated the effect of a single dose of simvastatin, 
20mg/Kg/day, on BMD and QBH parameters of bone turnover. These effects of statins on 
BMD and QBH as demonstrated in the previous two studies, Study 3.1 and 3.2, would be 
further validated if a dose response relationship could be demonstrated. 
3.3.2. Hypothesis 
The following hypotheses were thus stated:- 
• There will be a dose response relationship between the dose of simvastatin 
and the effect on BMD, with an increasing effect on BMD with increasing doses 
of simvastatin following a curvilinear or plateau-shaped curve. 
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• There will be a dose response relationship between the dose of simvastatin 
and the effect on QBH parameters of bone formation, with an increasing effect 
on QBH parameters of bone formation with increasing dose of simvastatin 
3.3.3. Aims of the study 
The aims of the study were the following:- 
• To examine the effect of different doses of simvastatin (20mg, 10mg, 5mg and 
1mg/Kg/day) on BMD 
• To examine the effect of different doses of simvastatin (20mg, 10mg, 5mg and 
1mg/Kg/day) on quantitative bone histomorphometric parameters of bone 
formation and resorption. 
• To establish a dose response curve for simvastatin and BMD, QBH parameters 
of bone formation and QBH parameters of bone resorption. 
3.3.4. Methodology 
The general rat model as well as the associated handling of the rats, feeding, 
weighing, method of drug and placebo administration, time-spaced tetracycline marking, 
sacrifice and harvesting of bones as described in chapter 2.3.4 was utilised.  
Fifty rats were randomly allocated to five groups of ten rats each. Four groups 
received active medication by way of simvastatin 20mg/Kg/day (S20), 10mg/Kg/day (S10), 
5mg/Kg/day (S5) and 1mg/Kg/day (S1) respectively, dissolved in vegetable oil as vehicle, 
while an equivalent amount of vehicle was administered to the fifth group as placebo. 
Treatment was continued for 12 weeks. 
The methodology for the measurement of the BMD as described in chapter 2.3.5 
was utilised. The methodology for the measurement of QBH as described in chapter 2.3.6 
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was utilised. This standardized methodology was used for all studies thereby making 
these results comparable. 
3.3.5. Results  
The BMD showed a linear decreasing trend for all the doses of simvastatin (Fig. 
3.3.1). The lowest BMD and the greatest decrease in BMD was found with the lowest 
dose of simvastatin (1mg/Kg/day) (S1) (Table 3.3.1; Fig. 3.3.1). Statistically significant 
differences in BMD (p = 0.038) when compared to control (C) were recorded for 
simvastatin 1mg/Kg/day (S1). A correlation between the dose of simvastatin and BMD 
was found (r2 = 0.029; r = 0.17; p = 0.2) and an inverse correlation between the dose of 
simvastatin and the degree of reduction in BMD was observed (r2 = 0.03; r = -0.19; p = 
0.2) but neither reached statistical significance (Fig. 3.3.2).  
The effect of the simvastatin on the QBH parameters of bone turnover varied with 
the different doses of simvastatin, and varying degrees of statistical significance were 
found (Table 3.3.1). Static as well as dynamic QBH parameters of bone formation 
increased with simvastatin 20mg/Kg/day (S20) but were reduced at lower doses (S1) (Fig. 
3.3.3). This is additionally evident when these formative parameters are expressed as a 
percent change from the control value (Fig. 3.3.4); at the higher doses the QBH 
parameters of bone formation are increased (S20) but at lower doses these formative 
parameters were decreased. 
The QBH parameters of bone resorption were increased by simvastatin 
20mg/Kg/day (S20) (Fig. 3.3.5) and this is also evident when these parameters are 
expressed as a percent change from the control value (Fig. 3.3.6). With simvastatin 
10mg/Kg/day and 5mg/Kg/day parameters of bone resorption decreased when compared 
to controls but with 1mg/Kg/day these parameters showed a percentage increase when 
compared to control (Figs. 3.3.5 and 3.3.6; Table 3.3.1). 
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The different QBH parameters of bone formation showed the same trend and 
moved in parallel for the different doses of simvastatin (Figs. 3.3.3 and 3.3.4). Similarly all 
the QBH parameters of bone resorption also showed a similar trend and moved in parallel 
with each other (Figs. 3.3.5 and 3.3.6). It is evident that the dose response curve for both 
the QBH parameters of bone formation and resorption were not linear, nor plateau-
shaped. Furthermore, the dose response curve for bone formation differed qualitatively 
and quantitatively from the dose response curve of bone resorption (Figs. 3.3.4 and 
3.3.6).  
There was a statistically significant correlation between the doses of simvastatin 
and the different QBH parameters of bone formation (Table 3.3.2; Fig. 3.3.7). A similar 
statistically significant correlation between the different doses of simvastatin and the 
different parameters of bone resorption was evident (Table 3.3.2; Fig. 3.3.8). 
The descriptive statistics and statistical analyses of the data on BMD as well as 
the data on the QBH parameters of bone resorption and formation, are presented in 
Appendices section (Appendix C 3.3). 
The raw data as well as the statistical analyses and comparison of all the rat 
weights are presented in the Appendices section (Appendix C 3.3). The weights of the 
rats in the different groups were similar and there was no statistical difference in the 
weights of the different groups at baseline (Fig 3.3.9). There was no statistical difference 
in the weight gain between the different groups.  
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3.3.6. Tables 
Table 3.3.1. Bone Mineral Density and Histomorphometry: Different Simvastatin Dosages. 
  Animal Group 
 C S20 S10 S5 S1 
      
Bone Mineral Density 0.105(0.002) 0.103(0.002) 0.1(0.002) 0.102(0.002) 0.099(0.002) 
Histomorphometric parameter      
Bone volume (BV/TV) (%) 23.97(1.48) 22.66(1.01) 20.41(1.27) 22.97(0.87) 21.04(1.62) 
Osteoid volume (OV/BV) (%) 0.56(0.05) 0.92(0.24) 0.48(0.15) 0.42(0.06) 0.43(0.14) 
Osteoid volume (OV/TV) (%) 0.13(0.01) 0.20(0.04) 0.09(0.02) 0.10(0.01) 0.08(0.02) 
Osteoid surface (OS/BS) (%) 4.66(0.41) 6.91(1.49) 3.96(1.18) 3.68(0.5) 2.86(1.13) 
Osteoblast surface (Ob.S/BS) (%) 0.84(0.15) 1.75(0.42) 0.44(0.17) 0.67(0.11) 0.53(0.18) 
Osteoid thickness (O.Th) (mcm) 6.06(0.58) 6.57(0.79) 6.55(1.34) 6.46(1.06) 8.51(1.26) 
Eroded surface (ES/BS) (%) 7.39(0.34) 9.35(0.66) 6.95(1.22) 5.30(0.36) 6.78(0.73) 
Osteoclast surface (Oc.S/BS) (%) 0.80(0.06) 1.36(0.15) 0.74(0.21) 0.56(0.12) 0.97(0.14) 
Osteoclast number (N.Oc/TA) (/mm2) 0.07(0.01) 0.11(0.01) 0.07(0.02) 0.06(0.01) 0.10(0.01) 
Mineralizing surface (MS/BS) (%) 7.05(0.5) 7.92(0.48) 5.42(1.22) 4.54(0.25) 5.04(1.01) 
Mineralisation lag time (mlt) (days) 0.37(0.048) 0.33(0.04) 0.73(0.18) 0.40(0.07) 1.22(0.27) 
Bone formation rate (BFR/BS) (mcm3/mcm2/yr)  17.28(1.44) 20.56(1.41) 12.14(2.65) 16.71(1.41) 9.69(2.4) 
 
% change of parameter and significance 
 S20 S10 S5 S1 
 * % ** p * % ** p * % ** p * % ** p 
Bone Mineral Density -2.04 0.4 -4.9 0.085 -2.7 0.338 -5.84 0.0386 
Histomorphometric parameter         
Bone volume (BV/TV) (%) -5 0.406 -15 0.070 -4 0.450 -12 0.191 
Osteoid volume (OV/BV) (%) 66 0.226 -13 0.112 -24 0.151 -23 0.060 
Osteoid volume (OV/TV) (%) 54 0.326 -29 0.096 -27 0.089 -40 0.033 
Osteoid surface (OS/BS) (%) 48 0.174 -15 0.070 -21 0.096 -39 0.007 
Osteoblast surface (Ob.S/BS) (%) 110 0.070 -47 0.016 -20 0.496 -37 0.142 
Osteoid thickness (O.Th) (mcm) 8 0.545 8 0.850 7 1.000 40 0.079 
Eroded surface (ES/BS) (%) 27 0.041 -6 0.151 -28 0.002 -8 0.327 
Osteoclast surface (Oc.S/BS) (%) 70 0.008 -7 0.070 -30 0.034 22 0.369 
Osteoclast number (N.Oc/TA) (/mm2) 75 0.016 13 0.450 -14 0.257 49 0.165 
Mineralizing surface (MS/BS) (%) 12 0.290 -23 0.019 -36 0.002 -29 0.014 
Mineralisation lag time (mlt) (days) -10 0.705 98 0.326 9 0.940 230 0.007 
Bone formation rate (BFR/BS) (mcm3/mcm2/yr)  19 0.151 -30 0.013 -3 0.705 -44 0.022 
 
Data expressed as mean (SE); C = Control; S20 = simvastatin 20mg/Kg/dy; S10 = simvastatin 10mg/Kg/dy; S5 = simvastatin 
5mg/Kg/dy; S1 = simvastatin 1mg/Kg/dy; * = % change from Control; ** = vs. C. 
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Table 3.3.2. Correlation between different dosages of simvastatin 
and quantitative histomorphometric parameters. 
Formative Parameters 
 r(X,Y) r2 t p 
Osteoid Volume (OV/BV) 0.369 0.136 2.415 0.0208 
Osteoid Volume (OV/TV) 0.449 0.201 3.054 0.004 
Osteoid Surface 0.403 0.162 2.676 0.011 
Osteoblast Surface 0.490 0.240 3.423 0.001 
Bone Formation Rate 0.445 0.198 3.023 0.004 
Resorptive Parameters 
 r(X,Y) r2 t p 
Eroded Surfaces 0.438 0.191 2.964 0.005 
Osteoclast Surface 0.362 0.131 2.367 0.023 
Osteoclast Number 0.238 0.056 1.492 0.144 
Total Osteoclasts 0.279 0.078 1.767 0.085 
Bone Osteoclast Interface 0.405 0.164 2.697 0.010 
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3.3.7. Figures 
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Figure 3.3.1. The effect of simvastatin 20mg/Kg/day, 10mg/Kg/day, 5mg/Kg/day and 
1mg/Kg/day on bone mineral density compared to a control group. * = vs. C. 
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Figure 3.3.2. Correlation between simvastatin dose and BMD. 
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Figure 3.3.3. The effect of different doses of simvastatin on QBH parameters of bone 
formation. * = vs. C. 
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Figure 3.3.4. The effect of different doses of simvastatin on the percent changes in 
the QBH parameters of bone formation. 
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administered for 12 weeks, on bone mineral density and quantitative bone histomorphometry in intact female Sprague-Dawley 
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Figure 3.3.5. The effect of different doses of simvastatin on QBH parameters of bone 
resorption. * = vs. C. 
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Figure 3.3.6. The effect of different doses of simvastatin on the percent changes in 
QBH parameters of bone resorption. 
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Figure 3.3.7. Correlation between dose of simvastatin and QBH parameters of bone 
formation. 
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Figure 3.3.8. Correlation between dose of simvastatin and QBH parameters of bone 
resorption. 
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administered for 12 weeks, on bone mineral density and quantitative bone histomorphometry in intact female Sprague-Dawley 
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Figure 3.3.9. Weights of the different simvastatin dose groups and control over the 
duration of the study. 
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3.3.8. Discussion 
It has been demonstrated in this study that as the dose of simvastatin changes so 
do the QBH parameters of bone turnover. A significant correlation between the dose of 
simvastatin and the QBH parameters of bone formation has been demonstrated in this 
study and accordingly a dose response curve has been constructed. At an high dose of 
20mg/Kg/day simvastatin stimulated osteoblastic activity and increased bone formation. 
However, at lower doses (1mg/Kg/day) this effect was not seen and instead osteoblast 
activity was inhibited and formation was decreased.  
Similarly a significant correlation between the dose of simvastatin and QBH 
parameters of bone resorption has been demonstrated and accordingly it has been 
possible to construct a dose response curve. At the highest dose of simvastatin, 
20mg/Kg/day, osteoclasts are stimulated and bone resorption increased. At the lower 
doses of simvastatin (10mg/Kg/day and 5mg/Kg/day) osteoclasts are inhibited and bone 
resorption is decreased. At lower doses still, simvastatin 1mg/Kg/day again increases 
bone resorption. Accordingly a U-shaped dose response curve is evident. 
It is clear, particularly when looking at the percent changes in the QBH parameters 
of bone formation, that all the static and dynamic parameters move in the same direction 
and in a parallel fashion. This is also seen with the parameters of bone resorption when 
expressed as percent changes from baseline; all the parameters move in concert in the 
same direction and in a parallel fashion.  
If the dose response curves of the QBH parameters of bone formation are 
compared with the dose response curves of the resorptive parameters it is clearly evident 
that these dose response curves are not the same. This finding may have important 
implications for explaining the findings seen on the BMD measurements.  
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It is apparent that the effects of simvastatin on the QBH parameters of bone 
resorption and formation at high doses differ from those seen at low doses. Clearly these 
dose-response curves are also not complete. The simvastatin needs to be investigated at 
ever smaller doses till the smallest dose is found where there is no effect on any of the 
QBH parameters of bone formation or resorption. If the dose response curve of the 
formative parameters is extended to the left to a point where they reach the nil value on 
the Y-axis, (Response axis), then it becomes evident that there is a biphasic response to 
simvastatin. Bone formation is stimulated at high doses and at lower doses this does not 
simply decrease to a nil value where no response is seen but the response goes below 
the baseline nil value, i.e. bone formation is decreased at lower doses. For bone 
resorption the dose-response is somewhat more complex but also shows a biphasic 
response.  
The underlying mechanism for this biphasic response is not immediately clear. The 
one possible explanation for this phenomenon would be that there could be two or more 
signaling pathways involved in mediating the response to simvastatin and the final effect 
on the osteoblast or osteoclast. If the dose response curves for these signalling pathways 
differ then it may happen that at a lower dose only a single signalling pathway may be 
stimulated whereas at a higher dose more than one pathway may be stimulated with a 
resultant differing effect. However, this is purely supposition and there is no data to 
support this. 
The different doses of simvastatin have a significant effect on BMD (ANOVA). 
There is a linear relationship between the doses of simvastatin and BMD.  
There is a indirect correlation between the dose of simvastatin and the BMD with 
the highest and lowest doses of simvastatin associated with the lost and highest BMD 
respectively. There is an inverse relationship between the dose of simvastatin and the 
amount of reduction in the BMD i.e. the largest decreases were seen with the smallest 
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dose of simvastatin while little change was seen with the largest doses of simvastatin. 
This effect is rather unconventional and unexpected. However, this kind of response is 
possible if there are two process present which together determine the BMD reading and 
if the dose response curves of these two processes differ. And there are indeed two 
processes that determine the BMD, namely bone formation and bone resorption. If the 
dose response curves of bone formation and resorption were to differ then it could happen 
that bone resorption is stimulated at low doses of simvastatin and that bone formation is 
only stimulated at higher doses of simvastatin. This would mean that at low doses of 
simvastatin, only resorption would be stimulated, with a resultant decrease in BMD. At 
higher doses resorption and formation would be stimulated, the two processes would tend 
to balance one another and there would be little change in the BMD. Differing dose 
response curves for bone resorption and bone formation have been demonstrated in this 
study and the above could be a plausible explanation for the BMD findings in this study. 
3.3.9. Conclusions 
The study allowed the following conclusions to be made:- 
1. Simvastatin has an influence on BMD and small doses of simvastatin are 
associated with a reduction in the BMD. 
2. The effect of simvastatin on QBH parameters of bone turnover differs 
according to dose of simvastatin used 
3. The dose-response curve for simvastatin on QBH parameters of bone 
formation differs from the dose-response curve for QBH parameters of 
bone resorption. 
4. At high simvastatin doses of 20mg/Kg/day both bone formation and bone 
resorption are stimulated with little associated effect in the BMD. 
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5. At the low dose of simvastatin 1 mg/kg/day bone formation is suppressed 
whereas bone resorption is mildly stimulated, resulting in a marked 
decrease in BMD. 
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3.4 The effect atorvastatin 2.5mg/Kg/day and pravastatin 10mg/Kg/day 
administered for 12 weeks, on bone mineral density in intact female Sprague-
Dawley rats. 
3.4.1. Background 
In studies 3.1, 3.2 and 3.3 it was established that simvastatin, at various doses, 
had an effect on bone metabolism.  The effect of simvastatin on bone formation and 
resorption differed according to the dosage of simvastatin. The statins all inhibit the rate-
limiting enzyme of the cholesterol synthetic pathway, hydroxymethylglutaryl CoA 
reductase. Research done by others indicates that the effect of statins on bone involves 
the inhibition of prenylation via the reduction of substrates, an effect shared by all the 
statins. [Coxon FP, Benford HL et al., 1998; Frith JC, Armour KJ et al., 2001; Garret IR, 
Esparza J et al., 2000; Garret IR, Gutierrez G et al., 2001; Guijarro C, Blanco-Colio LM et 
al., 1998; Hughes AD, 1996; Laufs U and Liao JK, 2000]   There is little reason to believe 
that statins other than simvastatin will not also have a similar on the inhibition of 
prenylation and therefore have an effect on bone metabolism.  
Statins have other effects and it is commonly assumed that all the effects of one 
statin are automatically shared by all the other statins via a class effect. The statins 
simvastatin, atorvastatin and pravastatin differ from each other in major ways and it would 
not be unreasonable to suspect that effect that they might have on bone will also differ. 
There are reasons enough to expect that there will not be a class-effect for many 
of the effects attributed to statins. The chemical formulae of the statins differ markedly and 
are often divided into the “natural” and “synthetic" statins” where simvastatin and 
pravastatin are classed as "natural" and atorvastatin classed as "synthetic”. [Rosenson 
RS and Tangney CC, 1998]   These dissimilarities may affect the way that they bind to 
target molecules, and engender different properties to the various statins.  
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The metabolism of the statins differ to a major degree. Atorvastatin, lovastatin, 
simvastatin and cerivastatin are primarily metabolised by cytochrome CYP3A4  [Corsini A, 
Bellosta S et al., 1999a; Kantola T, Kivisto KT, and Neuvonen PJ, 1998]    whereas the 
metabolism of fluvastatin utilises a different cytochrome. Pravastatin is metabolised to a 
large degree in the stomach and pravastatin does not make use of the cytochrome P450 
systems for its metabolism. This can have important implications regarding interactions 
with drugs that also use of these P450 systems. [Azie NE, Brater DC et al., 1998]   
Atorvastatin is eliminated mainly by the liver whereas pravastatin is eliminated by other 
mechanisms. 
The lipid solubility of the statins differs. Pravastatin is hydrophilic whereas all the 
others are lipophilic. Consequently, based on lipid solubility, the ability of different statins 
to cross membranes will differ. Accordingly, the intracellular effect of the statins will also 
differ when delivered from the exterior of the cell. For these reasons, the first pass 
extraction by the liver after oral administration will also differ; for simvastatin this exceeds 
90% [Vickers S, Duncan CA et al., 1990; Desager JP and Horsmans Y, 1996]   and for 
pravastatin it is in the order of 60% [Komai T, Kawai K et al., 1992]   and as a result the 
amount of statin which reaches peripheral target cells other than the liver will be different. 
Relatively little active simvastatin reaches the systemic circulation where it can 
consequently affect peripheral tissues such as bone cells. On the other hand more 
pravastatin reaches the systemic circulation and relatively more pravastatin is therefore 
available to have an effect on peripheral cells such as bone cells.  [Germershausen JI, 
Hunt VM et al., 1989; Hatanaka T, 2000].  
Compared to other statins, pravastatin has more sterol-inhibitory action in the liver 
than in peripheral tissues such the spleen and testis despite having similar drug levels in 
those particular tissues. [Koga T, Fukuda K et al., 1992]   However, because of its 
hydrophilicity, pravastatin does not cross membranes readily and much of the pravastatin 
that reaches peripheral tissues is present extracellularly, compared to other lipophilic 
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statins which are located intracellulary. [Koga T, Fukuda K et al., 1992]   This inability of 
pravastatin to cross membranes easily might therefore offset the lower first pass effect 
and consequent higher plasma levels seen with pravastatin. Presumably this lesser action 
on peripheral tissues and cells might also apply to bone. The first pass extraction by liver 
has other important implications. Statins delivered by dermal application will bypass the 
first pass extraction by the liver and a greater proportion of the drug will reach the bone. 
The above factors will all affect the arterial concentration of the different statins 
and therefore also the concentration of drug that reaches the blood bone interface. We 
have already shown that the effect of simvastatin on bone is dependant on the dosage of 
the drug. The differing relative arterial concentrations of the statin will therefore also 
influence to what degree they will affect bone metabolism. 
The half-life of most statins is in the order of 2 hours whereas atorvastatin has a 
half-life exceeding 18 hours. [Posvar EL, Radulovic LL et al., 1996; Cilla DD, Whitfield LR 
et al., 1996; Desager JP and Horsmans Y, 1996]   The administration of atorvastatin 
therefore results in continuously raised blood levels of the drug during the course of a 24 
hour day with no dips in the drugs levels; consequently cells are continuously exposed to 
the effect of the statin. This may be one of the reasons for the cholesterol-lowering 
potency of the drug. The other statins have therapeutic levels for only part of the day and 
there are long periods when cells are not under the influence of these drugs. The use of 
atorvastatin therefore amounts to continuous dosing compared to micro-intermittent 
dosing with the use of the other statins. Differences in the effect of parathyroid hormone 
on bone have been noted when continuous dosing is compared to intermittent dosing. 
Continuous dosing with PTH results in osteopenia whereas intermittent dosing with PTH is 
associated with an increase in BMD. [Masiukiewicz US and Insogna KL, 1998]   Bearing in 
mind the number of important signalling systems that are impinged upon by the statins, 
particularly those utilising prenylated proteins which play a pivotal role in cell growth, 
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differentiation and activation of cells, these differences in half-life may have important 
consequences in different organ systems. 
It can therefore be expected that other statins such as atorvastatin and pravastatin 
will also have an effect on bone health and which might differ from that seen with 
simvastatin.  
3.4.2. Hypothesis 
Based on differences in the pharmacokinetics and metabolism of the statins the 
following hypothesis was stated:- 
• The effect of the long-acting atorvastatin on BMD will differ from that seen with 
the short-acting simvastatin. 
• The effect of the hydrophilic pravastatin on BMD will differ from that seen with the 
lipophilic simvastatin. 
3.4.3. Aims of the study 
Accordingly the aims of the study were the following:- 
• To investigate the effect of atorvastatin 2.5mg/Kg/day and pravastatin 
10mg/Kg/day on BMD compared to controls 
3.4.4. Methodology. 
The general rat model with the associated handling of the rats, feeding, weighing, 
method of drug and placebo administration, sacrifice and harvesting of bones as 
described in chapter 2.3.4 was utilised. 
Thirty rats were randomly allocated to three groups of ten rats each. One group 
received atorvastatin 2,5mg/Kg/day (A) dissolved in vegetable oil vehicle, another 
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received pravastatin 10mg/Kg/day (P) in a similar fashion while the remaining group 
received only vehicle as placebo and acted as control (C). The treatment was continued 
for 12 weeks. 
The dose of atorvastatin and pravastatin chosen, (2.5mg/Kg/day and 10mg/Kg/day 
respectively) was that which was expected to produce the same cholesterol-lowering 
effect as simvastatin 5mg/Kg/day. There is no data on the comparative doses of statin 
which produce the same cholesterol-lowering effect in rats. The doses used in this study 
were therefore chosen because of  the cholesterol-lowering comparisons and 
recommendations between different statins in humans [Illingworth DR and Tobert JA, 
1994]. From these comparisons, it is generally accepted that simvastatin 20mg, 
pravastatin 40mg and atorvastatin 10mg per day have the same cholesterol-lowering 
effect in humans. 
The methodology for bone mineral density measurements as described in chapter 
2.3.5 was utilised.  
3.4.5. Results 
 Both atorvastatin 2,5mg/Kg/day (A) and pravastatin 10mg/Kg/day (P) 
administered for 12 weeks produced a highly significant reduction in BMD when compared 
to the control group (C) (Fig. 3.4.1; Table 3.4.1). 
The descriptive statistics and statistical analyses of the BMD data, are presented 
in Appendices section (Append. 3.4). 
There was an average weight gain of 25g for all the groups and the weight gain by 
each group did not differ statistically.  
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3.4.6. Tables 
Table 3.5.1. Bone Mineral Density: Atorvastatin,  Pravastatin vs. Control 
 Animal Group 
 Control Atorvatstin Pravastatin 
 * % ** p * % ** p  * % ** p 
Bone Mineral Density 0.1053 0.0942 -10.5 0.0002 0.0965 -8.3 0.005 
Data expressed as mean (SE); * = % change from Control; ** = vs. Control. 
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3.4.7. Figures 
BMD: Control vs. Atorva, Prava  
 Mean 
 ±SE 
C A P
0.092
0.094
0.096
0.098
0.100
0.102
0.104
0.106
0.108
B
M
D
3 
g/
cm
2
p = 0.04
p = 0.0002
 
Figure 3.4.1. The effect of atorvastatin 2,5mg/Kg/day (A) and pravastatin 
10mg/Kg/day (P) on BMD compared to the control group (C). 
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3.4.8. Discussion 
The discussion of these results will follow in Chapter 4. 
3.4.9. Conclusions 
The following conclusion were made after the completion of the study:- 
• Both atorvastatin 2.5mg/Kg/day and pravastatin produced marked and 
significant reductions in BMD compared to the untreated controls 
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Chapter 4: Discussion 
4.1. Validity of the rat model and the study results. 
These studies have shown that simvastatin 1mg/Kg/day, atorvastatin 
2,5mg/Kg/day and pravastatin 10mg/Kg/day decrease BMD, and that statins have a 
variable effect on QBH parameters of bone formation and resorption. However, some of 
these findings are in conflict with hypotheses stated at the start of the studies. Could these 
results have been the result of a methodological error?  
The studies were all performed in a standard fashion and under identical 
conditions. One rat in the S1 group died at nine weeks of unknown causes. No other 
illnesses amongst the rats were noted, they were otherwise healthy and there were no 
other deaths. The rats were randomly allocated between the different groups and there 
were no significant differences in the weights of the different groups. The rat feeds were 
adjusted to keep the weight of the all groups constant but despite this there was a modest 
weight gain by all the rat groups. The weight gain in the different groups was similar and 
there was no statistical difference in the weight gain between the different groups.  
The BMD of the same specimens was measured at two different accredited 
academic centres. The results obtained at these two centres were identical and did not 
differ statistically from each other. The BMDs at our centre were measured by a single 
experienced technologist who was blinded to the treatment groups of the rats. Similarly 
the technologist who performed the QBH was also blinded to the treatment group of the 
rats. Therefore bias at this level does not seem probable. 
Except for the treatment given, the methodology for all the groups was identical in 
all the studies. The results of the QBH and BMD obtained from the ovariectomised (OVX) 
and sham-operated rats (Sh) were also consistent with the expected findings of an 
ovariectomy model. The OVX rats showed the expected large and significant decrease in 
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BMD compared to the Sh rats. Additionally the OVX rats also showed the anticipated 
increase of bone turnover, with an increase in both bone formation and resorption 
compared to the Sh group supporting the validity of the model. Furthermore the effects of 
simvastatin 20mg/Kg/day on BMD and QBH in the sham-operated rats (Sh-S) were 
independently confirmed in a separate later study utilising simvastatin 20mg/Kg/day in 
intact rats (S20).  
From the histology there is also no reason to believe that the statins used in our 
study caused osteomalacia or an increase in bone marrow fat, known to result in an 
underestimation of BMD. Our data showing that the administration of statins was 
associated with a reduced BMD are convincing.  
4.2. Additional data supporting a statin effect on bones. 
Since the start and completion of our studies, further basic science and 
experimental data has become available to support the notion that statins will have an 
effect on bones and that bisphosphonates, like statins, inhibit prenylation [Luckman SP, 
Hughes DE et al., 1998]:- 
4.2.1. Bisphosphonates, prenylation and the effects on osteoclasts 
There is evidence that the ultimate target for bisphosphonates is the osteoclast 
and that these drugs inhibit the activity of, and cause apoptosis of, osteoclasts, and also 
inhibit osteoclastogenesis. [Rodan GA, 1998; Luckman SP, Coxon FP et al., 1998a] 
Indeed, the nitrogen-containing bisphosphonate, alendronate, inhibits the cholesterol 
synthetic pathway via inhibition of isopentenyl pyrophosphate isomerase/ 
farnesylpyrophosphate synthase, an enzyme two steps distal to HMG-CoA reductase. 
[van Beek ER, Pieterman E et al., 1999; Bergstrom JD, Bostedor RG et al., 2000; Dunford 
JE, Thompson K et al., 2001]   This inhibition has also been demonstrated for other 
nitrogen-containing bisphosphonates, namely zoledronic acid [Bergstrom JD, Bostedor 
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RG et al., 2000]   and risedronate [Green JR, 2001; Thompson K, Coxon FP et al., 2001; 
Coxon FP, Dunford JE et al., 2001; Benford HL, Frith JC et al., 1999] and has also been 
demonstrated in vivo. [Frith JC, Armour KJ et al., 2001]    
The effect of alendronate on osteoclasts can be prevented by the administration of 
geranylgeranylpyrophosphate and demonstrates that the inhibition of prenylation, and in 
particular the inhibition of geranylgeranylation, plays a major role in the inhibitory effect of 
alendronate on osteoclasts. [van Beek ER, Löwik C et al., 1999; Coxon FP, Helfrich MH et 
al., 2000; Fisher JE, Rogers MJ et al., 1999; Rogers MJ, Gordon S et al., 2000]   
Lovastatin and other statins can mimic the effects of alendronate on the osteoclast and 
this effect by statins can be reversed by the addition of geranylgeranylpyrophosphate but 
not farnesol - a clear indication that they prevent prenylation. [Fisher JE, Rogers MJ et al., 
1999; Frith JC, Armour KJ et al., 2001; Luckman SP, Hughes DE et al., 1998; van Beek 
ER, Löwik C et al., 1999; Woo JT, Kasai S et al., 2000]   Osteoclastogenesis can also be 
inhibited by alendronate and this effect can similarly be mimicked by statins. [Fisher JE, 
Halasy JM et al., 1998]   There are therefore various lines of evidence demonstrating a 
similarity between the effect of alendronate and statins via their inhibition of prenylation. 
[Woo JT, Kasai S et al., 1998; Woo JT, Kasai S et al., 2000] 
4.2.2. Bisphosphonates and apoptosis 
The apoptosis of osteoclasts induced by bisphosphonates and statins, is 
associated with protein synthesis as well as the appearance of a caspase-3 protease-like 
activity. [Coxon FP, Benford HL et al., 1998; Benford HL, Frith JC et al., 1999; Benford 
HL, McGowan NW et al., 2001; Reszka AA, Halasy NJ et al., 1999]  This rise in caspase-3 
protease activity gives rise to cleavage and activation of a Mst-1 kinase that results in the 
formation of a 34-kDa species that is associated with the apoptosis of osteoclasts. [Laufs 
U and Liao JK, 1998; Lim L, Manser E et al., 1996; Reszka AA, Wesolowski G et al., 
1998; Reszka AA, Halasy NJ et al., 1999]   The activation of these kinases by the 
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aminobisphosphonates can be reversed by the addition of geranylgeraniol as well as 
farnesol. [Benford HL, Frith JC et al., 1998; Benford HL, Frith JC et al., 1999]   However, 
these workers later show that the apoptosis of osteoclasts is prevented by inhibitors of 
geranylgeranylation but not by inhibitors of farnesylation, and they conclude that the 
apoptosis is mediated via a geranylgeranylation pathway. [Benford HL, McGowan NW et 
al., 2001]   Conversely and surprisingly, other workers show that geranylgeraniol induces 
caspase- 3-like activity. [Masuda Y, Nakaya M et al., 1997]   Clearly the last word on the 
effect of prenylation inhibitors such as alendronate and statins on the osteoclast has not 
been written. 
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4.2.3. Effects of statins on bone 
In the majority of the experiments demonstrating the role of prenylation in alendronate 
action, and investigating the effect of alendronate on bone, statins were used as controls. 
Osteoclast formation and activity was inhibited by both alendronate and lovastatin and this 
effect can be prevented by geranylgeranylpyrophosphate and mevalonate respectively. 
[Fisher JE, Rogers MJ et al., 1999]   The ability of statins to mimic the effect of 
alendronate on bone, and that this occurs via the inhibition of prenylation, has been 
demonstrated by some authors.  [Luckman SP, Hughes DE et al., 1998]   Other 
researchers show that a statin, compactin, clearly affects the osteoclast by inhibiting the 
fusion of pre-osteoclasts and by inhibiting the formation of an actin ring. [Woo JT, Kasai S 
et al., 2000]   They show that the dosage of compactin at which these effects are seen 
corresponds to the anti-resorptive dose of the compactin and that apoptosis of osteoclasts 
is not required for the anti-resorptive effect. They also show that the dose where these 
effects are seen is not the same as the dose where apoptosis of the osteoclast is 
observed. Consequently they show that the effects of compactin on the osteoclasts differs 
at different doses. Surprisingly they also show that these effects on osteoclast fusion and 
inhibition of the actin ring can be reversed by the addition of farnesol as well as 
geranylgeraniol whereas others show that certain effects of statins are only inhibited by 
geranylgeraniol. [Woo JT, Kasai S et al., 2000]   The implication, therefore, is that different 
doses of a statin might have different effects on the osteoclast and that different pathways 
may be involved in these processes.  
4.2.4. Bisphosphonates and statins in metastases 
Osteoclasts play a major role in some cancer metastases where the osteoclasts 
are stimulated by the local production of the tumor peptide, parathyroid hormone-related 
peptide. [Mundy GR, 1997]   The nitrogen-containing bisphosphonates, including 
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alendronate, are potent inhibitors of prenylation. [van Beek ER, Pieterman E et al., 1999]   
These agents are now frequently used as adjuvant therapy in oncology to inhibit 
metastases. [Body JJ, Bartl R et al., 1998]  Their inhibition of prenylation and inhibitory 
effect on malignant metastases raises the possibility that they might have an effect on 
Ras, another prenylated protein. [Luckman SP, Hughes DE et al., 1998]   However, 
although the aminobisphosphonates are potent inhibitors of osteoclast growth and 
differentiation, they mediate their effect on the osteoclasts by a mechanism other than via 
the inhibition of the oncogene Ras. [Coxon FP, Helfrich MH et al., 2000]   Statins are also 
able to inhibit cell growth, have been investigated as adjuvants in cancer chemotherapy 
[Fisher JE, Rogers MJ et al., 1999; van Beek ER, Löwik C et al., 1999]  and this anti-
proliferative effect involves prenylation of proteins other than Ras. [Bellosta S, Ferri N et 
al., 2000b; Soma MR, Corsini A, and Paoletti R, 1992]   This provides further evidence 
that the inhibition of prenylation affects cell growth by pathways other than those involving 
Ras. 
4.2.5. Effect of statins in vitro and in vivo 
At the time of the conclusion of our studies, it was demonstrated, largely by the 
Mudy group, that bone formation is increased by simvastatin and that this occurs via an 
increased production of bone morphogenic protein-2 (BMP-2) by osteoblasts. [Mundy G, 
Gutierrez G et al., 1998; Mundy G, Garrett R et al., 1999]   This led to a flurry of activity in 
this field. Unfortunately, this also led to numerous articles, not only in the lay press 
[1999b; 1999a]    but also in the scientific literature, suggesting that statins will increase 
BMD and that statins may be used for the treatment of osteoporosis or for the prevention 
of osteoporosis. None of the results in the scientific literature could support these claims. 
Mundy and his co-workers did not make these claims. They did not at that time produce 
any data regarding the effect of statins on BMD in the rats that they studied. [Garret IR, 
Esparza J et al., 2000; Garret IR, Gutierrez G et al., 2001; Garret IR, Chen D et al., 2001; 
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Garrett IR, Gutierrez G, and Mundy GR, 2001; Mundy G, Gutierrez G et al., 1998; Mundy 
G, Garrett R et al., 1999; Mundy GR, 2001]   Nonetheless, the work by Mundy et al.  is a 
landmark study and focussed attention on the effect of statins on bone.  
Further research done by Mundy and his co-workers confirmed that BMP-2 was 
involved in the effect of simvastatin on bone, and they also demonstrated that nitric oxide 
(NO) was involved in this process. [Garret IR, Esparza J et al., 2000; Garret IR, Chen D et 
al., 2001; Garrett IR, Gutierrez G, and Mundy GR, 2001; Whang K, Zhao M et al., 2000]   
The increase in BMP-2 caused by simvastatin has been confirmed by others [Sugiyama 
M, Kodama T et al., 2000]   who also demonstrated that this could be produced by 
compactin but not pravastatin, indicating a possible differential effect of statins on bone.  
The initial and subsequent work by Mundy et al. indicates that the effect of statins 
on the osteoblast is stimulatory. This occurs despite the inhibition of the small GTP 
binding protein Rho that is involved in cytoskeletal organisation. It would be expected that 
simvastatin may also have a stimulatory effect on other cells including osteoclasts but this 
effect not been demonstrated in other cells. Indeed the effect of statins on other cell 
lineages, including malignant cells, appears to be inhibitory. Statins have an inhibitory 
effect on various functions of macrophages. [Allen WE, Jones GE et al., 1997; Bellosta S, 
Ferri N et al., 2000a; Corsini A, 2000; Alfon J, Guasch JF et al., 1999]   Statins also have 
an inhibitory effect on mesangial cell function and proliferation. [Ghosh PM, Mott GE et al., 
1997; Ishikawa S, Kawasumi M, and Saito T, 1995; Kasiske BL, ODonnell MP et al., 1994; 
O'Donnell MP, Kasiske BL et al., 1993]   Mesangial cells and macrophages are polarised 
cells and belong to the same lineage as osteoclasts. Therefore, given the effect of statins 
on other cells of the same lineage, it would be expected that the inhibition of prenylation 
would have a similar inhibitory effect on osteoclasts. The question arises as to why the 
statins should stimulate the osteoblast and yet inhibit the osteoclast. In contrast to the 
above, we have clearly shown in more than one experiment that osteoclast function and 
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number is increased by simvastatin and also that the effect may be dosage dependent. To 
date these remain the only in vivo studies to specifically examine the effect of statins on 
different parameters of bone resorption. 
Other workers have demonstrated that in vitro, compactin suppresses osteoclast 
function by inhibiting pre-osteoclast fusion. [Woo JT, Kasai S et al., 1998; Woo JT, Kasai 
S et al., 2000; Woo JT, Krecic AM et al., 2000]   They demonstrate that this occurs via 
inhibition of actin ring formation and conclude that this is the result of lack of prenylation 
by the small GTP-binding proteins Rac and Rho. 
4.2.6. Effects on Rab proteins 
The above mechanisms all seem to involve prenylation of the small GTP-binding 
protein Rho. However, it is evident that other prenylated members of the Ras superfamily 
of small GTP-binding proteins, including Rab, may also be involved in bone turnover. 
Indeed it would be surprising if they were not involved in osteoclast function. Extensive 
intracellular vesicular trafficking is essential for the polarisation and bone resorbing 
activities of osteoclasts. It is therefore to be expected that the Rab proteins, intimately 
involved in vesicle targeting and trafficking [Kinsella BT and Maltese WA, 1991; Novick P 
and Zerial M, 1997]   will play an important role in the function of these cells. [Väänänen 
HK, 2001; Abu-Amer Y, Teitelbaum SL et al., 1999]   Rab-3 isoforms are expressed in 
bone marrow macrophages and their expression is enhanced by a variety of haemopoetic 
cytokines that promote the osteoclastic differentiation of these cells. [Abu-Amer Y, 
Teitelbaum SL et al., 1999; Väänänen HK, 2001]   Of note is that the Rab-3 co-localises 
with the H+ATPase or the vacuolar proton pump of osteoclasts. [Abu-Amer Y, Teitelbaum 
SL et al., 1999]  The involvement of other Rab proteins in osteoclast function has been 
demonstrated. Anti-sense nucleotides against Rab-7 have resulted in a reduction in the 
number of resorbing osteoclasts, and significantly inhibited osteoclastic bone resorption in 
vitro. [Zhao HB, Ettala O, and Väänänen HK, 2001]   
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The nitrogen-containing bisphosphonates, including risedronate, have been 
demonstrated to inhibit farnesylpyrophosphate synthase and to potently inhibit 
prenylation. [van Beek ER, Pieterman E et al., 1999]  As such they can also be expected 
to inhibit prenylation of Rab. An analogue of risedronate has been shown to be an inhibitor 
of GGTase II, a prenyl transferase that is intimately involved in the prenylation of Rab, and 
which is the only bisphosphonate tested that has this activity. [Coxon FP, Dunford JE et 
al., 2001; Coxon FP, Helfrich MH et al., 2001]    Although this bisphosphonate also weakly 
inhibits farnesylpyrophosphate synthase, it results in a selective loss of 
geranylgeranylation of Rab proteins The inhibition of Rab prenylation and the inhibition of 
Rab function by statins has previously been demonstrated. [Kinsella BT and Maltese WA, 
1992]   It is clear that Rab proteins play an important role in osteoclast function. Their 
inhibition might be an important method by which certain drugs, including statins, exert 
their effect on bone. 
The above data illustrate the similarities between the modes of action between the 
aminobisphosphonate and the statins.  The data also indicate that, although the effect of 
statins on osteoblasts is stimulatory, there is sufficient evidence to suggest that the effect 
of statins on osteoclasts should be inhibitory. However, there are many variables that may 
influence the effect of statins on bone and result in effects other than those indicated 
above. So it may be that under certain circumstances a statin may cause inhibition of the 
osteoblast and stimulation of the osteoclast. These variables include the type of statin 
used, the dosage of the statin used, the differential effects of nitric oxide on osteoblasts 
and osteoclasts, and the effects of statins on BMP-2. These additional signalling 
molecules and signalling pathways have received increasing attention in the control of 
bone metabolism. They have also been implicated in the mechanisms by which 
prenylation inhibitors and statins act on bone. These factors will be discussed in later 
paragraphs. 
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4.3. The demonstrated effect of statins on bone. 
4.3.1. Effect of statins on bone formation 
We have shown that simvastatin 20mg/Kg/day significantly affects parameters of 
bone turnover in non-ovariectomised rats. This was demonstrated in the sham-operated 
group (Sh-S) in the ovariectomy model (Fig. 3.1.2) and was reproduced in a further study 
using the same dose in intact rats (S20) (Fig. 3.2.2). QBH parameters of bone formation 
were increased and this is especially evident when looking at the percent change over the 
controls induced by simvastatin (Figs. 3.1.4 and 3.2.4).   
This increase in bone formation is supported by the work of Mundy and his co-
workers.  [Mundy G, Gutierrez G et al., 1998; Mundy G, Garrett R et al., 1999]   Their 
treatment with similar doses of simvastatin result in a 39% increase in trabecular bone 
volume in intact rats and a 25% to 94% dosage-dependant increase in trabecular bone 
volume in ovariectomised rats. An increase in new bone formation is induced by statins 
when added to neonatal murine calvarial bones in organ culture, as well as when injected 
into the subcutaneous tissue overlying murine calvaria. Furthermore, the effect of 
systemic administration of statins was investigated in ovariectomised and intact rats as 
measured by histomorphometric parameters. Simvastatin in dosages ranging from 
1mg/Kg/day to 10mg/Kg/day were reported, and these doses increase bone formation 
rate and trabecular bone volume. They also clearly demonstrate that simvastatin is able to 
activate the promoter region of the bone morphogenetic protein-2 (BMP-2) gene and 
increase the expression of BMP-2 mRNA in a specific fashion. [Mundy G, Garrett R et al., 
1999]   This effect on BMP-s is also demonstrated for mevastatin and fluvastatin. Of note 
is that they do not see any differences in the effects of the different statins. 
Mundy et al. state that they investigated the effect of simvastatin with doses up to 
50mg/Kg/day. [Mundy G, Garrett R et al., 1999]   Unfortunately the effect of these large 
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doses on bone are not reported. Also, the effect of simvastatin on the bone formation rate 
of their intact rats is also not reported.  
4.3.2. Effect of statins on bone resorption 
In addition to increasing bone formation, we have also shown an increase in 
parameters of bone resorption with many doses of simvastatin, and for more than one 
statin. This was demonstrated with the sham-operated group of the ovariectomy model 
(Sh-S) (Fig 3.1.3) and again reproduced in the intact rat group (S20) (Fig 3.2.3; Figs. 3.1.4 
and 3.2.4). This is in contrast to the work of Mundy et al. who found that osteoclast 
numbers were reduced. [Mundy G, Gutierrez G et al., 1998; Mundy G, Garrett R et al., 
1999]   Unfortunately they seem to indicate in their article that osteoclasts and their 
function were not completely assessed in their experiments. Where these figures are 
reported, they show that osteoclast numbers are decreased in the intact as well as the 
ovariectomised rats. As will be seen later, this is an important observation. They also 
comment that the effect on the osteoclasts seems to be minor in comparison with the 
effect on bone formation. [Mundy G, Garrett R et al., 1999]   The above findings of 
increased bone formation and resorption in our experiments apply only to simvastatin at a 
dose of 20mg/Kg/day. As will be shown later, at lesser doses different effects are 
observed on these parameters of bone metabolism. 
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4.3.3. Effect of statins on BMD 
We have also shown that three classes of statins, two lipophilic and one 
hydrophilic, decrease BMD. Our findings that statins decrease BMD are supported by our 
data that statins significantly increase bone resorption whereas effects on bone formation 
are modest.   
Very little in vivo research on statins and bone has been done in laboratory 
animals. One published study supports the hypothesis that statins will increase BMD. 
They looked at compressive strength of the vertebrae in rats and found that the 
compressive strength was increased in those rats treated with oral simvastatin 
10mg/Kg/day over 3 months. [Oxlund H and Andreasse TT, 2000]   A further study in 
laboratory animals indicates that a statin was not able to prevent the bone loss induced by 
ovariectomy in laboratory rats [Yao W, Li CY et al., 2001]   These researchers used doses 
of simvastatin ranging from 0.3mg/Kg/day to 10mg/Kg/day in ovariectomised rats and the 
results show there were no changes in the bone volume, bone formation rate and eroded 
surfaces. This supports our findings that simvastatin was not able to prevent the bone loss 
which occurs after ovariectomy and also supports our supposition that the effect of 
simvastatin on bone may require the permissive effect of oestrogens. Other researchers, 
however, using the same dose of simvastatin, 10mg/Kg/day, were able to demonstrate 
that simvastatin was able to prevent the bone loss induced by ovariectomy. [Jiang Y, Zhao 
Y et al., 2001]  Similarly, another group of researchers were able to demonstrate that 
simvastatin in similar and equivalent doses was able to partially prevent the bone loss 
after ovariectomy. [Jiang Y, Zhao Y et al., 2001; Masarachia PJ, Wesolowski G et al., 
2001]   Furthermore, they also demonstrate that atorvastatin 10mg/Kg/day was not able to 
prevent this bone loss in the same manner as simvastatin and suggests a possible 
differential effect of statins on bone similar to our findings.   
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In summary, it is evident from available data that statins affect bone, but that the 
effect seems to vary. What appears to be constant is that statins increase bone formation, 
whereas effects on bone resorption vary. These differences may be explained by 
differences in experimental design and certainly require more research. [Oxlund H, 
Dalstra M, and Andreassen TT, 2001] 
4.4. The effect of different doses of simvastatin on QBH parameters. 
We have shown, for the first time, that the effect of simvastatin on parameters of 
bone formation and bone resorption differs according to the dose of simvastatin 
administered.  
4.4.1. Different doses examined. 
Mundy et al. administered simvastatin in doses ranging from 1mg/Kg/day to 
50mg/Kg/day in their in vivo experiments. [Mundy G, Garrett R et al., 1999]   
Unfortunately, not all the results pertaining to the different doses are reported. In 
particular, no indication is given regarding the effect of the very large doses of simvastatin 
on the parameters of bone turnover. It would appear that the different doses of simvastatin 
were administered in different experiments and therefore no direct comparisons can be 
made between the effects of the different doses of simvastatin on the different parameters 
of bone turnover. No comparison is consequently available between the effect of the 
smallest simvastatin dose, 1mg/Kg/day, and simvastatin 50mg/Kg /day. Nonetheless, from 
the data there seems to be a big difference in the increase of bone volume between 
simvastatin 1mg/Kg/day and 10mg/Kg/day, the former being less than the latter. No 
comparable dataq exist for different different dosages of compactin, simvastatin and 
pravastatin, or any other statins. [Sugiyama M, Kodama T et al., 2000; Woo JT, Kasai S et 
al., 2000] 
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We have shown that with simvastatin 20mg/Kg/day (Sh-S, S20), bone formation is 
increased compared to the matching controls (Fig. 3.3.4; Table 3.3.1). Thereafter, with 
decreasing doses of simvastatin bone formation also decreases. With 10mg/Kg/day bone 
formation is suppressed, and is already less than the amount seen in the control group. 
This suppression of bone formation is further evident with smaller doses of simvastatin, 
5mg/Kg/day and 1mg/Kg/day. Our data also demonstrate that simvastatin increases bone 
resorption at a dose of 20mg/Kg/day (Fig. 3.3.6; Table 3.3.1). Thereafter bone resorption 
steadily decreases with decreasing doses of simvastatin. At 5mg/Kg/day bone resorption 
is clearly suppressed and is less than that seen in the control group. However, with 
simvastatin 1mg/Kg/day there is again an increase in parameters of bone resorption 
above the levels seen in the control group.  
4.4.2. Biphasic response 
It is clear from these results that there is a biphasic effect of simvastatin on both 
resorption and formation; at one dose there is an increase of bone formation and at 
another there is an inhibition of bone formation (and not merely a lesser increase of bone 
formation). A similar biphasic phenomenon is evident for the parameters of bone 
resorption. This is an important observation. There is no immediate precedent for this 
effect and it needs to be explained. Plausible explanations are offered in a later part of this 
chapter. 
It is true that the doses of simvastatin used in our studies do not go low enough, 
and do not follow back to the dose of simvastatin where there is no effect on the particular 
parameter of bone turnover. At the time that these studies were started, we had no idea 
what the minimum effective doses of simvastatin would be. Nonetheless, a dose response 
curve for the existing doses could be constructed (Study 3.3; Figs. 3.3.3., 3.3.6., 4.4.).  
4.4.3. Dose-response curves 
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Another way of looking at the data is to view the percent change over the control 
value of any parameter, or stated another way, the delta value expressed as a percent of 
the control. Considering the QBH parameters of formation, they all change in the same 
direction and in parallel for all the different doses of simvastatin (Fig 3.3.4). In addition, the 
percent changes for all the parameters of bone formation are nearly of the same 
magnitude - no parameter has a percent change that is dramatically more than the 
percent change of any other parameter for any particular dose. Therefore the mean 
percent change of all the formative parameters for any particular dose of simvastatin 
relatively accurately describes the percent change seen with any individual formative 
parameter at that particular dose. The same can be said for the QBH parameters of bone 
resorption Fig. 3.3.6). From these mean formative and resorptive values, a dose response 
curve for bone formation and for bone resorption can be constructed (Fig. 4.1.). It is 
evident that the dose-response curves for the QBH parameters of bone formation are not 
the same as the dose-response curves for bone resorption (Fig. 4.1.). As will be seen, this 
may have important implications for the BMD measured in these animals. 
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Figure 4.1. Dose response curve for the QBH parameters of formation and resorption. 
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These findings that different doses of statins have different effects on the 
parameters of bone formation and resorption will have important consequences for the 
interpretation of existing data. They will also have an important impact on the planning of 
future studies that aim to look at the effect of statins on bone health. 
4.5. The effect of different dosages of simvastatin on BMD  
We have clearly been able to show that the effect that simvastatin has on BMD 
differs with different doses of the drug. This is the first set of data to show this effect and is 
also the only study to have looked at this effect. 
In our studies the influence of simvastatin on the BMD in the non-ovariectomised 
rats differs with different doses of simvastatin. At a dose of 20mg/Kg/day simvastatin, 
there was a downward trend in the BMD in the groups treated with simvastatin (Sh-S, 
S20) compared to their controls (Sh, C) but this was not statistically significant. This 
suggests that simvastatin caused a balanced increase in both formation and resorption at 
this dose. Thereafter there was a progressive decrease in BMD with decreasing doses of 
simvastatin. At a dose of 1mg/Kg/day, simvastatin produced a significant reduction in 
BMD. This means that the largest reduction in BMD occurs with the smallest dose of 
simvastatin. 
When the changes in QBH parameters of formation and resorption that are 
induced by simvastatin 1mg/Kg/day, are considered together, then the resultant BMD 
induced by simvastatin 1mg/Kg/day can be qualitatively predicted; resorption is increased 
and formation is reduced, resulting in a reduction of BMD. The BMD measured at any 
particular dose of simvastatin can also be expressed as a percent change of BMD from 
control - put another way, the delta value expressed a percent of the control value.  In this 
way a dose-response curve for BMD is described.  
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It should be possible to predict the change in BMD from the summated influences 
of bone formation and bone resorption e.g. if formation and resorption were to be 
increased, but resorption were to outstrip formation, then the BMD would be predicted to 
decrease. Such a supposed predicted-effect curve can be constructed by summating the 
previously described dose percent-response curves for formation and resorption (Fig. 
4.3). This curve should then reflect the changes seen in BMD, at least qualitatively if not 
quantitatively.  Indeed, if this predicted change in BMD is compared to the actual percent 
change in the BMD (multiplied by 10 for graphical purposes) then there is a remarkable 
similarity between the two curves (Fig. 4.4.). The curves parallel each other and the 
predicted curve accurately reflects what did actually happen to the BMD.  
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Figure 4.2. Predicted change in BMD deduced from the summation of the 
formation and resorption dose %-response curves.  
The above method to describe the predicted BMD from the summation of the 
changes in the QBH parameters of formation and resorption has not been used before. 
Whether this is a valid method to describe the predicted change in BMD is debatable.  It 
also assumes that the effects on resorption and formation, which we assesses at weeks 8 
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and 12, remain unchanges throughout the entire study period. A 100% increase in the 
parameters of formation does not necessarily offset a 100% increase in resorption 
parameters and consequently lead to no change in the BMD. In this sense it cannot be 
used to quantitatively predict the resultant change in BMD. However, qualitatively it does 
give an indication regarding what should be happening to the BMD and from that point of 
view gives some kind of rough idea as to the accuracy of the findings. It is evident that in 
our studies, if not validly, then certainly serendipitously, this method did accurately predict 
the change in BMD that did occur.   
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Figure 4.3. The predicted change in BMD compared to the actual % change in 
BMD. 
 
4.6. Studies in humans  
At the time of the first announcement of their findings by Mundy et al. [Mundy G, 
Gutierrez G et al., 1998]   some data was presented outlining a meta-analysis of a large 
number of patients in two ongoing prospective studies, the Study of Osteoporotic 
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Fractures (SOF) and the Fracture Intervention Trial (FIT). [Bauer DC, Mundy G et al., 
1999]   The authors concluded that statin use was possibly associated with a higher BMD 
and a reduced fracture risk. They were able to show this for the more potent lipophilic 
statins, but not for pravastatin, and that this effect was not seen with non-statin lipid-
lowering drugs. Shortly thereafter, there was a flurry of reports on the same topic and to 
date there have been 23 studies which explored the hypothesis that statins will improve 
bone health. 
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4.6.1. Case controlled observational studies with fracture risk as endpoint 
Three studies were case-controlled observational studies which looked at the 
fracture risk as an endpoint in a large number of patients from UK-based General Practice  
Research Database (GPRD) [Meier CR, Schlienger RG et al., 2000], the Medicare and 
Medicaid Pharmacy assistance program [Wang PS, Solomon DH et al., 2000]   and six 
health maintenance programs in the USA.  [Chan KA, Andrade SE et al., 2000]   They all 
concluded that the use of statins was associated with a reduced fracture risk. Furthermore 
they were able to show that this reduced fracture risk was not conferred by the use of non-
statin lipid-lowering agents.  
Four further similar studies were unable to confirm an association between statin 
use and fractures. These studies looked at large numbers of patients from the Women's 
Health Initiative Observational Study, [LaCroix AZ, Cauley JA et al., 2000]   the GPRD 
database ( the same database as studied by Meier et al.) [van Staa TP, Wegman SLJ et 
al., 2000; van Staa TP, Wegman S et al., 2001b]   and two large statin and cardiovascular 
studies, the LIPID Study [Reid IR and Haugue W, 2000; Reid IR, Haue W et al., 2001]   
and the 4S study. [Pedersen TR and Kjekshus J, 2000]   These researchers conclude that 
statin use did not change the fracture risk in these patients.  
The results of these trials have been the source of much debate. It appeared to be 
strange that two studies looking at the same GPRD database found such diametrically 
opposite results [Meier CR, Schlienger RG et al., 2000; van Staa TP, Wegman S et al., 
2001b]   which remained even after re-analysis of different permutations of the data. [van 
Staa TP, Wegman S et al., 2001a]   These studies were subjected to further critique. 
[Cummings SR and Bauer DC, 2000; Hennessy S and Strom BL, 2001; Mundy GR, 2001]   
It is well known that an increased body mass is protective against fractures  [Barengolts 
EI, Karanouh D et al., 2001]   and that those subjects with the most unfavorable BMD 
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have a lower weight and a more favourable lipid profile, whereas those who are 
overweight tend to have dyslipidaemia, and consequently take statins, have the most 
favourable BMD. [Adami S, Braga V et al., 2001b; Adami S, Braga V, and Gatti D, 2001a] 
[Solomon DH, Finkelstein JS et al., 2001; Cauley JA, Jackson R et al., 2000]  Even 
allowing for the possible confounding effects of body mas index (BMI) in reanalyses, this 
made no difference to the conclusions drawn. [Hennessy S and Strom BL, 2001]   The 
study by Meier et al. [Meier CR, Schlienger RG et al., 2000]   found that short-term statin 
use, even after only 1 month, also conferred a reduced fracture risk and it is inconceivable 
how an anabolic agent like a statin could strengthen bones to this degree over such a 
short time. Nonetheless, a different meta-analysis was done on the 8 trials completed by 
this time and they concluded that the use of statins did confer protection against fractures. 
[Bauer DC, Black DM, and van der Klift M, 2001]   There has been some anecdotal 
evidence, that pravastatin does not affect bone metabolism and that many of the effects 
seen on bone with other statins are not seen with pravastatin. [Cauley JA, Jackson R et 
al., 2000; Watanabe S, Fukomoto S, and Takeuchi Y, 2000](Mundy G - personal 
communication, April 2001). If this is indeed so then it is not surprising that no protection 
against fractures was seen in the Lipid Trial as this cardiovascular trial utilised pravastatin. 
[Reid IR and Haugue W, 2000; Reid IR, Haue W et al., 2001] 
4.6.2. Studies with BMD as endpoint 
Although the above 8 trials all looked at fractures as the end-point, a further 
important study analysed both the fracture risk and measured the BMD in a large cohort 
from the Barwon Statistical Division in Australia. [Pascoe JA, Kotowicz MA et al., 2001]   
These authors find that the use of statins is associated with a small increase in BMD of 
the femoral neck only, and a decreased risk (odds ratio of 0.42) of sustaining a fracture. 
However, they conclude that this large decrease in fracture risk in statin users cannot be 
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explained by the modest increase in the femoral BMD. They advise that other reasons be 
sought for the reduction in the fracture risk.  
There are many reasons, other than an increase in BMD, why statin use could be 
associated with a reduced fracture risk. It is very likely that statins are prescribed to 
patients who are more likely to have a longer survival. Those patients who, for whatever 
reason or underlying illness, are unlikely to have a prolonged survival are less likely to 
receive a statin. These patients, due to their associated co-morbidities, are also more 
likely to be osteopaenic. There is therefore a bias for patients with healthier bones to 
receive statins.  
Fractures are related to falls, and falls in the elderly are frequently caused by 
transient cardiac dysrythmias precipitated by ischaemia or heart disease. Statins reduce 
these cardiac dysrythmias, improve transient ischaemia [van Boven AJ, Jukema JW et al., 
1996] and have been shown have to have a favourable affect on the QT dispersion, which 
plays a role in these arrythmias. [Mark L and Katona A, 2000]   Consequently, statin-users 
are less likely to fall from cardiac causes. Statins also have neuroprotective effects and 
may improve cognition in elderly patients. [Vaughan CJ and Delanty N, 1999]   The 
confounding effect of BMD has already been alluded to. There is also a likelihood that 
people who take statins regularly also start taking medications and other measures which 
reduce the fracture risk.  
The first study to look at the effect of statins on BMD rather than fracture risk, 
investigated the effect of statins on the BMD in type 2 diabetics. [Chung YS, Lee MD et 
al., 2000]   They were able to conclude that statin use was associated with a higher BMD. 
Seven further studies investigated the effect of statins on BMD. Four of these studies 
were able to show that statin use was associated with an increase in BMD compared to 
controls. [Barengolts EI, Karanouh D et al., 2001; Cauley JA, Jackson R et al., 2000; 
Edwards CJ, Hart DJ, and Spector TD, 2000; Watanabe S, Fukomoto S, and Takeuchi Y, 
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2000]   Of these, two showed that the use of pravastatin was not associated with any 
increase in the BMD. [Cauley JA, Jackson R et al., 2000; Watanabe S, Fukomoto S, and 
Takeuchi Y, 2000]   One of these studies measured biochemical markers of bone turnover 
in addition to the BMD, in a group of patients > 55 years of age. [Watanabe S, Fukomoto 
S, and Takeuchi Y, 2000]   These researchers show that 3 months of treatment with 
fluvastatin significantly decreased urinary N-terminal telopeptide (NTx) whereas 
pravastatin did not have an effect. Neither bone-specific alkaline phosphatase nor 
osteocalcin were affected by the statins used. Only the BMD of the lumbar spine, not the 
rest of the skeleton, was increased with fluvastatin, whereas BMD of the lumbar spine 
decreased with pravastatin. Furthermore they show that the effect of the statins is 
predominately seen in females. This is intriguing in that the effect was seen only in 
patients in whom estrogen was absent. The remaining 3 studies [Sirola J, Honkanen R et 
al., 2001; Solomon DH, Finkelstein JS et al., 2001; Yaturu S, Alferos MG et al., 2001] 
investigated the effect of statins on BMD in large groups of patients, including a cohort 
from the Kuopio Osteoporosis Risk Factor and Prevention Study in Finland [Sirola J, 
Honkanen R et al., 2001].  None of these studies were able to find any association 
between statin use and an increase in BMD. 
4.6.3. Studies investigating the effect on biochemical markers of bone turnover 
Six other studies investigated the effect of statins on biochemical markers of bone 
turnover. Salbach et al. found that atorvastatin decreased bone-type alkaline phosphatase 
in the first 3 days, which then returned to baseline by day 30. No effect was seen on 
osteocalcin or urinary carboxyterminal telopeptide (CTx). They also found that the effect 
was most pronounced in males - in contrast to a previous study. [Salbach P, Kreuzer J, 
and Seibel MJH, 2001]   Rejnmark et al. show that statin use is associated with 16% 
higher parathyroid hormone levels and that all the biochemical markers of bone turnover, 
namely osteocalcin, bone-type alkaline phosphatase and CTx, were decreased in statin 
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users. They conclude that statins reduce bone turnover. [Rejnmark L, Buus NH et al., 
2001]   Fluvastatin was investigated in another trial and was found not to influence 
biochemical markers of bone turnover. [Bjarnason NH, Shalmi M et al., 2000; Bjarnason 
NH, Riis BJ, and Christiansen C, 2001]   Whereas the patients included in the above 3 
trials were relatively small, Stein et al. measured the stored serum samples from a large 
cohort of patients who were included in a trial comparing the safety and lipid-lowering 
effect of 40mg to 80mg of simvastatin with 20mg to 40mg of atorvastatin. [Stein EA, 
Farnier M et al., 2001]   They found that simvastatin, but not atorvastatin, significantly 
decreased the bone-specific alkaline phosphatase in both males and females by 4% - 7% 
and that this appeared to be a dose-dependent effect with a greater reduction on 
simvastatin 80mg. Simvastatin caused a non-significant reduction in urinary CTx also with 
an apparent dosage effect. Atorvastatin had no effect on these biochemical markers. The 
authors remark that these effects are beneficial in those using simvastatin. However, 
these effects could equally be detrimental. Paradoxically, EA Stein has also stated that 
investigations into large databases of lipid-lowering trials involving simvastatin have 
shown no effect of simvastatin on alkaline phosphatase. (Personal communication, Sept 
1988, Cardiology Congress, Durban.) 
In contrast, a further prospective study on a small group of patients showed a 
significant increase in osteocalcin levels in those patients using simvastatin 20mg per day.  
No effect was seen on bone alkaline phosphatase, urine deoxypyridinoline and urinary 
NTx. [Chan MH, Mak TW et al., 2001]   Another well designed prospective randomised 
trial investigated the effect of cerivastatin 0.4mg per day on biochemical markers of bone 
turnover in patients over 12 weeks. [Cosman F, Nieves J et al., 2001]   These researchers 
measured osteocalcin, propeptide Type I procollagen, NTx and CTx and found no 
significant change in any parameter. 
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4.6.4. In summary. 
Overall, the studies in humans on fracture rate, BMD and biochemical markers of 
bone turnover show no consistent effect. They have no uniform design and many can be 
criticised for their poor execution. Furthermore, none of these studies confirm or refute, 
any of the data obtained in laboratory animals. This could mean that statins have differing 
effects on bone which differ according to the circumstances under which the study was 
performed, with variables, such as dose of the statin, the kind of statin, the bioavailability 
of the statin and concomitant medication all playing a role. We have already shown that 
the dose of the statin plays a role in the effect of statins on bone. Presumably this reflects 
the amount that reaches the bone/plasma interface and therefore means that 
bioavailability must also play a role. What is required is a large prospective trial, which is 
thoughtfully designed, specifically to explore the influence of statins on bone in humans.  
4.7. Mechanisms by which statins could affect bone 
We have clearly demonstrated that statins affect bone and mineral metabolism 
albeit in a complex manner. This supports  the work of others who have shown that 
simvastatin increases bone formation. [Mundy G, Gutierrez G et al., 1998; Mundy G, 
Garrett R et al., 1999]   Statins other than simvastatin also affect bone. [Cosman F, 
Nieves J et al., 2001; Gasser JA, 2001; Miller SC, Bowman BM, and Bagi C, 2001; 
Sato.M., Schmidt A et al., 2001]   The question arises, "By what mechanism do statins 
affect bone and mineral metabolism?".  
It would be wrong to group all the statins into this answer as there is reason to 
believe that some statins might behave in a different fashion from simvastatin. Our data 
and that of others pertain mostly to simvastatin. It is also quite possible that the 
biomolecular effect of statins on osteoblastic bone formation may differ from those seen 
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with osteoclastic bone resorption. Statins have been shown to have different effects on 
different cell lines. [Newman A, Clutterbuck RD et al., 1994] 
Although we stated in the preamble to our hypotheses that the effect of statins on 
bone would involve the inhibition of prenylation, we certainly have not proven this in our 
studies. The effect of statins on bone could have been as a result of the inhibition of HMG-
CoA reductase, thereby reducing the downstream components of the cholesterol synthetic 
pathway. Alternatively the effect of simvastatin on bone could have been due to a 
mechanism that has nothing to do with its inhibition of HMG-CoA reductase. It could have 
been due to another effect that has not become apparent, or it could even have been due 
to a toxic effect of the drug. 
There are no reports in the literature indicating a consistent toxic effect of 
simvastatin on rats at the doses used in our studies. There is also no reported data to 
indicate that the effects of statins on bone may due to a toxic effect. Although no other 
organ examinations were done in our rats, and apart from one unexplained death in one 
rat, our rats appeared to be healthy. A strong argument against a toxic effect is that the 
largest effect on BMD were seen with the smallest doses of simvastatin. 
Many receptors and proteins involved in signal transduction pathways are 
prenylated are therefore targets for prenylation inhibitors including statins. Simvastatin has 
been demonstrated to inhibit sterol synthesis and attenuate pregostrone secretion by 
human granulose cells. [van Vliet AK, van Thiel GC et al., 1996]   Given that the effect of 
simvastatin on bone in our experiments were the largest in non-ovariectomised rats, this 
raises the possibility that simvastatin may have caused hypogonadism. However, the 
oestrogen and rFSH levels of Study 3.1 clearly indicate that this is not the case (Table 
3.1.2.). 
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4.7.1. Multiplicity of effects 
Mundy and his co-workers confirm that simvastatin increases bone formation and 
demonstrated that this is due to an increase in BMP-2 production induced by the 
simvastatin. [Mundy G, Gutierrez G et al., 1998; Mundy G, Garrett R et al., 1999; Garret 
IR, Esparza J et al., 2000; Garret IR, Chen D et al., 2001; Gutierrez G, Garret IR et al., 
2001; Whang K, Zhao M et al., 2000; Garrett IR, Gutierrez G, and Mundy GR, 2001]   
They have demonstrated that it is the active form of simvastatin and not the inactive 
prodrug which stimulates bone formation, indicating that the inhibition of HMG-CoA is 
paramount in the process of stimulation of bone formation by simvastatin. [Garret IR, 
Esparza J et al., 2000; Garret IR, Chen D et al., 2001]   This was further confirmed by 
their finding that the process was inhibited by the addition of mevalonate or 
geranylgeranylpyrophosphate to their cell cultures. Because Rho is geranylgeranylated, it 
was supposed that Rho was involved and they could show that the process was blocked 
by the addition of the specific Rho inhibitor, Clostridium botulinium C3 transferase. They 
demonstrated that the bone formation was blocked by NOS inhibitors, indicating that NO 
signalling was important and also concluded that the eNOS activation was the result of 
Rho inhibition. The NO in turn leads to increased BMP-2 expression. In addition they 
convincingly showed that BMP-2 was essential in the process as the process did not take 
place in the presence of cells with inactive BMP-2 receptors. Lastly, BMP-2 leads to 
osteoblast differentiation and bone formation. [Garret IR, Esparza J et al., 2000; Garret IR, 
Chen D et al., 2001] 
 Since their initial publication, Mundy and his co-workers have also clearly 
confirmed that the inhibition of prenylation is involved in this process of stimulation of bone 
formation by simvastatin. [Garret IR, Esparza J et al., 2000]   This supports our initial 
hypothesis that simvastatin would affect bone metabolism via an inhibition of prenylation. 
However, the end result of the inhibited prenylation demonstrated by these researchers is 
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different from what we had hypothesised. We proposed that the inhibition of prenylation 
would inhibit Rho function in these bone cells.  This has clearly been confirmed by Mundy 
et al.. [Garret IR, Esparza J et al., 2000]   Based on previous research by others we 
further proposed that this inhibition of Rho function would lead to an inhibition of cell 
growth. [Burridge K and Chrzanowska WM, 1996; Hotchin NA and Hall A, 1996; Laufs U, 
Marra D et al., 1999; Lebowitz PF, Casey PJ et al., 1997; Olson MF, Ashworth A, and Hall 
A, 1995; Symons M, 1996]   What emanates from the work of Mundy et al. is that Rho 
inhibition causes, or is associated with, other effects such as an increase in NO 
production which is able to override the suppressive effect of Rho inhibition on cell growth 
and lead to stimulation of growth. If the effect on the osteoclast is similar, then it is quite 
conceivable that simvastatin shpuld stimulates osteoclastic bone resorption. This we have 
indeed demonstrated.  
From the studies by Mundy and his co-workers it is also clear that BMP-2 and 
nitric oxide (NO) are intimately, and possibly obligatorily, involved in mediating the effect 
of simvastatin on bone. A brief discussion of these mechanisms is warranted. 
4.7.2. Bone Morphogenetic Proteins 
Bone Morphogenetic Proteins (BMP) are cytoplasmic proteins found in 
chondrocytes, osteoblasts and osteoclasts. BMP-2 provides a tonic baseline control of the 
rate of bone remodeling by promoting osteoblast differentiation and also 
osteoblastogenesis. [Abe E, Yamamoto M et al., 2000]   This stimulatory effect of BMP-2 
on osteoblasts has been well established.  However in addition, BMP-2 also increases 
osteoclastogenesis and activates osteoclasts, possibly with the assistance of stromal 
cells. [Kanatani M, Sugimoto T et al., 1995]  
Simvastatin stimulates osteoblast numbers and bone formation via an increase in 
BMP-2 expression [Mundy G, Gutierrez G et al., 1998; Mundy G, Garrett R et al., 1999; 
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Garret IR, Chen D et al., 2001]   and this has been confirmed by other researchers. 
[Sugiyama M, Kodama T et al., 2000]  It has further been demonstrated that the effect of 
the statin on bone is mediated via inhibition of HMG-C0A reductase and also by the 
resultant inhibition of Rho. This is associated with an increase in eNOS expression, which 
in turn results in an increase in BMP-2 transcription. [Garret IR, Esparza J et al., 2000]   
These effects have been demonstrated, not only for simvastatin, but also for other statins 
such as compactin [Sugiyama M, Kodama T et al., 2000]   and lovastatin. [Garret IR, 
Esparza J et al., 2000]   However, these effects could not be demonstrated for hydrophilic 
pravastatin in vitro. [Sugiyama M, Kodama T et al., 2000]   This indicates that there might 
be a differential effect by statins on bone, possibly dictated by bioavailability and other 
properties of these drugs.  
Apart from increasing the expression of BMP-2, statins are able to induce other 
bone genes such as osteocalcin, alkaline phosphatase and osteopontin. [Carley W and 
Phan S, 2001]   It also appears as if different statins have different effects on the 
activation of the different bone genes; messenger RNA for osteocalcin, alkaline 
phosphatase, osteopontin and BMP-2 were increased by cerivastatin whereas only 
alkaline phosphatase and BMP-2 were increased by atorvastatin, and only BMP-2 and 
osteocalcin were increased by simvastatin. [Carley W and Phan S, 2001]   This suggests 
that there may be promoter thresholds that differ between statins. Mundy and his co-
workers found that simvastatin increased the expression of BMP-2 but not of BMP-4, 
interleukin-6 or of the parathyroid hormone (PTH)-related peptide, and they were of the 
opinion that the effects of statins were rather specific for the BMP-2 gene. [Mundy G, 
Garrett R et al., 1999]   Nonetheless, the question still arises whether the effect of statins 
on bone may not also, at least partially, be due to an effect on the promoter region of bone 
genes other than BMP-2.  
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It is clear therefore that statins have a profound effect on bone metabolism and 
that there seems to be a differential effect produced by the different statins. These 
differential effects may be the result of different effects of statins on signalling molecules 
such as BMP-2 and other bone gene products, or of differing chemical composition and 
half life resulting in differing concentrations reaching the bones. 
4.7.3. Nitric oxide signalling and the influence of caveolae. 
Nitric oxide (NO) is involved in several distinct signalling pathways in blood 
vessels:- 
• Endothelium-dependent vasodilation 
• Cytokine/endotoxin-induced vasodilation 
• Nerve-dependent vasodilation 
Nitric oxide is produced from arginine by a specific homodimeric enzyme, nitric 
oxide synthase (NOS)(Fig. 4.2.). [Knowles RG and Moncada S, 1992]   The above three 
processes that lead to vasodilation are partially the result of three distinct isoforms of 
NOS, which differ in the way that they are stimulated. Two of these NOS isoforms, those 
involved with endothelium-dependent (eNOS) and nerve-dependent vasodilation (nNOS), 
are constitutive and the NOS involved with cytokine-dependent vasodilation is inducible 
(iNOS). The NOS reaction produces NO from L-Arginine in a complex reaction which 
incorporates O2 into NO and citrulline, and utilises NADPH, FMN, FAD, 
tetrahydrobiopterin, non-haem iron. For the endothelial form of NOS, Ca++ and calmodulin 
are also required and essential. [Knowles RG and Moncada S, 1992] 
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Figure 4.4. Nitric oxide signalling. 
Endothelial NOS 
Endothelium-dependent vasodilation is the result of activation of the constitutive 
endothelial cell NOS (eNOS). Endothelium-dependent relaxation occurs in response to a 
wide variety of stimuli including acetyl choline, bradykinin, substance P, thrombin and 
adenine nucleotides. Binding of these ligands to their receptor leads to an influx of Ca++ 
and eNOS is activated by the increased Ca++ concentration (Fig. 1.10). [Knowles RG and 
Moncada S, 1992]   The calmodulin/Ca++ complex is involved in this process and directly 
activates eNOS. Nitric oxide, being a gas, is not contained to the cytoplasm but freely 
disperses, without the need for carrier proteins or receptor, to surrounding cells including 
vascular smooth muscle cells. The NO then stimulates guanilyl cyclase that converts GTP 
to cGMP, which in turn leads to relaxation of the vascular smooth muscle cell. [Mancini L 
and Brandi ML, 1999] 
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Induced NOS 
Cytokine-induced vasodilation differs in that the activation of NOS involved is not 
dependent on the concentration of Ca++. This process is mediated by a distinctly different 
and inducible isoform of NOS (iNOS) which in turn is induced by a variety of cytokines and 
endotoxin. Binding of these ligands to their receptors leads to an induction of iNOS and 
increased production of iNOS mRNA. The consequent increase in NO production leads to 
the same increase in cGMP and resultant vasodilation. Nitric oxide release also occurs in 
the central nervous system and at nerve ends and is the result of activation of another 
distinct NOS isoform, nNOS. The subsequent effects are the same as for the other 
systems. [Knowles RG and Moncada S, 1992] 
It is therefore evident that NO mediates its effects by more than one means. On 
the one hand NO activates an enzyme, namely guanilyl cyclase. Enzymes other than 
NOS that are not directly involved in vascular biology may also be activated in a similar 
fashion. On the other hand NO can, as in the case of BMP-2, also induce the transcription 
of proteins. Not only is the NO system operative in the cells of the vasculature but it has 
become evident that this signalling system is also present in other cells and plays a role in 
other organ systems including bone.  
NO and arterial health 
NO plays an important role in vascular physiology including the maintenance of 
vascular smooth muscle tone and many aspects of normal endothelial function. Abnormal 
endothelial function precipitated by various atherogenic insults is postulated to play an 
important role in atherogenesis. Nitric oxide has accordingly been stated to play a 
protective role in this respect. [Aengevaeren WR, 1999]   Experimentally, an inhibition of 
NO production is associated with enhanced atherosclerosis that is reversed when the NO 
production is again normalised. [Boger RH, Bode-Boger SM et al., 1997]   
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The statins have also been observed to have a beneficial effect on atherosclerosis 
and its consequences, which cannot be explained solely by their effect on blood lipids and 
LDL-C. [Sessa WC, 2001]   Numerous studies have demonstrated that statins increase 
eNOS activity, enhance the iNOS expression induced by cytokines and growth factors, 
and consequently increase NO production and the resultant effects thereof. [Chen H, 
Ikeda U et al., 2000a; Hernandez-Perera O, Perez-Sala D et al., 1998; Kaesemeyer WH, 
Caldwell RB et al., 1999; Laufs U, La Fata V et al., 1998; Mital S, Zhang X et al., 2000]   
Statins augment cerebral blood flow, reduce infarct size and neurological function when 
administered prophylactically in normocholesterolaemic mice. [Endres M, Laufs U et al., 
1998]   This effect prompted researchers, notably those from the Mundy group, to explore 
the effect of statins on bone and whether these  did not also involve NO. [Garret IR, 
Esparza J et al., 2000; Garret IR, Chen D et al., 2001; Garrett IR, Gutierrez G, and Mundy 
GR, 2001]   The effect of statins on eNOS expression is prevented if the cells are cultured 
in the presence of mevalonate or geranylgeranylpyrophosphate but not in the presence of 
farnesylpyrophosphate [Laufs U and Liao JK, 1998]   indicating that prenylation is 
important, and suggesting that the process is mediated via Rho prenylation. The 
involvement of Rho prenylation was later proven by elegant studies showing that eNOS 
expression could be increased by the Rho inhibitor Clostridium botulinum C3 transferase 
and also by dominantly negative RhoA mutants, whereas eNOS expression could be 
decreased by E. Coli cytotoxic necrotising factor-1, an activator of Rho. [Laufs U and Liao 
JK, 1998; Laufs U, Gertz K et al., 2000]   A major protective effect, or non lipid-modifying 
effect, of statins with respect to atherosclerosis has therefore been attributed to their 
enhancement of NO production.  
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NO and the cytoskeleton 
There is a profound interaction between the elements of the cytoskeleton on the 
one hand and NOS activity and NO production on the other hand. The states of the actin 
microfilaments influence L-arginine transport and can thereby increase NO production. 
[Zharikov SI, Sigova AA et al., 2001]   Inhibition of NO synthesis results in alterations of 
the endothelial cytoskeleton, which results in a venular leak of albumin. [Baldwin AL, 
Thurston G, and al NH, 1998]   Inhibition of Rho, either by inhibition of prenylation with the 
statin mevastatin, or directly by Clostridium botulinum C3 exoenzyme, results in an 
enhanced iNOS activity and NO production evoked by the inflammatory cytokines. 
[Muniyappa R, Xu R et al., 2000]  Therefore, Rho negatively regulates eNOS expression 
and activity. This effect of Clostridium botulinum exotoxin can be duplicated by statins via 
their inhibition of the geranylgeranylation of Rho that in turn inhibits Rho activity. [Laufs U 
and Liao JK, 1998; Hausding M, Witteck A et al., 2000]  Statins therefore increase NOS 
activity and increase NO production. Indeed, withdrawal of statin treatment leads to a 
transient rise in Rho activity that results in an up to 90% reduction in NO production. 
[Laufs U, Endres M et al., 2000]     
NO and osteoclasts 
The effects of NO are not limited to endothelial cells or vascular smooth muscle 
cells. The enhancement of NO production via increased eNOS or iNOS activity also 
extends to macrophages, those cells that play a pathogenic role in atherosclerosis. [Sumi 
D, Hayashi T et al., 2001; Chen H, Ikeda U et al., 2000b]   In addition mesangial cells, 
which also belong to the macrophage lineage, are affected by statins in a similar manner 
to macrophages. [Chen H, Ikeda U et al., 2000b]    Given these effects of NO on other 
cells of the macrophage lineage, it would be expected that osteoclasts would react in a 
similar fashion when exposed to NO.  
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Constitutive eNOS and iNOS have been identified in osteoclasts. [Alam AS, Huang 
CL et al., 1992]   Together with Ca++, NO has been identified as one of the local factors 
controlling osteoclastic resorption and it has been demonstrated to inhibit bone resorption. 
[Alam AS, Huang CL et al., 1992; Mancini L, Becherini L et al., 1997; Mancini L, Moradi-
Bidhendi N et al., 1998; Mancini L and Brandi ML, 1999]      Nitric oxide causes osteoclast 
detachment and contraction accompanied by a profound inhibition of bone resorption. 
[Brandi ML, Hukkanen M et al., 1995]  [Dong SS, Williams JP et al., 1999]    Others show 
that inhibition of NOS activity is associated with an increase in bone resorption. [Kasten 
TP, Collin-Osdoby P et al., 1994]   Consequently it is postulated that NO maintains a 
central control of bone resorption by exerting a tonic restraint on osteoclast number and 
activity. [Brandi ML, Hukkanen M et al., 1995]   Seemingly paradoxically, other 
researchers show that osteoclast generation is increased by cytokine-induced NO 
production from iNOS. NO may play an important role in certain pathologic conditions of 
bone. [Chae HJ, Park RK et al., 1997]   It seems therefore that NO has a biphasic effect 
on the osteoclast. 
NO and osteoblasts    
Osteoblasts are also affected by NO. Marked abnormalities of postnatal bone 
formation are found in eNOS knockout mice; they display reduced bone formation and 
volume which is due to impaired osteoblast function and which can be restored by an 
exogenous NO donor. [Aguirre J, Buttery L et al., 2001]   Mundy et al. have elegantly 
demonstrated that statins increase osteoblast activity via an increase of NO production. 
Unfortunately the origin of this increased production of NO has not been defined and 
could be from the osteoblasts themselves or from endothelial cells. The importance of NO 
in osteoblast differentiation has been demonstrated. [Afzal F, O'Shaughnessy M et al., 
2000]   These workers demonstrate that NO is required for proper differentiation and show 
that NO knockout mice have severe skeletal defects and that their osteoblasts have 
Chapter 5: Conclusions and future directions. 
 145
impaired chemotaxis. Other workers demonstrate in eNOS knockout mice that eNOS and 
NO are essential for osteoblast development, maintenance of BMD and the response to 
estrogen after ovariectomy.  
Osteoblasts themselves produce NO after stimulation by IL-1 alpha but not after 
exposure to other cytokines such as IL-1 beta, TNF-alpha or FN-gamma and also very 
little in the unstimulated state. Other researchers found that FN-gamma increased NO 
production by osteoblasts, and although IL-1 beta and TNF-alpha had a weak stimulatory 
effect on their own, they showed a strong synergy with NF-gamma. [Hukkanen M, Hughes 
FJ et al., 1995]   Cytokine-stimulated NO production by cytokines can occur via iNOS as 
well as eNOS. [Gallagher ME, van't Hof RJ et al., 2002]   This NO production by 
osteoblasts may play a role in the osteoblast-osteoclast interactions during inflammatory 
processes and the NO produced by osteoblasts acts as an important mediator of the 
effects of pro-inflammatory cytokines on bone. [Helfrich MH, Evans DE et al., 1997]   
Other researchers show that this cytokine-induced NO production by iNOS significantly 
suppresses osteoblast activity. [Hukkanen M, Hughes FJ et al., 1995]   An animal model 
of inflammation-induced osteoporosis that is associated with increased levels of NO 
production by iNOS, when compared to controls, was characterised by increased 
numbers of osteoclasts and decreased numbers of osteoblasts. These deleterious effects 
in the inflammation-induced osteoporosis model could be reversed by the administration 
of a NOS inhibitor. [Armour KE, Van'T HR et al., 1999]   It would appear therefore that NO 
has a variable effect on osteoclasts and osteoblasts depending on the amount of NO 
present, and biphasic responses induced by NO have been documented in numerous cell 
systems including osteoclasts. [Calabrese EJ, 2001]    This would be an explanation for 
the biphasic effect of bone formation and bone resorption in response to different doses of 
simvastatin documented by us.  
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In summary, it appears that both osteoblasts and osteoclasts low levels of NO are 
required for normal cell function and differentiation where high concentrations as found 
with the inflammatory response give rise to inhibition of cell activity and formation. [Brandi 
ML, 1999] 
It is of note that apart from the inflammatory cytokines, oestrogens and mechanical 
stress also stimulate NO production and this undoubtedly contributes to their effect on 
bone metabolism. [Ralston SH, 1997]   Given the strong influence of stains on NO 
production and the important effect that NO has on osteoclast and osteoblast function, NO 
might be the final common pathway for the effect of statins on bone. It is also quite 
possible that certain levels of NO production are able to override the suppressive effect of 
Rho inhibition on cell growth. It is clear that NO is an important molecule that mediates 
many effects on bone and its constituents and may therefore play a role in the genesis of 
various processes leading to osteopenia.  
4.7.4.  Inhibition of Rab proteins by Statins 
The effect of statins on bone might involve the inhibition of prenylation of other 
proteins including Rab. As has been mentioned before, an aminobisphosphonate has 
been developed which inhibits Rab prenylation selectively via the inhibition of 
geranylgeranyl transferase II. [Coxon FP, Helfrich MH et al., 2001; Coxon FP, Dunford JE 
et al., 2001]   Rab prenylation is therefore important for the function of bone cells. It has 
previously been shown that statins inhibit prenylation of Rab and it is quite possible that a 
similar process might be involved in the statin effect on bone.  
4.7.5.  Integrins 
As alluded to earlier, the effect of statins on bone might involve a process that has 
nothing to do with prenylation. In the introduction the importance of integrins in the 
activation of polarised and motile cells including osteoclasts was emphasised. [Burridge K 
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and Chrzanowska WM, 1996]   The blocking of the alpha(v)beta3 integrin of osteoclasts 
by the snake venom echistatin, which is an RGD containing disintegrin, prevents fusion of, 
as well as the function of, osteoclasts. [Nakamura I, Tanaka H et al., 1998]   Antisense 
oligodeoxynucleotide targeted against an integrin gene suppresses osteoclast function. 
[Villanova I, Townsend PA et al., 1999]   It is clear therefore that integrin function is 
important for osteoclast activity. Lovastatin has been shown to bind directly to a regulatory 
domain of leukocyte functional antigen, LFA-1, and consequently to prevent the 
conformational change of the integrin on binding with its ligand. [Frenette PS, 2001; Kallen 
J, Welzenbach K, and Ramage P, 1999; Weitz-Schmidt G, Welzenbach K, and Brinkmann 
V, 2001]   It is therefore quite plausible that statins might have a similar non-prenylation-
related effect on an osteoclast integrin. 
4.7.6. The effect of lipids on bone health 
It is known that statins have effects on the cardiovascular system that cannot be 
explained solely by their cholesterol-lowering effect, an effect referred to as the 
"pleiotropic effect of the statins". [Bellosta S, Bernini F et al., 1998]   Because statin use is 
always associated with a reduction in cholesterol, it is difficult to divorce the cholesterol 
lowering effect from the pleiotropic effects experimentally. Although there are plausible 
biomolecular mechanisms by which statins could affect bone cells, the question arises 
whether the effects of statins on bone could be mediated via a lowering of cholesterol per 
se. That this might be so was suggested some years ago. [Wang GJ, Chung KC, and 
Shen WJ, 1995]   These researchers investigated the effect of lipid clearing agents on 
steroid- induced osteoporosis in rabbits. They found that the statin lovastatin was able to 
prevent the steroid-induced bone loss of  the femoral head of these animals. They were 
also able to demonstrate this effect for bezafibrate. The fibrates had at that stage not been 
shown to share any of the pleiotropic effects of the statins. These studies were performed 
before the ideas surrounding the pleiotropic effects of statins had been formulated and 
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before peroxisome proliferation activated receptors (PPAR), nuclear receptors, were 
discovered. Superficially, the assumption at the time must therefore have been made that 
these bone sparing effects were mediated directly via an alteration of the serum lipid 
levels. However, it is now known that the fibrates, including bezafibrate, are PPAR-α 
agonists and able to bind and activate this receptor. In addition it has now been 
established that the statin-mediated inhibition of Rho is also able to activate PPAR-α. 
[Martin G, Duez H et al., 2001]   Therefore these drugs do partially share a common 
pathway involving Rho, which may be a plausible explanation for their effect on bone. 
Nonetheless, the question must be asked whether there are any biomolecular 
mechanisms by which an alteration in serum cholesterol levels could affect bone turnover 
or BMD. 
Links between lipids and bone health 
There are numerous links between atherosclerosis, dyslipidaemia [Parhami F, 
Morrow AD et al., 1997]   and osteopenia. [Barengolts EI, Berman M et al., 1998; Hak AE, 
Pols HA et al., 2000; Jie KG, Bots ML et al., 1996; Stulc T, Ceska R et al., 2000]   
Osteoporosis and atherosclerosis both increasingly occur in advanced years of life. The 
occurrence of osteoporosis and atherosclerosis in the same age group suggests that 
these two conditions may share pathogenic factors. Osteoporosis is associated with 
atherosclerosis and vascular calcification [Boukhris R and Becker KL, 1972; Barengolts 
EI, Berman M et al., 1998; Hak AE, Pols HA et al., 2000]  and this association has also 
been noted in South Africa. [Dent CE, Engelbrecht HE, and Godfrey RC, 1968]   There is 
also an association between osteoporosis and various risk factors for atherosclerosis. 
[Broulik PD and Kapitola J, 1993]   This association was thought to be purely due to age 
but other researchers have been able to demonstrate this association even when 
adjusting for age [Boukhris R and Becker KL, 1972]   while others have not been able to 
confirm this. [Vogt MT, San Valentin R et al., 1997]   Women with osteoporosis have a 
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greater risk for atherosclerosis than age-matched controls. [von der Recke P, Hansen MA, 
and Hassager C, 1999]   Patients with osteoporosis also have more severe 
atherosclerosis and higher lipid levels, [Barengolts EI, Berman M et al., 1998]   and have a 
greater risk for stroke death. [Uyama O, Yoshimoto Y et al., 1997]   It has been 
demonstrated that high lipid levels inhibit osteoblastic differentiation and that 
hyperlipidaemia is associated with a reduced BMD in mice. [Demer LL, 2001]   In humans 
a link between osteoporosis and lipid genotype has been established. [Hak AE, Pols HA 
et al., 2000]   However, these findings have not been consistent and other workers have 
found that males with the most favourable lipid profiles have the lowest bone mineral 
density and those with the most atherogenic lipid profiles have the best BMD. [Adami S, 
Braga V et al., 2001b] Statins are known to be able to cause regression of atherosclerosis 
[Corsini A, Pazzucconi F et al., 1998]   and this effect has also been demonstrated to 
occur with etidronate. [Zhu BQ, Sun YP et al., 1994]   Furthermore, there is evidence that 
steroid-induced osteoporosis [Wang GJ, Chung KC, and Shen WJ, 1995]   and other 
deleterious effects of steroids including suppression of osteoblast 
by steroids, and osteonecrosis, can be prevented by the use of statins. [Cui Q, Wang GJ 
et al., 1997] 
Similarities between bone and vascular tissue[Adami S, Braga V, and Gatti D, 2001a; Braga 
V, Gatti D et al., 2001] 
Bone and vascular tissue share many biomolecular and cellular features. [Parhami 
F, 2000]   The endothelial cells, pre-osteoblasts and monocyte-derived osteoclasts found 
in bone have been shown to have counterparts in atherosclerotic lesions. Osteopontin, 
bone morphogenetic protein, matrix Gla protein, collagen I, osteonectin, osteocalcin, nitric 
oxide, and matrix vesicles are found in both bone and atherosclerotic lesions. Both 
atherosclerotic lesions and bone recruit monocytic cells that ultimately form foam cells and 
osteoclasts respectively. The arterial wall contains cells that can differentiate into 
Chapter 5: Conclusions and future directions. 
 150
osteoblasts and go through the same stages of differentiation as bone osteoblasts and 
can produce bone mineral. [Parhami F, Morrow AD et al., 1997]   Oxidised lipoproteins are 
known to promote atherosclerosis and are also able to induce mineralisation in the vessel 
wall. [Parhami F, Morrow AD et al., 1997; Towler DA, Bidder M et al., 1998]   Somewhat 
paradoxically, these same oxidised lipids inhibit the osteoblastic differentiation of cells in 
bone. [Parhami F, Morrow AD et al., 1997]  
Therefore various lines of evidence indicate that there seems to be more than a 
casual relationship between osteoporosis and atherosclerosis. It would therefore not be 
inconceivable that the treatment of one of the risk factors of atherosclerosis, namely 
dyslipidaemia, might have an impact on the bone health. In particular, the common origin 
of circulating monocytes and osteoclasts suggests a common reaction or response to 
drugs used to prevent either atherosclerosis or osteoporosis. 
Role of caveolae 
It was previously thought that the treatment for dyslipidaemia resulted in a change 
of the lipid composition of the cell membrane and that this in some way affected the 
behavior of the cell. However, no explanations were ever given as to the mechanisms by 
which these membrane changes could affect signal transduction pathways from the cell 
surface to the cytoplasm or even the nucleus. Research into this field has yielded insights 
into possible ways in which the treatment of dyslipidaemia could affect signalling within 
cells including the endothelium and possibly even bone cells.  
Calmodulin and the protein caveolin play important roles in the regulation of NOS. 
[Kone BC, 2000]   Cells, including endothelial cells, have small cholesterol-rich 
invaginations of the plasma membrane called caveolae which also contain large amounts 
of the protein caveolin. Caveolae have been demonstrated to play an important role in 
signal transduction and also a role in endothelial function through their association with 
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NOS and NO production. [Fielding CJ, 2001; Kinlay S, Libby P, and Ganz P, 2001]   The 
caveolae contain and concentrate a number of signalling molecules in so-called lipid rafts; 
G protein-coupled receptors including muscarinic and bradykinin receptors,  protein 
kinases, and the transmembrane protein, caveolin. Caveolae are also intimately related to 
the cytoskeleton, which may thus contribute to transduction of signals mediated by NO. 
Endothelial nitric oxide synthase binds caveolin or calmodulin in a mutually exclusive 
manner. Caveolin inhibits eNOS and calmodulin activates eNOS. In the resting state 
eNOS is bound to caveolin and eNOS is consequently suppressed. When Ca++ enters the 
cells it binds to and activates calmodulin, which then promotes a dissociation of eNOS 
from caveolin. The Ca++/calmodulin complex then binds to eNOS and activates it. [Michel 
T and Feron O, 1997]    
The cellular free cholesterol content also regulates the functions of caveolar 
proteins, including caveolin. [Fielding CJ, 2001]   Hypercholesterolaemia and LDL 
cholesterol increase the synthesis of caveolin and its inhibitory binding to eNOS. [Feron 
O, Dessy C, and Moniotte S, 1999]   Consequently it is not surprising to find a reduced 
production of NO in the presence of hypecholesterolaemia. In addition, oxidant stress may 
decrease the number of caveolae. [Peterson TE, Poppa V, and Ueba H, 1999]   Statins 
have been shown to decrease caveolin expression and thereby to increase eNOS 
activation. [Feron O, Dessy C et al., 2001]   However, LDL cholesterol reverses this direct 
effect of statins on eNOS, suggesting that the inhibition of caveolin expression results 
primarily from the reduction of LDL-cholesterol. [Davis ME and Harrison DG, 2001]   
These effects on caveolae might be a further mechanism by which statins could have an 
influence on NO production via an alteration of LDL-C, not only in endothelial cells but 
also other cells, and consequently also dictate their behavior and growth. 
There is an additional mechanism by which altering the plasma cholesterol could 
affect  cells. Sterol regulatory element binding proteins (SREBP) are membrane bound 
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transcription factors that regulate the transcription of HMG-CoA reductase and other 
genes. [Brown MS and Goldstein JL, 1997; Brown MS and Goldstein JL, 1998]   SREBPs 
are released by a proteolytic mechanism that is regulated by the cellular sterol and 
cholesterol content, an effect that could therefore also be influenced by statins. SREBPs 
bind to sterol regulatory elements (SRE) and regulate the transcription of numerous gene 
products. These SREs play an important role in all cells including bone cells. 
There are therefore numerous mechanisms for which supportive evidence is 
available by which statins could affect the behaviour of cells. It may well be that more than 
one mechanism may be operative under certain circumstances and it may also be that 
one mechanism will override another mechanism under other circumstances. 
It has been proposed that the direct cholesterol-lowering effect of statins might 
play a role in the behaviour of bone cells. [Demer LL, ]   However, very little in the way of 
biomolecular mechanisms are offered to explain this effect. Differences in the chow 
administered to our rats and those of Mundy et al could have resulted in different LDL-
cholesterol levels in our animals that may then have affected bone cells differently.  
However, the work by Mundy et al appears to have been thorough and one must conclude 
that the explanation offered by them seems to be the most plausible.[Parhami F, 2000; 
Parhami F, Tintut Y et al., 2001] 
4.8. The biphasic effect 
We have been the first researchers to demonstrate a biphasic effect for statins on 
parameters of bone turnover. We have shown that the relatively large dose of simvastatin, 
20mg/Kg/day, increased parameters of bone formation. Conversely, the much smaller 
dose of simvastatin, 1mg/Kg/day, inhibited bone formation when compared to controls. Of 
note is that these smaller dose of simvastatin resulted in an inhibition of parameters of 
bone formation and not merely a lesser increase - conceptually an important point. 
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Similarly, simvastatin 20mg/Kg/day produced an increase of the parameters of bone 
resorption whereas smaller doses of simvastatin resulted in a decrease in these resorptive 
parameters when compared to their controls - again, an inhibition of resorption rather than 
merely a lesser increase. At the smallest dose of simvastatin, 1mg/Kg/day, the 
parameters of bone resorption again increased, resulting in a U-shaped curve.  
This initially seemed to be without precedent. However, other workers, while 
researching the effect of a bisphosphonate, EB-1053, on osteoclast function have 
unwittingly recorded a similar biphasic effect. The researchers concluded in their article 
that overall, this bisphosphonate inhibited osteoclast function. However, in the series of 
dosages that they tested, it is recorded that the smallest dose resulted in an increase in 
osteoclast function. [van der Pluijm G, Binderup L et al., 1992]   Unfortunately no further 
comment is made by the authors regarding this phenomenon. It seems more than 
coincidental that two different prenylation inhibitors, a statin and a bisphosphonate, result 
in similar biphasic response.  
4.8.1. Multiple signalling pathways 
The signalling pathways involved in the activation of polarised and motile cells are 
complex and multiple. (Fig. 1.9.) [Denhardt DT, 1996]   Amongst others, they involve 
multiple receptors, various second messengers, re-arrangement of the cytoskeleton and 
induction of growth factors such as BMP-2. In addition there is a substantial amount of 
cross-talk between the different signalling cascades. It is therefore conceivable that 
signalling down one pathway can be overridden in a dose-dependant fashion by signalling 
down another pathway that has an opposing effect. Indeed, this seems to be what is 
happening. Theoretically, if the prenylation of Rho is inhibited then this should lead to 
diminished Rho activity, which in turn should led to reduced osteoblast activity. However, 
this diminished Rho activity actually leads to the activation of the NO and BMP-2 
pathways which then stimulate the osteoblast. 
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4.8.2. The biphasic effect of NO signalling 
Research into NO signalling, including its effects on bone, has also offered another 
plausible explanation of the biphasic effect of statins on parameters of bone turnover. 
Cytokines combined with IFN-gamma result in a superinduction of NO synthesis that is 
largely responsible for the selective inhibitory effect of IFN-gamma on cytokine-induced 
bone resorption. [Evans DM and Ralston SH, 1996]   These high concentrations of NO are 
also inhibitory to osteoblasts and are partly responsible for the inhibitory action of 
cytokines on osteoblast proliferation. However, at lower doses the NO has different 
effects; moderate induction of NO increases bone resorption and promotes the 
proliferation of osteoblasts. [Evans DM and Ralston SH, 1996]   The bi-directional nature 
of NO signalling in the osteoclast has also been demonstrated; a basal production of NO 
is required for osteoclast differentiation while at higher doses osteoclast activity is 
inhibited. [Mancini L, Becherini L et al., 1997]   These biphasic effects of cytokine-induced 
NO production have been demonstrated by others. [Ralston SH, Ho LP et al., 1995; 
Ralston SH, 1997]   Mundy et al. have clearly shown that NO is involved in the effect of 
statins on bone. It is equally conceivable that different doses statin will produce different 
rates of production of NO and hence a biphasic effect as described above. Therefore the 
biphasic response noted by us has a plausible explanation which is based on sound 
research and further supports our findings. 
It is also clear that we did not study the smallest non-effective dose of simvastatin 
and did not follow the dose response curve back to where there would be not effect on 
bone. Had we done so we would have demonstrated a U-shaped dose response curve for 
BMD. Clearly these finding require an explanation.  
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4.8.3. Biphasic effect from signalling pathways with differing dose-response curves 
The presence of a U-shape dose-response curve implies that there are two 
different processes or signalling pathways, with different sensitivities, operative. In fact the 
BMD is the cumulative effect of two processes, namely bone formation and bone 
resorption. If the dose-response curves of these two processes differed, as indeed they 
have been demonstrated by us to do, then it is conceivable that one process could start 
working before the other has had time to exert its effect. We have clearly demonstrated 
that the dose response curves of bone formation and bone resorption differ from each 
other. It has also been demonstrated that different cell types have different sensitivities to 
statins. [Newman A, Clutterbuck RD et al., 1994] Accordingly, if osteoclasts were to be 
more sensitive to simvastatin then bone resorption would be the first to be stimulated at 
small doses of simvastatin (Figs. 4.5.).  
Dose
Effect
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dose-
response
curve.
Osteoblast
dose-
response
curve.
Zone 1: Osteoclastic
bone resorption
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osteoclast and
osteoblast activity
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Osteoblastic bone
formation
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Figure 4.5. The effect of differing dose response curves of 
bone turnover on BMD. 
At higher doses osteoblasts would also be stimulated and bone resorption would 
start balancing the effect of resorption. A dose would then be reached where resorption 
and formation are equally active and balance each other, resulting in no change in the 
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BMD. At higher dose still, a zone could be reached where formation outstrips resorption 
and the BMD would increase. This model fits and explains our data very well. Clearly the 
dose-response curve for simvastatin on BMD is the cumulative effect of the dose 
response of resorption and of formation and cannot logically be explained in any other 
way. Indeed this is the first time that this conceptual model has been used to explain the 
dose responses for the effect of drugs on BMD. There is no reason to believe that there 
will not be similar dosage effects in humans and a similar model would be important to 
interpret findings at a clinical level.  
4.9. Possible reasons for differences in results between studies. 
We think that there are not many, but certainly fundamental as they pertain to 
resorption, differences between the findings of our studies and those of Mundy et al. In 
both our studies simvastatin at doses of 10mg - 20mg were investigated and in both our 
studies an increase in parameters of bone formation were found. Therefore in this respect 
the results of the studies are not contradictory. Regarding bone formation, one of the 
differences between our studies is that we found a decrease in bone formation at the 
lesser doses of simvastatin whereas Mundy et al did not. However, Mundy et al. did not 
report any data relating to simvastatin at the very low doses used i.e. 1mg/Kg/day. 
Therefore our findings at these low doses are not strictly comparable with the findings of 
Mundy et al who report on the effect of higher doses. We also found varying results of 
bone resorption in response to different doses of simvastatin whereas Mundy et al. only 
state that bone resorption was decreased and provide very little in the way of data to 
illustrate this. Herein might be a further point of difference but again, the data is not truly 
comparable. There might be other reasons why these differences have been observed 
between our data and that of Mundy et al. 
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4.9.1. Differences in experimental animals 
The first factor, which might have made a difference between our studies, is the 
animals used in the studies. Mundy et al used male Swiss ICR white mice for their 
calvarial studies. In their studies exploring the effect of systemic simvastatin via oral 
gavage they used rats but do not comment on the type of rats used. We used female 
Sprague Dawley rats throughout our studies. Due to differences in size it would be 
expected that the metabolism of the animals will be different but unfortunately no literature 
could be found which directly compares the bone metabolism of mice and rats. Otherwise 
the age of the rats and the timing of the ovariectomy between the studies were not 
markedly different. The age of the rats in our studies and those of Mundy et al. was three 
months and therefore not different. Our rats started receiving simvastatin within 10 days of 
their ovariectomy or sham operation. Mundy et al. included groups of rats that received 
simvastatin within 7 days of their ovariectomy. Therefore it is unlikely that the type rats or 
the timing of the operative procedure would have made a difference to the findings in 
these studies. 
4.9.2. Duration of treatment 
The duration of treatment might have been important in explaining the differences 
in the results between the studies. Mundy et al administered the simvastatin orally for 35 
days whereas our rats were given simvastatin orally for 56 or 84 days. Although no data 
could be found to indicate that the duration of treatment with a statin makes any difference 
in the ultimate effect produced by the statin, this is certainly a possibility.  
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4.9.3. Differences in bioavailability 
We convincingly showed that different doses of simvastatin produce different 
effects on parameters of bone turnover and also on BMD. n effect the only difference 
between the rats receiving the different doses of simvastatin is the amount of statin that 
reaches the blood/bone interface. Therefore any factor which affects the amount of statin 
that reaches the bone will conceivably also have an influence on the effect of the statin on 
bone. Consequently, statins that bypass the first pass extraction by the liver, either due to 
systemic administration such as dermal application, or because of pharmacokinetic 
properties such as hydrophilicity, will have different concentrations that reach the 
plasma/bone cell interface. 
In our studies there were clear and marked differences in the parameters of bone 
turnover between the rats that received simvastatin versus the rats that served as controls 
and only received placebo. We can therefore categorically state that some unknown 
proportion of simvastatin was absorbed but we cannot be sure of the amount. We 
administered the simvastatin orally by dissolving it in vegetable oil and mixing it in the 
feeds of the animals. Feed supply was controlled to ensure that all drug was consumed 
every day. The first pass extraction of simvastatin by the liver exceeds 90% and therefore 
at best only 10% of the amount of simvastatin administered reached the systemic 
circulation. Furthermore, the admixture of the simvastatin with the vegetable oil and the 
feeds could further have reduced the bioavailability of the simvastatin so that the amount 
that ultimately reached the blood/bone interface could have been even less.  
On the other hand, in their ex vivo calvarial experiments Mundy et al injected 
simvastatin into the subcutaneous tissue overlying the calvaria of their mice and therefore 
exposing the underlying bone to relatively large doses of simvastatin. This could have 
important consequences on the ultimate effect on the underlying bone.  In reporting the 
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results of their later studies the actual method of administration of the statin by these 
researchers is not stated. [Garret IR, Esparza J et al., 2000; Garret IR, Chen D et al., 
2001; Garrett IR, Gutierrez G, and Mundy GR, 2001]   The group of Mundy has been 
looking at alternative methods for delivery of the statin to the bone interface. [Whang K, 
Zhao M et al., 2000]  They have also developed an alternative method of administering 
the statin for these rat studies, namely by dermal application. [Gutierrez G, Garret IR et 
al., 2001]   If this is the case then the amount of statin that reaches the blood/bone 
interface will be much higher than with oral administration. Dermal or subcutaneous 
administration bypasses the first-pass extraction by the liver and the amount of 
simvastatin that reaches the bone could be at least 10-fold higher than after oral 
administration. It may well be that the effective concentration of simvastatin at the 
plasma/bone interface in our studies differs substantially from that achieved in the 
experiments by Mundy et al - the concentrations that they achieve may be many orders of 
magnitude higher than what we achieved. 
4.9.4. Differences in lipid-lowering achieved by statins 
If we are to believe that the plasma lipid or cholesterol concentration directly 
influence parameters of bone turnover [Parhami F, Jackson SM et al., 1999; Parhami F, 
2000; Parhami F, Tintut Y et al., 2001]   then it is possible that there could have been 
different lipid contents in the chow fed to the animals in the experiments by ourselves and 
those of Mundy. Accordingly this could have led to different cholesterol concentrations in 
the respective laboratory animal which could in turn have influenced the parameters of 
bone turnover. As pointed out in an earlier chapter, we do not think that this explanation is 
plausible. 
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4.10. Effect of oestrogen 
We have clearly shown that simvastatin has little effect on BMD and parameters of 
bone resorption and formation in ovariectomised animals. More importantly, our studies 
have made it evident that simvastatin at the doses we used was not able to prevent the 
loss of BMD and the other QBH features of the oestrogen-deprived state. (Study 3.1; Fig. 
3.1.5). Unfortunately it does not seem as if Mundy et al. made this kind of comparison in 
their study. [Mundy G, Garrett R et al., 1999]   Other researchers have also shown that 
simvastatin was unable to restore the bone loss after ovariectomy as determined by NMD 
and QBH. [Gallagher ME, van't Hof RJ et al., 2002; Solomon DH, Finkelstein JS et al., 
2001; Yao W, Li CY et al., 2001]  These findings suggest that oestrogen might play some 
permissive role in the action of statins on bone metabolism. However, an 
aminobisphosphonate and a potent inhibitor of prenylation, zoledronic acid, was able to 
inhibit all the negative effects in bone associated with estrogen deficiency in laboratory 
animals. [Green JR, 2001]   Although statins may have caused a similar effect by causing 
hypogondadism, this has been excluded in our studies by the appropriate oestrogen and 
rFSH in the ovariectomised and intact rats. 
The statins are able to induce a G1 phase cell cycle arrest by interfering with the 
mitogenic activity of wide range of cells including cancer cells. [Addeo R, Altucci L et al., 
1996]   When the culture medium of oestrogen-responsive MCF-7 breast cancer cells is 
augmented by oestrogen, then the cell cycle arrest induced by lovastatin or simvastatin 
does not occur and the HMG-Co reductase activity and the prenylation pattern are not 
affected.  This effect of oestrogen can be blocked by steroidal and non-steroidal anti-
oestrogens and also does not occur in oestrogen receptor negative cells. [Addeo R, 
Altucci L et al., 1996; Bonapace IM, Addeo R et al., 1996]   In this instance oestrogen is 
needed, and is permissive for, this particular effect of statins. 
Chapter 5: Conclusions and future directions. 
 161
Lastly, other researchers have also shown that simvastatin in doses ranging from 
0.3 to 10mg/Kg/day and administered for 60 days failed to prevent osteopenia after 
ovariectomy. [Yao W, Li CY et al., 2001] This data supports our findings that statins do not 
protect against the osteopenia which occurs after ovariectomy.  
4.11.The effects of other statins. 
Most of the research done on bone with statins has involved the use of 
simvastatin. We have shown that two other statins, namely atorvastatin and pravastatin, 
also reduced BMD in our rat model. Lovastatin, mevastatin and fluvastatin have been 
investigated regarding their effect on QBH and have been shown to have the same results 
on bone as simvastatin. [Mundy G, Garrett R et al., 1999]   This is not entirely surprising 
as these statins used by Mundy and co-workers all have similar pharmacokinetic 
properties and bioavailabilities i.e. their absorption, half-lives, first pass extraction by liver, 
lipid-solubility and hence their volume of distribution are similar. 
However, as stated in the preamble to Studies 3.4 and 3.5, there is reason to 
believe that statins might not all behave in the same way. The statins all inhibit the 
cholesterol synthetic pathway via inhibition of hydroxymethylglutaryl CoA reductase but do 
have other effects which are often assumed to be shared by all via an assumed class 
effect. The chemical formulae of the statins differ markedly and they are often divided into 
the “natural” and “synthetic" statins” where simvastatin and pravastatin are classed as 
"natural" and atorvastatin classed as "synthetic. [Rosenson RS and Tangney CC, 1998]   
These dissimilarities may affect the way that they bind to target molecules other than 
hydroxymethylglutaryl CoA reductase, and consequently engender different properties to 
the various statins.  
The metabolism, bioavailability and consequently the amount of drug that reaches 
the bone/plasma interface differs between the statins. We have already demonstrated the 
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importance of the dosage of statin in determining the effect seen by that statin. The lipid 
soluble statins such simvastatin and atorvastatin will have a high first pass extraction by 
the liver, in the region of >90%. Conversely they easily cross the membranes of peripheral 
cells and therefore the small amount statin remaining after passing through the liver does 
not have much difficulty in penetrating and affecting peripheral cells. Pravastatin is 
hydrophilic and therefore does not cross membranes easily and consequently the first 
pass extraction by the liver is only in the region of 60%.  The larger amount of statin 
remaining after passage through the liver finds it relatively difficult, because of its 
hydrophilic characteristics, to cross the membranes of peripheral cells to exert an effect. 
[Corsini A, Bellosta S et al., 1999a; Desager JP and Horsmans Y, 1996]    
The half-life of most statins is in the order of 2 hours whereas atorvastatin has a 
half-life exceeding 18 hours. [Posvar EL, Radulovic LL et al., 1996; Cilla DD, Whitfield LR 
et al., 1996; Desager JP and Horsmans Y, 1996]   The administration of atorvastatin 
therefore results in continuously raised blood levels of the drug during the course of a 24 
hour day with no dips in the drugs levels; consequently cells are continuously exposed to 
the effect of the statin. This may be one of the reasons for the cholesterol-lowering 
potency of the drug. The other statins have therapeutic levels for only part of the day and 
there are long periods when cells are not under the influence of these drugs. The use of 
atorvastatin therefore amounts to continuous dosing, compared to micro-intermittent 
dosing with the use of the other statins. Differences in the effect of parathyroid hormone 
on bone have been noted when continuous dosing is used compared to intermittent 
dosing. Continuous dosing with PTH results in osteopenia whereas intermittent dosing 
with PTH is associated with an increase in bone mineral density. [Masiukiewicz US and 
Insogna KL, 1998]   Bearing in mind the number of important signalling systems that are 
impinged upon by the statins, particularly those utilising prenylated proteins which play a 
pivotal role in cell growth, differentiation and activation of cells, these differences in half-
life may have important consequences in different organ systems. 
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We have found that atorvastatin potently reduces BMD in our rat model. Although 
the studies were not designed to directly compare the effect of different types statins on 
BMD, the tests with the different equipotent cholesterol-lowering doses of atorvastatin, 
pravastatin and simvastatin were performed simultaneously and a comparison of the 
effect seen with different statins would not be totally invalid. The reduction of BMD seen 
with atorvastatin 2,5mg/Kg/day was of a much greater magnitude than the equipotent 
cholesterol-lowering dose of simvastatin 5mg/Kg/day. This suggests that there might be 
some differences in the way that these two statins affect bone. Atorvastatin has a greater 
effect on increasing fibrinogen levels when compared with simvastatin which is neutral. 
[Song JC and White CM, 2001; Rosenson RS and Tangney CC, 1998]   It has been 
shown that atorvastatin use leads to tachyphylaxis which has been ascribed to its long 
half-life and which has not been identified with other statins. [Cromwell WC and Ziajka PE, 
] 
It is therefore easy to understand that statins may differ in their effect on bones, as 
well as the mechanisms by which they achieve this. 
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 Chapter 5: Conclusions and future directions 
5.1. Conclusions. 
The following conclusions can be made from the studies 
• Statins affect bone and mineral metabolism 
• Statins, under certain circumstances, decrease BMD 
• The effect of simvastatin on parameters of bone turnover is dose-dependant 
• Simvastatin increases parameters of formation  at higher doses 
• Simvastatin decreases parameters of bone formation at lower doses 
• Simvastatin increases parameters of bone resorption  at higher doses 
• Simvastatin decreases parameters of bone resorption  at lower doses 
• Dose response curves of simvastatin for parameters of bone formation  and 
bone resorption  differ 
• Statins have very little effect in the absence  of estrogen 
• Statins are not able to prevent post-ovariectomy osteopaenia 
• Statins, other than simvastatin, namely atorvastatin and pravastatin, also 
reduce BMD. 
5.2. Future  directions. 
• A wider range of doses for simvastatin must be investigated i.e. smaller doses 
going back to a dose where there is no effect of the statin must be obtained. In 
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other words, a complete dose response curve for simvastatin should be 
obtained. Only in that way can we get a better picture of what happens to bone 
at different doses of the simvastatin. 
• The effect of different times of statin exposure must be investigated. It may be 
that the effect early during the exposure to the statin is different from effect 
obtained later during exposure. For a full understanding of the effect of statins 
on parameters of bone turnover and for the interpretation of different studies, it 
will be important to know whether the effect seen after a short time exposure is 
the same as a long exposure. The exposure time from 2 weeks to 12 weeks is 
suggested. 
• The experiments that have been done for simvastatin must also be repeated 
for other statins to determine the different ways that they affect bone health. 
• The effect of statins on bone in the presence and absence of estrogen must be 
investigated in more detail to determine what the interaction is between 
oestrogen and statins. 
• It is assumed that all the effect of the statins on bone are via the inhibition of 
prenylation and this has been confirmed by Mundy and his co-workers. 
However, there is a possibility that there may be more that one mechanism 
operative simultaneously. It would therefore be of use to see if the 
administration of farnesol or geranylgeraniol in vivo would be able to totally 
prevent the effects of statins on bone. Furthermore it would be important to see 
whether NO inhibitors in vivo can totally inhibit the effects of statins on bone 
and thereby also determine whether there are not other mechanisms by which 
statins have their effect on bones. 
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• Prospective studies using statins in humans with BMD and biochemical 
markers of bone turnover as endpoints are required to see what the effects if 
satins are on bone health in humans. Simultaneous QBH would be of great 
help but this is an invasive procedure and might not be acceptable to a large 
number of people.  
It is evident that statins have an effect on bone in laboratory animals and it is also 
clear that the effect of statins on bone in laboratory animals may under certain 
circumstance be detrimental. It is therefore important that further research be done to 
determine the extent of the effect of statins on bone both in the laboratory animals and 
humans. In the meantime, an automatic assumption that statins will increase BMD cannot 
be made and the assumption that these drugs will have a beneficial effect in the treatment 
of osteoporosis not warranted with the relative paucity of information available. Indeed, 
the available evidence suggests that there is a reasonable chance that statins may, under 
certain circumstance have a detrimental effect on bone health. 
 
 
Reference List 
 167
Reference List 
 
 1.  Consensus developement conference: diagnosis, prophylaxis and treatment of osteoporosis.  
Am J Med  1993; 94: 646-650. 
 2.   Cholesterol drugs restore bone. Associated Press. 3 December 1999. 
 3.   Drugs make no bones about it. Sunday Times, 12 December 1999. 
 4.  Abe E, Yamamoto M, Taguchi Y, Lecka-Czernik B, O'Brien CA, Economides AN, Stahl N, 
Jilka RL, Manolagas SC. Essential requirement of BMPs-2/4 for both osteoblast and 
osteoclast formation in murine bone marrow cultures from adult mice: antagonism by 
noggin.  J Bone Miner Res  2000; 15: 663-673. 
 5.  Abu-Amer Y, Teitelbaum SL, Chappel JC, Schlesinger P, Ross FP. Expression and regulation 
of RAB3 proteins in osteoclasts and their precursors.  J Bone Miner Res  1999; 14: 
1855-1860. 
 6.  Adami S, Braga V, Gatti D. Association between bone mineral density and serum lipids.  
JAMA  2001a; 286: 791-792. 
 7.  Adami S, Braga V, Zamboni M, Gatti D, Bakri J. Relationship between lipid profile and bone 
mass in healthy males. [Abstract]  Bone  2001b; 28 (Suppl): S194 
 8.  Adamson P, Marshall CJ, Hall A, Tilbrook PA. Post-translational modifications of p21rho 
proteins.  J Biol Chem  1992; 267: 20033-20038. 
 9.  Addeo R, Altucci L, Battista T, Bonapace IM, Cancemi M, Cicatiello L, Germano D, Pacilio C, 
Salzano S, Bresciani F, et al.  Stimulation of human breast cancer MCF-7 cells with 
estrogen prevents cell cycle arrest by HMG-CoA reductase inhibitors.  Biochem 
Biophys Res Commun  1996; 220: 864-870. 
 10.  Aengevaeren WR. Beyond lipids - the role of the endothelium in coronary artery disease.  
Atherosclerosis  1999; 147 (Suppl 1): S11-S16. 
 11.  Afzal F, O'Shaughnessy M, Nohadani RM, Huang PL, MacIntyre I, Polak JM, Buttery LD. 
Osteoblast Growth and Differentiation is Retarded in Endothelial Nitric Oxide 
Synthase Knockout Mice. [Abstract] J Bone Min Res  2000; 15(Suppl): S217. 
Reference List 
 168
 12.  Aguirre J, Buttery L, O'Shaughnessy M, Afzal F, Fernandez dM, Hukkanen M, Huang P, 
MacIntyre I, Polak J. Endothelial nitric oxide synthase gene-deficient mice 
demonstrate marked retardation in postnatal bone formation, reduced bone volume, 
and defects in osteoblast maturation and activity.  Am J Pathol  2001; 158: 247-257. 
 13.  Aktories K. Rho proteins: targets for bacterial toxins.  Trends Microbiol  1997; 5: 282-288. 
 14.  Alam AS, Huang CL, Blake DR, Zaidi M. A hypothesis for the local control of osteoclast 
function by Ca2+, nitric oxide and free radicals.  Biosci Rep  1992; 12: 369-380. 
 15.  Alexandrov K, Horiuchi H, Steele MO, Seabra MC, Zerial M. Rab escort protein-1 is a 
multifunctional protein that accompanies newly prenylated rab proteins to their target 
membranes.  EMBO J  1994; 13: 5262-5273. 
 16.  Alfon J, Guasch JF, Berrozpe M, Badimon L. Nitric oxide synthase II (NOS II) gene expression 
correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA 
reductase inhibitors.  Atherosclerosis  1999; 145: 325-331. 
 17.  Allen WE, Jones GE, Pollard JW, Ridley AJ. Rho, Rac and Cdc42 regulate actin organization 
and cell adhesion in macrophages.  J Cell Sci  1997; 110: 707-720. 
 18.  Alvarez DS, Andriantsitohaina R. Simvastatin and Ca(2+) signaling in endothelial cells: 
involvement of rho protein.  Biochem Biophys Res Commun  2001; 280: 486-490. 
 19.  Ando S, Kaibuchi K, Sasaki T, Hiraoka K, Nishiyama T, Mizuno T, Asada M, Nunoi H, 
Matsuda I, Matsuura Y. Post-translational processing of rac p21s is important both for 
their interaction with the GDP/GTP exchange proteins and for their activation of 
NADPH oxidase.  J Biol Chem  1992; 267: 25709-25713. 
 20.  Armour KE, Van'T HR, Grabowski PS, Reid DM, Ralston SH. Evidence for a pathogenic role 
of nitric oxide in inflammation-induced osteoporosis.  J Bone Miner Res  1999; 14: 
2137-2142. 
 21.  Armstrong SA, Hannah VC, Goldstein JL, Brown MS. CAAX geranylgeranyl transferase 
transfers farnesyl as efficiently as geranylgeranyl to RhoB.  J Biol Chem  1995; 270: 
7864-7868. 
 22.  Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with 
lovastatin and pravastatin.  Clin Pharmacol Ther  1998; 64: 369-377. 
Reference List 
 169
 23.  Baldwin AL, Thurston G, al NH. Inhibition of nitric oxide synthesis increases venular 
permeability and alters endothelial actin cytoskeleton.  Am J Physiol  1998; 274: 
H1776-H1784. 
 24.  Barengolts EI, Berman M, Kukreja SC, Kouznetsova T, Lin C, Chomka EV. Osteoporosis and 
coronary atherosclerosis in asymptomatic postmenopausal women.  Calcif Tissue In  
1998; 62: 209-213. 
 25.  Barengolts EI, Karanouh D, Kolodny L, Kukreja S. Risk Factors for Hip Fractures in 
Predominantly African-American Veteran Male Population.  J Bone Min Res  2001; 
16(Suppl): 1135. 
 26.  Bauer DC, Black DM, van der Klift M. Statin use and fracture: a meta-analysis of 8 
observational studies. [Abstract] Bone  2001; 28(Suppl): S89. 
 27.  Bauer DC, Mundy G, Jamel SA, Black DM, Cauley JA, Harris F, Duong T, Cummings SR. 
Statin use, bone mass and fracture: an analysis of two prospective studies. [Abstract] 
J Bone Min Res  1999; 14(Suppl.): S179. 
 28.  Beaird SL. HMG-CoA reductase inhibitors: assessing differences in drug interactions and 
safety profiles.  J Am Pharm Assoc  2000; 40: 637-644. 
 29.  Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, Fumagalli R, Paoletti R, 
Corsini A. Direct vascular effects of HMG-CoA reductase inhibitors.  Atherosclerosis  
1998; 137 Suppl: S101-S109. 
 30.  Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, Corsini A. Pleiotropic effects of statins in 
atherosclerosis and diabetes.  Diabetes Care  2000a; 23 Suppl 2: B72-B78. 
 31.  Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins.  Ann 
Med  2000b; 32: 164-176. 
 32.  Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgeraniol 
prevent activation of caspases by aminobisphosphonates: biochemical evidence for 
two distinct pharmacological classes of bisphosphonate drugs.  Mol Pharmacol  1999; 
56: 131-140. 
Reference List 
 170
 33.  Benford HL, Frith JC, Auriolo S, Monkonnen J, Rogers MJ. Farnesol and geranylgeraniol 
prevent activation of caspases by amino-bisphosphonates: Evidence for two distinct 
pharmacological classes of bisphonate drugs. [Abstract] Bone  1998; 23: S551-S551 
 34.  Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ. Visualization of 
bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro.  Bone  
2001; 28: 465-473. 
 35.  Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, 
nanomolar inhibitor of farnesyl diphosphate synthase.  Arch Biochem Biophys  2000; 
373: 231-241. 
 36.  Bjarnason NH, Riis BJ, Christiansen C. The effect of fluvastatin on parameters of bone 
remodeling.  Osteoporos Int  2001; 12: 380-384. 
 37.  Bjarnason NH, Shalmi M, Riis BJ, Christiaansen C. No Clinically Relevant Effect of Fluvastatin 
on Postmenopausal Bone Remodeling. [Abstract] J Bone Min Res  2000; 15(Suppl.): 
S427. 
 38.  Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors 
and the risk of cancer: a nested case-control study.  Arch Intern Med  2000; 160: 
2363-2368. 
 39.  Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, 
Paterson AH, et al.  Current use of bisphosphonates in oncology. International Bone 
and Cancer Study Group.  J Clin Oncol  1998; 16: 3890-3899. 
 40.  Boger RH, Bode-Boger SM, Brandes RP, Phivthong-ngam L, Bohme M, Nafe R, Mugge A, 
Frolich JC. Dietary L-arginine reduces the progression of atherosclerosis in 
cholesterol-fed rabbits: comparison with lovastatin.  Circulation  1997; 96: 1282-1290. 
 41.  Bokoch GM, Der CJ. Emerging concepts in the Ras superfamily of GTP-binding proteins.  The 
FASEB Journal  1993; 7: 750-759. 
 42.  Bonapace IM, Addeo R, Altucci L, Cicatiello L, Bifulco M, Laezza C, Salzano S, Sica V, 
Bresciani F, Weisz A. 17 beta-Estradiol overcomes a G1 block induced by HMG-CoA 
reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 
MAP kinases activation.  Oncogene  1996; 12: 753-763. 
Reference List 
 171
 43.  Boukhris R, Becker KL. Calcification of the aorta and osteoporosis.  JAMA  1972; 219: 1307-
1311. 
 44.  Braga V, Gatti D, Adami S, Adami. Association Between Lipid Profile and Bone Mass in 
Healthy Men.  J Bone Min Res   2001; 16 (Suppl.): F307-F307. 
 45.  Brandi ML. Nitric oxide and bone. European Calcified Tissue Society Reviews  1999;  
 46.  Brandi ML, Hukkanen M, Umeda T, Moradi-Bidhendi N, Bianchi S, Gross SS, Polak JM, 
MacIntyre I. Bidirectional regulation of osteoclast function by nitric oxide synthase 
isoforms.  Proc Natl Acad Sci U S A  1995; 92: 2954-2958. 
 47.  Broulik PD, Kapitola J. Interrelations between body weight, cigarette smoking and spine 
mineral density in osteoporotic Czech women.  Endoc Reg  1993; 2: 57-60. 
 48.  Brown MS, Goldstein JL. Multivalent feedback regulation of HMG CoA reductase, a control 
mechanism coordinating isoprenoid synthesis and cell growth.  J Lipid Res  1980; 21: 
505-517. 
 49.  Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by 
proteolysis of a membrane-bound transcription factor.  Cell  1997; 89: 331-340. 
 50.  Brown MS, Goldstein JL. Sterol regulatory element binding proteins (SREBPs): controllers of 
lipid synthesis and cellular uptake.  Nutr Rev  1998; 56: S1-S3. 
 51.  Burridge K, Chrzanowska WM. Focal adhesions, contractility, and signaling.  Ann Rev Cell 
Dev Biol  1996; 12: 463-518. 
 52.  Calabrese EJ. Nitric oxide: biphasic dose responses.  Crit Rev Toxicol  2001; 31: 489-501. 
 53.  Carley W, Phan S. Cerivastatin induces bone-specific gene-expression in stromal 
preadipocystes. [Abstract] Bone  2001; 28 (Suppl): S148. 
 54.  Carpenter CL, Tolias KF, Couvillon AC, Hartwig JH. Signal transduction pathways involving 
the small G proteins rac and Cdc42 and phosphoinositide kinases.  Adv Enzyme 
Regul  1997; 37: 377-390. 
Reference List 
 172
 55.  Cauley JA, Jackson R, Pettinger M, et.al. Statin use and bone mineral density (BMD) in older 
women: the Women's Health Initiative Observational Study. [Abstract] J Bone Min Res  
2000; 15(Suppl.): S155. 
 56.  Chae HJ, Park RK, Chung HT, Kang JS, Kim MS, Choi DY, Bang BG, Kim HR. Nitric oxide is 
a regulator of bone remodelling.  J Pharm Pharmacol  1997; 49: 897-902. 
 57.  Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz 
JH, LaCroix AZ, Platt R. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase 
and risk of fracture among older women.  Lancet  2000; 355: 2185-2188. 
 58.  Chan MH, Mak TW, Chiu RW, Chow CC, Chan IH, Lam CW. Simvastatin increases serum 
osteocalcin concentration in patients treated for hypercholesterolaemia.  J Clin 
Endocrinol Metab  2001; 86: 4556-4559. 
 59.  Chen H, Ikeda U, Shimpo M, Ikeda M, Minota S, Shimada K. Fluvastatin upregulates inducible 
nitric oxide synthase expression in cytokine-stimulated vascular smooth muscle cells.  
Hypertension  2000a; 36: 923-928. 
 60.  Chen H, Ikeda U, Shimpo M, Shimada K. Direct effects of statins on cells primarily involved in 
atherosclerosis.  Hypertens Res  2000b; 23: 187-192. 
 61.  Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA. HMG-CoA reductase inhibitors increase 
BMD in type 2 diabetes mellitus patients.  J Clin Endocrinol Metab  2000; 85: 1137-
1142. 
 62.  Cilla DD, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL. Multiple-dose pharmacokinetics, 
pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in 
healthy subjects.  Clin Pharmacol Ther  1996; 60: 687-695. 
 63.  Clark EA, King WG, Brugge JS, Symons M, Hynes RO. Integrin-mediated signals regulated by 
members of the rho family of GTPases.  J Cell Biol  1998; 142: 573-586. 
 64.  Cobos A, Jovell AJ, Garcia-Altes A, Garcia-Closas R, Serra-Majem L. Which statin is most 
efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.  
Clin Ther  1999; 21: 1924-1936. 
 65.  Corsini A. Fluvastatin: effects beyond cholesterol lowering.  J Cardiovasc Pharmacol Ther  
2000; 5: 161-175. 
Reference List 
 173
 66.  Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the 
pharmacodynamic and pharmacokinetic properties of statins.  Pharmacol Ther  
1999a; 84: 413-428. 
 67.  Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the 
pharmacodynamic and pharmacokinetic properties of statins.  Pharmacol Ther  
1999b; 84: 413-428. 
 68.  Corsini A, Pazzucconi F, Arnaboldi L, Pfister P, Fumagalli R, Paoletti R, Sirtori CR. Direct 
effects of statins on the vascular wall.  J Cardiovasc Pharmacol  1998; 31: 773-778. 
 69.  Cosman F, Nieves J, Zion M, Cruz J, Gordon S, Lindsay R. Effects of Short-term Cerivastatin 
on Bone Turnover.  J Bone Min Res  2001; 16(Suppl): SA415. 
 70.  Cox AD, Der CJ. Protein prenylation: more than just glue?  Curr Opin Cell Biol  1992; 4: 1008-
1016. 
 71.  Coxon FP, Benford HL, Russell RG, Rogers MJ. Protein synthesis is required for caspase 
activation and induction of apoptosis by bisphosphonate drugs.  Mol Pharmacol  1998; 
54: 631-638. 
 72.  Coxon FP, Dunford JE, Seabra MC, Ebetino FH, Luckman SP, Rogers MJ. Identification of a 
phosphonocarboxylate analogue of risedronate which inhibits geranylgeranyl 
transferase ii and selectively prevents prenylation of rab proteins in osteoclasts. 
[Abstract] Bone  2001; 28 (Suppl): S90. 
 73.  Coxon FP, Helfrich MH, Larijani B, Muzylak M, Dunford JE, Marshall D, McKinnon AD, Nesbitt 
SA, Horton MA, Seabra MC, et al.  Identification of a novel phosphonocarboxylate 
inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation 
in osteoclasts and macrophages.  J Biol Chem  2001; 276: 48213-48222. 
 74.  Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ. Protein 
geranylgeranylation is required for osteoclast formation, function, and survival: 
inhibition by bisphosphonates and GGTI-298.  J Bone Miner Res  2000; 15: 1467-
1476. 
 75.  Craig SW, Johnson RP. Assembly of focal adhesions: progress, paradigms, and portents.  
Curr Opin Cell Biol  1996; 8: 74-85. 
Reference List 
 174
 76.  Cremers FP, Armstrong SA, Seabra MC, Brown MS, Goldstein JL. REP-2, a Rab escort 
protein encoded by the choroideremia- like gene.  J Biol Chem  1994; 269: 2111-
2117. 
 77.  Cromwell WC, Ziajka PE. Development of tachyphylaxis among patients taking HMG CoA 
reductase inhibitors.  Am J Cardiol 2000 Nov 15 ;86 (10 ):1123 -7 86: 1123-1127. 
 78.  Cui Q, Wang GJ, Su CC, Balian G. The Otto Aufranc Award. Lovastatin prevents steroid 
induced adipogenesis and osteonecrosis.  Clin Orthop  1997; 8-19. 
 79.  Cummings SR, Bauer DC. Do statins prevent both cardiovascular disease and fracture?  
JAMA  2000; 283: 3255-3257. 
 80.  Daniels ED, Pettifor JM, Schnitzler CM, et al. Differences in mineral homeostasis, volumetric 
bone mass and femoral neck axis legnth in black and white South Africa women.  
Osteoporosis Int  1997; 7: 105-112. 
 81.  Dansette PM, Jaoen M, Pons C. HMG-CoA reductase activity in human liver microsomes: 
comparative inhibition by statins.  Exp Toxicol Pathol  2000; 52: 145-148. 
 82.  Davis ME, Harrison DG. Cracking down on caveolin: role of 3-hydroxy-3-methylglutaryl 
coenzyme A reductase inhibitors in modulating edothelial cell nitric oxide production.  
Circulation  2001; 103: 2-4. 
 83.  Demer LL. Boning up (or down) on statins.  Arterioscler Thromb Vasc Biol  2001; 21: 1565-
1566. 
 84.  Denhardt DT. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho 
proteins in the mammalian cell: the potential for multiplex signalling.  Biochem J  
1996; 318: 729-747. 
 85.  Dent CE, Engelbrecht HE, Godfrey RC. Osteoporosis of lumbar vertebrae and calcification of 
abdominal aorta in women living in Durban.  BMJ  1968; 4: 76-79. 
 86.  Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl- coenzyme 
A reductase inhibitors.  Clin Pharmacokinet  1996; 31: 348-371. 
 87.  Dineen LC, Blakesley LC. A generator for the sampling distribution of the Mann Whitney U 
statistic. Applied Statistics  1973; 22: 269-273. 
Reference List 
 175
 88.  Dong SS, Williams JP, Jordan SE, Cornwell T, Blair HC. Nitric oxide regulation of cGMP 
production in osteoclasts.  J Cell Biochem  1999; 73: 478-487. 
 89.  Doyle R. Lifestyle blues.  Scientific American  2001; 284: 30. 
 90.  Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, 
Rogers MJ. Structure-activity relationships for inhibition of farnesyl diphosphate 
synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing 
bisphosphonates.  J Pharmacol Exp Ther  2001; 296: 235-242. 
 91.  Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in 
postmenopausal women.  Lancet   2000; 355: 2218-2219. 
 92.  Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. Stroke 
protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by 
endothelial nitric oxide synthase.  Proc Natl Acad Sci U S A  1998; 95: 8880-8885. 
 93.  Evans DM, Ralston SH. Nitric oxide and bone.  J Bone Miner Res  1996; 11: 300-305. 
 94.  Farnier M. [The hyperlipidemias. Role of various statins].  Presse Med  1999; 28: 2002-2010. 
 95.  Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins.  Am 
J Cardiol  1998; 27: 3J-10J. 
 96.  Feron O, Dessy C, Desager JP, Balligand JL. Hydroxy-methylglutaryl-coenzyme A reductase 
inhibition promotes endothelial nitric oxide synthase activation through a decrease in 
caveolin abundance.  Circulation  2001; 103: 113-118. 
 97.  Feron O, Dessy C, Moniotte S. Hypercholesterolemia decreases nitric oxide production by 
promoting the interaction of caveolin and endothelial nitric oxide synthase.  J Clin 
Invest  1999; 103: 897-905. 
 98.  Fielding CJ. Caveolae and signalling.  Curr Opin Lipidol  2001; 12: 281-287. 
 99.  Fisher JE, Halasy JM, Masarachia PJ, Wesolowski G, Rodan GA, Reszka AA. Alendronate 
mechanism of action: Inhibition of osteoclatogenesis and bone resorption are 
mimicked by lovastatin and blocked by geranylgeraniol. [Abstract] Bone  1998; 23: 
S339-S339 
Reference List 
 176
 100.  Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, 
Russell RG, Rodan GA, Reszka AA. Alendronate mechanism of action: 
geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of 
osteoclast formation, bone resorption, and kinase activation in vitro.  Proc Natl Acad 
Sci U S A  1999; 96: 133-138. 
 101.  Fourie, J. and Steyn, K.  MRC Technical Report; 1995. 
 102.  Frenette PS. Locking a leukocyte integrin with statins.  NEJM  2001; 345: 1419-1421. 
 103.  Frith JC, Armour KJ, Feyen JHM, Rogers MJ. Statins Inhibit Protein Prenylation in Osteoclasts 
In Vivo.  J Bone Min Res  2001; 16(Suppl): M313. 
 104.  Gallagher ME, van't Hof RJ, Liew FY, Goedecke A, Ralston SH, Helfrich MH. Mechanism of 
Cytokine-Induced NO Production in Osteoblasts from iNOS Knockout Mice. [Abstract] 
J Bone Min Res  2002; 15(Suppl): S501. 
 105.  Garret IR, Chen D, Zhao M, Gutierrez G, Escobedo A, Horn D, Esparza J, Mundy G. Statin 
mediate bone formation by enhancing BMP2 expression. [Abstract] Bone  2001; 28 
(Suppl): S75. 
 106.  Garret IR, Esparza J, Chen D, Zhao M, Gutierrez G, Escobedo A, Horn D, Mundy G. Statins 
Mediate their Effects on Osteoblasts by Inhibition of HMG-CoA Reductase and 
Ultimately BMP-2. [Abstract] J Bone Min Res  2000; 15(Suppl): S225-S225. 
 107.  Garret IR, Gutierrez G, Chen D, Escobedo A, Horn D, Esparza J, Mundy GR. Statins 
Stimulate Bone Formation by Enhancing eNOS Expression.  J Bone Min Res  2001; 
16(Suppl): 1018. 
 108.  Garrett IR, Gutierrez G, Mundy GR. Statins and bone formation.  Curr Pharm Des  2001; 7: 
715-736. 
 109.  Gasser JA. Fluvastatin and Cerivastatin Are Not Anabolic for Bone After Local or Systemic 
Administration of Non-Toxic Doses in Mice and Rats.  J Bone Min Res  2001; 16 
(Suppl): SA412. 
 110.  Gauthier RC, Vignal E, Mériane M, Roux P, Montcourier P, Fort P. RhoG GTPase controls a 
pathway that independently activates Rac1 and Cdc42Hs.  Mol Biol Cell  1998; 9: 
1379-1394. 
Reference List 
 177
 111.  Germershausen JI, Hunt VM, Bostedor RG, Bailey PJ, Karkas JD, Alberts AW. Tissue 
selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in 
rats in vivo.  Biochem Biophys Res Commun  1989; 158: 667-675. 
 112.  Gerson RJ, MacDonald JS, Alberts AW, Kornbrust DJ, Majka JA, Stubbs RJ, Bokelman DL. 
Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-
coenzyme A reductase inhibitors.  Am J Med  1989; 87: 28S-38S. 
 113.  Ghosh PM, Mott GE, Ghosh CN, Radnik RA, Stapleton ML, Ghidoni JJ, Kreisberg JI. 
Lovastatin induces apoptosis by inhibiting mitotic and post-mitotic events in cultured 
mesangial cells.  Biochim Biophys Acta  1997; 1359: 13-24. 
 114.  Giancotti FG. Integrin signaling: specificity and control of cell survival and cell cycle 
progression.  Curr Opin Cell Biol  1997; 9: 691-700. 
 115.  Gibbs JB, Oliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.  
Annu Rev Pharmacol Toxicol  1997; 37: 143-166. 
 116.  Gotto AMJ. Results of recent large cholesterol-lowering trials and implications for clinical 
management [editorial].  Am J Cardiol  1997; 79: 1663-1666. 
 117.  Gómez J, Martínez AC, González A, Rebollo A. Dual role of Ras and Rho proteins: at the 
cutting edge of life and death.  Immunol Cell Biol  1998; 76: 125-134. 
 118.  Green JR. Chemical and biological prerequisites for novel bisphosphonate molecules: results 
of comparative preclinical studies.  Semin Oncol  2001; 28: 4-10. 
 119.  Grönroos E, Andersson T, Schippert A, Zheng L, Sjölander A. Leukotriene D4-induced 
mobilization of intracellular Ca2+ in epithelial cells is critically dependent on activation 
of the small GTP-binding protein Rho.  Biochem J  1996; 316: 239-245. 
 120.  Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, Diaz C, Hernandez G, 
Egido J. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation 
inhibitors induce apoptosis of vascular smooth muscle cells in culture.  Circ Res  
1998; 83: 490-500. 
 121.  Gutierrez G, Garret IR, Rossini G, Castano M, Chapa G, Escobedo A, Esparza J, Horn D, 
Qiao M, Taylor S, Lalka D, Mundy GR. Dermal Application of Lovastatin to Rats 
Causes Greater Increases in Bone Formation and Plasma Concentrations than when 
Reference List 
 178
Administered by Oral Gavage. [Abstract]  J Bone Min Res  2001; 15 (Suppl.): S427-
S427. 
 122.  Hak AE, Pols HA, van Hemert AM, Hofman A, Witteman JC. Progression of aortic calcification 
is associated with metacarpal bone loss during menopause: a population-based 
longitudinal study.  Arterioscler Thromb Vasc Biol  2000; 20: 1926-1931. 
 123.  Hall A. Rho GTPases and the actin cytoskeleton.  Science  1998; 279: 509-514. 
 124.  Hancock JF, Magee AI, Childs JE, Marshall CJ. All ras proteins are polyisoprenylated but only 
some are palmitoylated. [Abstract] Cell  1989; 57: 1167-1177. 
 125.  Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.  
Clin Pharmacokinet  2000; 39: 397-412. 
 126.  Hausding M, Witteck A, Rodriguez-Pascual F, von Eichel-Streiber C, Forstermann U, Kleinert 
H. Inhibition of small G proteins of the rho family by statins or clostridium difficile toxin 
B enhances cytokine-mediated induction of NO synthase II.  Br J Pharmacol  2000; 
131: 553-561. 
 127.  Helfrich MH, Evans DE, Grabowski PS, Pollock JS, Ohshima H, Ralston SH. Expression of 
nitric oxide synthase isoforms in bone and bone cell cultures.  J Bone Miner Res  
1997; 12: 1108-1115. 
 128.  Hennessy S, Strom BL. Statins and fracture risk.  JAMA  2001; 285: 1888-1889. 
 129.  Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, 
Diaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, 
atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric 
oxide synthase in vascular endothelial cells.  J Clin Invest  1998; 101: 2711-2719. 
 130.  Hotchin NA, Hall A. Regulation of the actin cytoskeleton, integrins and cell growth by the Rho 
family of small GTPases.  Cancer Surv  1996; 27: 311-322. 
 131.  Hughes AD. The role of isoprenoids in vascular smooth muscle: potential benefits of statins 
unrelated to cholesterol lowering.  J Hum Hypertens  1996; 10: 387-390. 
 132.  Hukkanen M, Hughes FJ, Buttery LD, Gross SS, Evans TJ, Seddon S, Riveros-Moreno V, 
MacIntyre I, Polak JM. Cytokine-stimulated expression of inducible nitric oxide 
Reference List 
 179
synthase by mouse, rat, and human osteoblast-like cells and its functional role in 
osteoblast metabolic activity.  Endocrinology  1995; 136: 5445-5453. 
 133.  Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors.  
Clin Ther  1994; 16: 366-385. 
 134.  Ishikawa S, Kawasumi M, Saito T. Simvastatin inhibits the cellular signaling and proliferative 
action of arginine vasopressin in cultured rat glomerular mesangial cells.  
Endocrinology  1995; 136: 1954-1961. 
 135.  Jiang Y, Zhao Y, Gutierrez G, Mundy GR, Garret IR, Genant HK. Effect of Simvastatin on 
Three-Dimensional Trabecular Architecture of Ovariectomized Rats.  J Bone Min Res  
2001; 16(Suppl): SA416. 
 136.  Jie KG, Bots ML, Witteman JC, Grobbee DE. Vitamin K status and bone mass in women with 
and without aortic atherosclerosis: a population-based study.  Calc Tissue In  1996; 
59: 352-356. 
 137.  Jones R; McClung A. Paul B Hoeber, editor.Handbook of Microscopic Technique. New York:  
1990. 
 138.  Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates 
endothelial nitric oxide synthase independent of its cholesterol-lowering actions.  J Am 
Coll Cardiol  1999; 33: 234-241. 
 139.  Kallen J, Welzenbach K, Ramage P. Structural basis for LFA-1 inhibition upon lovastatin 
binding to the CDa I-domain.  J Mol Biol  1999; 292-299. 
 140.  Kanatani M, Sugimoto T, Kaji H, Kobayashi T, Nishiyama K, Fukase M, Kumegawa M, 
Chihara K. Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell 
formation and bone-resorbing activity.  J Bone Miner Res  1995; 10: 1681-1690. 
 141.  Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of 
atorvastatin.  Clin Pharmacol Ther  1998; 64: 58-65. 
 142.  Kasiske BL, ODonnell MP, Kim Y, Atluru D, Keane WF. Cholesterol synthesis inhibitors inhibit 
more than cholesterol synthesis.  Kidney Int Suppl  1994; 45: S51-S53. 
Reference List 
 180
 143.  Kasten TP, Collin-Osdoby P, Patel N, Osdoby P, Krukowski M, Misko TP, Settle SL, Currie 
MG, Nickols GA. Potentiation of osteoclast bone-resorption activity by inhibition of 
nitric oxide synthase.  Proc Natl Acad Sci U S A  1994; 91: 3569-3573. 
 144.  Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ. Isoprenoid addition to Ras 
protein is the critical modification for its membrane association and transforming 
activity.  Proc Natl Acad Sci U S A  1992; 89: 6403-6407. 
 145.  Kawata S, Nagase T, Yamasaki E, Ishiguro H, Matsuzawa Y. Modulation of the mevalonate 
pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line 
(Hep G2).  Br J Cancer   1994; 69: 1015-1020. 
 146.  Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease.  Curr Opin Lipidol  
2001; 12: 383-389. 
 147.  Kinsella BT, Maltese WA. rab GTP-binding proteins implicated in vesicular transport are 
isoprenylated in vitro at cysteines within a novel carboxyl-terminal motif.  J Biol Chem  
1991; 266: 8540-8544. 
 148.  Kinsella BT, Maltese WA. rab GTP-binding proteins with three different carboxyl- terminal 
cysteine motifs are modified in vivo by 20-carbon isoprenoids.  J Biol Chem  1992; 
267: 3940-3945. 
 149.  Knowles RG, Moncada S. Nitric oxide as a signal in blood vessels.  Trends Biochem Sci  
1992; 17: 399-402. 
 150.  Koga T, Fukuda K, Shimada Y, Fukami M, Koike H, Tsujita Y. Tissue selectivity of pravastatin 
sodium, lovastatin and simvastatin. The relationship between inhibition of de novo 
sterol synthesis and active drug concentrations in the liver, spleen and testis in rat.  
Eur J Biochem  1992; 209: 315-319. 
 151.  Komai T, Kawai K, Tokui T, Tokui Y, Kuroiwa C, Shigehara E, Tanaka M. Disposition and 
metabolism of pravastatin sodium in rats, dogs and monkeys.  Eur J Drug Metab 
Pharmacokinet  1992; 17: 103-113. 
 152.  Kone BC. Protein-protein interactions controlling nitric oxide synthases.  Acta Physiol Scand  
2000; 168: 27-31. 
Reference List 
 181
 153.  Kranenburg O, Poland M, Gebbink M, Oomen L, Moolenaar WH. Dissociation of LPA-induced 
cytoskeletal contraction from stress fiber formation by differential localization of RhoA.  
J Cell Sci  1997; 110: 2417-2427. 
 154.  Kreck ML, Freeman JL, Abo A, Lambeth JD. Membrane association of Rac is required for high 
activity of the respiratory burst oxidase.  Biochemistry  1996; 35: 15683-15692. 
 155.  Kreck ML, Uhlinger DJ, Tyagi SR, Inge KL, Lambeth JD. Participation of the small molecular 
weight GTP-binding protein Rac1 in cell-free activation and assembly of the 
respiratory burst oxidase. Inhibition by a carboxyl-terminal Rac peptide.  J Biol Chem  
1994; 269: 4161-4168. 
 156.  LaCroix AZ, Cauley JA, Jackson R, et.al. Does statin use reduce risk of fracture in 
postmenopausal women? Results from the Women's Health Initiative Observational 
Study. [Abstract] J Bone Min Res  2000; 15(Suppl.): S155. 
 157.  Laufs U, Endres M, Custodis F, Gertz K, Nickenig G, Liao JK, Bohm M. Suppression of 
endothelial nitric oxide production after withdrawal of statin treatment is mediated by 
negative feedback regulation of rho GTPase gene transcription.  Circulation  2000; 
102: 3104-3110. 
 158.  Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, Endres M. Atorvastatin 
upregulates type III nitric oxide synthase in thrombocytes, decreases platelet 
activation, and protects from cerebral ischemia in normocholesterolemic mice.  Stroke  
2000; 31: 2442-2449. 
 159.  Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by 
HMG CoA reductase inhibitors.  Circulation  1998; 97: 1129-1135. 
 160.  Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA 
stability by Rho GTPase.  J Biol Chem  1998; 273: 24266-24271. 
 161.  Laufs U, Liao JK. Direct vascular effects of HMG-CoA reductase inhibitors.  Trends 
Cardiovasc Med  2000; 10: 143-148. 
 162.  Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors 
attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced 
down-regulation of p27(Kip1).  J Biol Chem  1999; 274: 21926-21931. 
Reference List 
 182
 163.  Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA. Farnesyltransferase inhibitors alter the 
prenylation and growth-stimulating function of RhoB.  J Biol Chem  1997; 272: 15591-
15594. 
 164.  Lerner EC, Hamilton AD, Sebti SM. Inhibition of Ras prenylation: a signaling target for novel 
anti-cancer drug design.  Anticancer Drug Des  1997; 12: 229-238. 
 165.  Lim L, Manser E, Leung T, Hall C. Regulation of phosphorylation pathways by p21 GTPases. 
The p21 Ras-related Rho subfamily and its role in phosphorylation signalling 
pathways.  Eur J Biochem  1996; 242: 171-185. 
 166.  Luckman SP, Coxon FP, Ebetino FH, Russel RGG, Rogers MJ. Molecular targets of nitrogen-
containing bisphosphonates. [Abstract] Bone  1998a; 23: S339-S339. 
 167.  Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ. Heterocycle-containing 
bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein 
prenylation: evidence from structure-activity relationships in J774 macrophages.  J 
Bone Miner Res  1998b; 13: 1668-1678. 
 168.  Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing 
bisphosphonates inhibit the mevalonate pathway and prevent post-translational 
prenylation of GTP- binding proteins, including Ras.  J Bone Miner Res  1998; 13: 
581-589. 
 169.  Maltese WA. Posttranslational modification of proteins by isoprenoids in mammalian cells.  
FASEB J  1990; 4: 3319-3328. 
 170.  Mancini L, Becherini L, Benvenuti S, Brandi ML. Bioeffects of a nitric oxide donor in a human 
preosteoclastic cell line.  Int J Clin Pharmacol Res  1997; 17: 93-96. 
 171.  Mancini, L. and Brandi, M. L. Nitric oxide and bone. European Calcified Tissue Society 1999 . 
1999. (GENERIC) Ref Type: Electronic Citation. 
 172.  Mancini L, Moradi-Bidhendi N, Brandi ML, MacIntyre I. Nitric oxide superoxide and 
peroxynitrite modulate osteoclast activity.  Biochem Biophys Res Commun  1998; 
243: 785-790. 
Reference List 
 183
 173.  Maritz FJ, Conradie MM, Gopal R, Hulley P, Hough FS. Statins increase bone formation and 
resorption, and decrease bone density in rodents. [Abstract] Journal of Endocrinology 
Metabolism and Diabetes of South Africa  2001; 6: 26-26. 
 174.  Maritz FJ, Conradie MM, Hulley P, Hough FS. The influence of an HMG-CoA reductase 
inhibitor on rat bones after ovariectomy. [Abstract] S Afr Med J  1999; 89: 478-478. 
 175.  Maritz FJ, Conradie MM, Hulley P, Hough FS. A comparison of the effect of equivalent doses 
of simvastatin, atorvastatin and pravastatin on bone mineral density in rodents. 
[Abstract] Journal of Endocrinology Metabolism and Diabetes of South Africa  2000a; 
5: 39-39. 
 176.  Maritz FJ, Conradie MM, Hulley P, Hough FS. Simvastatin increases bone formation and 
resorption in rodents. [Abstract] Journal of Endocrinology Metabolism and Diabetes of 
South Africa  2000b; 5: 39-39. 
 177.  Maritz FJ, Conradie MM, Hulley P, Hough FS. Statins increase bone formation and resorption, 
and decrease bone mineral density in rodents. [Abstract] Journal of Endocrinology 
Metabolism and Diabetes of South Africa  2000c; 5: 47-47. 
 178.  Maritz FJ, Conradie MM, Hulley P, Hough FS. Statins increase quantitative histomorphometric 
parameters of bone formation and resorption, and decrease bone density in rodents.  
Arterio Thromb Vasc Biol  2001; 21: 1636-1641. 
 179.  Mark L, Katona A. Effect of fluvastatin on QT dispersion: a new pleiotropic effect?  Am J 
Cardiol  2000; 85: 919-920. 
 180.  Martin G, Duez H, Blanquart C, Berezowsky C, Poulain P, Fruchart JC, Najib-Fruchart J, 
Glinear C, Staels B. Statin-induced inhibition of the Rho-signalling pathway activates 
PPAR alpha and induces ApoA1.  J Clin Invest  2001; 107: 1423-1432. 
 181.  Martin SS, Rose DW, Saltiel AR, Klippel A, Williams LT, Olefsky JM. Phosphatidylinositol 3-
kinase is necessary and sufficient for insulin-stimulated stress fiber breakdown.  
Endocrinology  1996; 137: 5045-5054. 
 182.  Masarachia PJ, Wesolowski G, Seedor JG, Weiss BL, Pennypacker MA, Gentile MA, Rodan 
GA, Kimmel DB. Effect of Statins on Bone Mass and Turnover in Ovariectomized 
Rats.  J Bone Min Res  2001; 16(Suppl): SA413. 
Reference List 
 184
 183.  Masiukiewicz US, Insogna KL. The role of parathyroid hormone in the pathogenesis, 
prevention and treatment of postmenopausal osteoporosis.  Aging (Milano )  1998; 10: 
232-239. 
 184.  Masuda Y, Nakaya M, Nakajo S, Nakaya K. Geranylgeraniol potently induces caspase-3-like 
activity during apoptosis in human leukemia U937 cells.  Biochem Biophys Res 
Commun  1997; 234: 641-645. 
 185.  Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors 
and the risk of fractures.  JAMA  2000; 283: 3205-3210. 
 186.  Merz WA, Schenk RK. Quantitative structural analysis of human cancellous bone.  Acta Anat  
1970; 75: 54-63. 
 187.  Michel T, Feron O. Nitric oxide synthase: which, where, how, and why.  J Clin Invest  1997; 
100: 2146-2152. 
 188.  Miller SC, Bowman BM, Bagi C. Cerivastatin increases some cancellous bone formation 
indices in OVX rats. [Abstract] Bone  2001; 28 (Suppl): S215. 
 189.  Mital S, Zhang X, Zhao G, Bernstein RD, Smith CJ, Fulton DL, Sessa WC, Liao JK, Hintze TH. 
Simvastatin upregulates coronary vascular endothelial nitric oxide production in 
conscious dogs.  Am J Physiol Heart Circ Physiol  2000; 279: H2649-H2657. 
 190.  Moores SL, Schaber MD, Mosser SD, Rands E, O'Hara MB, Garsky VM, Marshall MS, 
Pompliano DL, Gibbs JB. Sequence dependence of protein isoprenylation.  J Biol 
Chem  1991; 266: 14603-14610. 
 191.  Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. 
Stimulation of bone formation in vitro and in rodents by statins.  Science  1999; 286: 
1946-1949. 
 192.  Mundy G, Gutierrez G, Garret R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Robbins K, 
McKernan P, Gaspar S, Martinez T, West R, Durnam D. Identification of a new class 
of powerful stimulators of new bone formation in vivo; Clarification of mechanism of 
action, and use in animal models of osteoporosis. [Abstract] Bone  1998; 23: S183-
S183. 
 193.  Mundy GR. Mechanisms of bone metastasis.  Cancer  1997; 80: 1546-1556. 
Reference List 
 185
 194.  Mundy GR. Statins and their potential for osteoporosis.  Bone  2001; 29: 495-497. 
 195.  Muniyappa R, Xu R, Ram JL, Sowers JR. Inhibition of Rho protein stimulates iNOS expression 
in rat vascular smooth muscle cells.  Am J Physiol Heart Circ Physiol  2000; 278: 
H1762-H1768. 
 196.  Nakamura I, Tanaka H, Rodan GA, Duong LT. Echistatin inhibits the migration of murine 
prefusion osteoclasts and the formation of multinucleated osteoclast-like cells.  
Endocrinology  1998; 139: 5182-5193. 
 197.  Nass CM, Wiviott SD, Allen JK, Post WS, Blumenthal a. Global risk assessment for lipid 
therapy to prevent coronary heart disease.  Curr Cardiol Rep  2000; 2: 424-432. 
 198.  Newman A, Clutterbuck RD, Powles RL, Millar JL. Selective inhibition of primary acute 
myeloid leukaemia cell growth by lovastatin.  Leukemia  1994; 8: 274-280. 
 199.  Novick P, Zerial M. The diversity of Rab proteins in vesicle transport.  Curr Opin Cell Biol  
1997; 9: 496-504. 
 200.  O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. The mevalonate pathway: importance 
in mesangial cell biology and glomerular disease.  Miner Electrolyte Metab  1993; 19: 
173-179. 
 201.  Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell 
cycle progression through G1.  Science  1995; 269: 1270-1272. 
 202.  Oxlund H, Andreasse TT. Simvastatin given orally to adult rats increased the compressive 
stregnth of vertebral bodies. [Abstract] J Bone Min Res  2000; 15(Suppl.): S549. 
 203.  Oxlund H, Dalstra M, Andreassen TT. Statin given perorally to adult rats increases cancellous 
bone mass and compressive strength.  Calcif Tissue Int  2001; 69: 299-304. 
 204.  Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. 
Bone histomorphometry: Standardization of nomenclature, symbols and units. Report 
of the ASBMR Histomorphometry Nomenclature Committee.  J Bone Miner Res  
1987; 2: 595-610. 
 205.  Parhami F. Role of lipids in osteoporosis.  Arterio Thromb Vasc Biol  2000; 20: 2346-2348. 
Reference List 
 186
 206.  Parhami F, Jackson SM, Le V, Balucan JP, Tintut Y, Territo M, Demer LL. Atherogenic diet 
and minimally oxidized low density lipoprotein inhibit osteogenic and promote 
adipogenic differentiation of marrow stromal cells.  J Bone Min Res  1999; 14: 2067-
2078. 
 207.  Parhami F, Morrow AD, Balucan J, Leitinger N, Watson AD, Tintut Y, Berliner JA, Demer LL. 
Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell 
differentiation. A possible explanation for the paradox of arterial calcification in 
osteoporotic patients.  Arterio Thromb Vasc Biol  1997; 17: 680-687. 
 208.  Parhami F, Tintut Y, Beamer WG, Gharavi N, Goodman W, Demer LL. Atherogenic high-fat 
diet reduces bone mineralisation in mice.  J Bone Min Res  2001; 16: 182-188. 
 209.  Pascoe JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC. Association between Statin-
use, bone mass and fracture in Australian women: Geelong Osteoporosis Study. 
[Abstract] Bone  2001; 28 (Suppl): S73. 
 210.  Pedersen TR, Kjekshus J. Statin drugs and the risk of fracture. 4S Study Group.  JAMA  2000; 
284: 1921-1922. 
 211.  Peterson TE, Poppa V, Ueba H. Opposing effects of reactive oxygen species and cholesterol 
n endothelial nitric oxide synthase and endothelial cell activation.  Circ Res  1999; 85: 
29-37. 
 212.  Posvar EL, Radulovic LL, Cilla DD, Whitfield LR, Sedman AJ. Tolerance and 
pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA 
reductase, in healthy subjects.  J Clin Pharmacol  1996; 36: 728-731. 
 213.  Ralston SH. The Michael Mason Prize Essay 1997. Nitric oxide and bone: what a gas!  Br J 
Rheumatol  1997; 36: 831-838. 
 214.  Ralston SH, Ho LP, Helfrich MH, Grabowski PS, Johnston PW, Benjamin N. Nitric oxide: a 
cytokine-induced regulator of bone resorption.  J Bone Miner Res  1995; 10: 1040-
1049. 
 215.  Rao KN. The significance of the cholesterol biosynthetic pathway in cell growth and 
carcinogenesis (review).  Anticancer Res  1995; 15: 309-314. 
Reference List 
 187
 216.  Reid IR, Haue W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Shrarpe N. Effect of 
pravastatin on frequency of fracture in the LIPID study: secondary analysis of a 
rnadomised controlled trial. Long-tern intrvention with Pravastatin in Ischaemic 
Disease.  Lancet  2001; 357: 509-512. 
 217.  Reid IR, Haugue W. Effect of Pravastatin on Fracture Incidence in the Lipid Study: A 
Randomized Controlled Trial. [Abstract] J Bone Min Res  2000; 15(Suppl): S225. 
 218.  Rejnmark L, Buus NH, Vestergaard P, Andreasen F, Larsen ML, Mosekilde L. Decreased 
Bone Turnover in Postmenopausal Women Treated with Statins: A Cross-Sectional 
Study.  J Bone Min Res  2001; 16(Suppl): SA411. 
 219.  Reszka AA, Halasy NJ, Masarachia PJ, Rodan GA. Bisphosphonates act directly on the 
osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link 
between inhibition of the mevalonate pathway and regulation of an apoptosis-
promoting kinase.  J Biol Chem  1999; 274: 34967-34973. 
 220.  Reszka AA, Wesolowski G, Leu PJ, Masarachia PJ, Rodan GA. Osteoclast adhesion via a1b3 
integrin modulates activation of the apoptosis-related kinase Mst1. [Abstract] Bone  
1998; 23: S226-S226. 
 221.  Rodan GA. Mechanisms of action of bisphosphonates.  Annu Rev Pharmacol Toxicol  1998; 
38: 375-388. 
 222.  Rogers MJ, Chilton KM, Coxon FP, Lawry J, Smith MO, Suri S, Russell RG. Bisphosphonates 
induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent 
mechanism.  J Bone Miner Res  1996; 11: 1482-1491. 
 223.  Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular 
and molecular mechanisms of action of bisphosphonates.  Cancer  2000; 88: 2961-
2978. 
 224.  Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for 
cardiovascular event reduction [see comments].  JAMA  1998; 279: 1643-1650. 
 225.  Salbach P, Kreuzer J, Seibel MJH. Short-Term Treatment With Atorvastatin Does not Change 
Bone Turnover in Patients With Hypercholesterinemia: A Randomised, Controlled 
Study.  J Bone Min Res  2001; 16(Suppl): SA409. 
Reference List 
 188
 226.  Sasaki T, Takai Y. The Rho small G protein family-Rho GDI system as a temporal and spatial 
determinant for cytoskeletal control.  Biochem Biophys Res Commun  1998; 245: 641-
645. 
 227.  Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA. 
Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast 
ultrastructure.  J Clin Invest  1991; 88: 2095-2105. 
 228.  Sato.M., Schmidt A, Cole H, Smith S, Rowley E, Ma L. The skeletal efficacy of statins do not 
compare with low-dose parathyroid hormone. [Abstract] Bone  2001; 28 (Suppl): S80. 
 229.  Sessa WC. Can modulation of endothelial nitric oxide synthase explain the vasculoprotective 
actions of statins?  Trends Mol Med  2001; 7: 189-191. 
 230.  Siegel S. Non-parametric statistics for the behavioural sciences. New York: McGraw-Hill; 
1956. 
 231.  Sirola J, Honkanen R, Kroger H, Jurvelin J, Maenpaa P, Saarikoski S. Effects of HMG-CoA 
reductase inhibitors, statins, on bone loss: a prospective population-based cohort in 
early postmenopausal women. [Abstract] Bone  2001; 28 (Suppl): S220. 
 232.  Solomon DH, Finkelstein JS, Wang PS, Avorn J. Statin Lipid-Lowering Drugs and Bone 
Density.  J Bone Min Res  2001; 16(Suppl.): SA399. 
 233.  Solomon L. Bone density in aging Caucasian and African populations.  Lancet  1979; 44: 
1326-1330. 
 234.  Soma MR, Corsini A, Paoletti R. Cholesterol and mevalonic acid modulation in cell 
metabolism and multiplication.  Toxicol Lett  1992; 64-65 Spec No: 1-15. 
 235.  Song JC, White CM. Do HMG-CoA reductase inhibitors affect fibrinogen?  Ann Pharmacother  
2001; 35: 236-241. 
 236.  Stein EA, Farnier M, Waldstreicher J, Mercuri M. Effects of statins on biomarkers of bone 
metabolism: a randomised trial.   Nutr Metab Cardiovasc Dis  2001; 11: 84-87. 
 237.  Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia.  Am J 
Cardiol  1998; 81: 66B-69B. 
Reference List 
 189
 238.  Steyn K, Jooste PL, Bourne L, Fourie J, Badenhorst CJ, Bourne DE, Langenhoven ML, 
Lombard CJ, Truter H, Katzenellenbogen J. Risk factors for coronary heart disease in 
the black population of the Cape Peninsula. The BRISK study [published erratum 
appears in S Afr Med J 1996 May;86(5):572].  S Afr Med J  1991; 79: 480-485. 
 239.  Steyn K, Jooste PL, Langenhoven ML, Benadé AJ, Rossouw JE, Steyn M, Jordaan PC, Parry 
CD. Coronary risk factors in the coloured population of the Cape Peninsula.  S Afr 
Med J  1985; 67: 619-625. 
 240.  Stulc T, Ceska R, Horinek A, Stepan J. Hyperlipoproteinemia, the apo-E genotype and bone 
density.  Cas Lek Cesk  2000; 139: 267-271. 
 241.  Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S. Compactin and simvastatin, 
but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma 
cells.  Biochem Biophys Res Commun  2000; 271: 688-692. 
 242.  Sumi D, Hayashi T, Thakur NK, Jayachandran M, Asai Y, Kano H, Matsui H, Iguchi A. A 
HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other 
than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase 
and superoxide anion scavenging action.  Atherosclerosis  2001; 155: 347-357. 
 243.  Symons M. Rho family GTPases: the cytoskeleton and beyond.  Trends Biochem Sci  1996; 
21: 178-181. 
 244.  Takai Y, Kaibuchi K, Kikuchi A, Sasaki T, Shirataki H. Regulators of small GTPases.  Ciba 
Found Symp  1993; 176: 128-138. 
 245.  Tapon N, Hall A. Rho, Rac and Cdc42 GTPases regulate the organization of the actin 
cytoskeleton.  Curr Opin Cell Biol  1997; 9: 86-92. 
 246.  Thompson K, Coxon FP, Dunford JE, Ebetino FH, Rogers MJ. Identification of a 
bisphosphonate which inhibits fpp synthase and ipp isomerase. [Abstract] Bone  2001; 
28 (Suppl): S90. 
 247.  Towler DA, Bidder M, Latifi T, Coleman T, Semenkovich CF. Diet-induced diabetes activates 
an osteogenic gene regulatory program in the aortas of low density lipoprotein 
receptor-deficient mice.  J Biol Chem  1998; 273: 30427-30434. 
Reference List 
 190
 248.  Uyama O, Yoshimoto Y, Yamamoto Y, Kawai A. Bone changes and carotid atherosclerosis in 
postmenopausal women.  Stroke  1997; 28: 1730-1732. 
 249.  van Beek ER, Löwik C, van der Pluijm G, Papapoulos S. The role of geranylgeranylation in 
bone resorption and its suppression by bisphosphonates in fetal bone explants: a clue 
to the mechanism of action of nitrogen-containing bisphosphonates.  J Bone Miner 
Res  1999; 14: 722-729. 
 250.  van Beek ER, Löwik CW, Papapoulos SE. Effect of alendronate treatment on the 
osteoclastogenic potential of bone marrow cells in mice.  Bone  1997; 20: 335-340. 
 251.  van Beek ER, Pieterman E, Cohen L, Löwik C, Papapoulos S. Nitrogen-containing 
bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl 
pyrophosphate synthase activity with relative potencies corresponding to their 
antiresorptive potencies in vitro and in vivo.  Biochem Biophys Res Commun  1999; 
255: 491-494. 
 252.  van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJ, Lie KI, Bruschke AV. Reduction of 
transient myocardial ischemia with pravastatin in addition to the conventional 
treatment in patients with angina pectoris. REGRESS Study Group [see comments].  
Circulation  1996; 94: 1503-1505. 
 253.  van der Pluijm G, Binderup L, Bramm E, van der Wee-Pals L, De Groot H, Binderup E, Lowik 
C, Papapoulos S. Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-
bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo.  
J Bone Miner Res  1992; 7: 981-986. 
 254.  van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C. Statin drugs and the risk of 
fracture.  JAMA  2001a; 284: 1923. 
 255.  van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C. Use of statins and risk of 
fractures.  JAMA  2001b; 285: 1850-1855. 
 256.  van Staa TP, Wegman SLJ, de Vries F, et.al. Use of statins and risk of fracture. [Abstract] J 
Bone Min Res  2000; 15(Suppl.): S155. 
 257.  van Vliet AK, van Thiel GC, Naaktgeboren N, Cohen LH. Vastatins have a distinct effect on 
sterol synthesis and progesterone secretion in human granulosa cells in vitro.  
Biochim Biophys Acta  1996; 1301: 237-241. 
Reference List 
 191
 258.  Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke.  
Stroke  1999; 30: 1969-1973. 
 259.  Väänänen HK. Modulation of osteoclast function. [Abstract] Bone  2001; 28 (Suppl): S66. 
 260.  Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE. Metabolic disposition studies on 
simvastatin, a cholesterol-lowering prodrug.  Drug Metab Dispos  1990; 18: 138-145. 
 261.  Villanova I, Townsend PA, Uhlmann E, Knolle J, Peyman A, Amling M, Baron R, Horton MA, 
Teti A. Oligodeoxynucleotide targeted to the alphav gene inhibits alphav integrin 
synthesis, impairs osteoclast function, and activates intracellular signals to apoptosis.  
J Bone Miner Res  1999; 14: 1867-1879. 
 262.  Vogt MT, San Valentin R, Forrest KY, Nevitt MC, Cauley JA. Bone mineral density and aortic 
calcification: the Study of Osteoporotic Fractures.  J Am Geri Soc  1997; 45: 140-145. 
 263.  von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the 
menopause and cardiovascular mortality.  Am J Med  1999; 106: 273-278. 
 264.  Walker AR, Adam A, Küstner HG. Changes in total death rate and in ischaemic heart disease 
death rate in interethnic South African populations, 1978- 1989.  S Afr Med J  1993; 
83: 602-605. 
 265.  Wang GJ, Chung KC, Shen WJ. Lipid clearing agents in steroid-induced osteoporosis.  J 
Formos Med Assoc  1995; 94: 589-592. 
 266.  Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip 
fractures in elderly patients.  JAMA  2000; 283: 3211-3216. 
 267.  Watanabe S, Fukomoto S, Takeuchi Y. Effects of one year treatment with statins on bone 
mass and metabolism. [Abstract] J Bone Min Res  2000; 15(Suppl.): S194. 
 268.  Weitz-Schmidt G, Welzenbach K, Brinkmann V. Statins selectively inhibit leukocyte function 
antigen-1 by binding to a novel regulatory integrin site.  Nat Med  2001; 7: 687-692. 
 269.  Whang K, Zhao M, Oiao M, Rossini G, Horn D, Garret IR, Mundy G, Chen D. Administration of 
lovastatin locally in low doses in a novel delivery system induces prolonged bone 
formation. [Abstract] J Bone Min Res  2000; 15(Suppl): S225. 
Reference List 
 192
 270.  Wheeler DC. Are there potential non-lipid-lowering uses of statins?  Drugs  1998; 56: 517-522. 
 271.  Wolffenbuttel BH, Mahla G, Muller D, Pentrup A, Black DM. Efficacy and safety of a new 
cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and 
pravastatin, in subjects with hypercholesterolemia.  Neth J Med  1998; 52: 131-137. 
 272.  Woo JT, Kasai S, Stern PH, Nagai K. HMG-CoA reductase inhibitors reversibly inhibit fusion 
of mononucleated preosteoclasts and bone resorption by disrupting actin ring 
formation. [Abstract] Bone  1998; 23: S549. 
 273.  Woo JT, Kasai S, Stern PH, Nagai K. Compactin suppresses bone resorption by inhibiting the 
fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts.  J Bone 
Miner Res  2000; 15: 650-662. 
 274.  Woo JT, Krecic AM, Nagai K, Stern PH. The HMG-CoA Reductase Inhibitor, Compactin 
Reversibly Inhibits the Early Differentiation of Osteoclasts Induced by RANKL or 
TNFα . [Abstract] J Bone Min Res  2000; 15(Suppl): S512. 
 275.  Yao W, Li CY, Farmer RW, Chen JL, Mo A, Cooper R, Chmielewski P, Setterberg RB, Jee 
WSS, Lundy MW. Simvastatin Did Not Prevent Bone Loss In Ovariectomized Rats.  J 
Bone Min Res  2001; 16 (Suppl.): SA407. 
 276.  Yaturu S, Alferos MG, Deprisco C, Tynes J, Wade S. Statins and Bone Mineral Density.  J 
Bone Min Res  2001; 16(Suppl): SA408. 
 277.  Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional 
consequences.  Annu Rev Biochem  1996; 241-269. 
 278.  Zhao HB, Ettala O, Väänänen HK. Expression and function of small gtpases of rab family in 
bone-resorbing osteoclasts. [Abstract] Bone  2001; 28 (Suppl): S70. 
 279.  Zharikov SI, Sigova AA, Chen S, Bubb MR, Block ER. Cytoskeletal regulation of the L-
arginine/NO pathway in pulmonary artery endothelial cells.  Am J Physiol Lung Cell 
Mol Physiol  2001; 280: L465-L473. 
 280.  Zhu BQ, Sun YP, Sievers RE, Isenberg WM, Moorehead TJ, Parmley WW. Effects of 
etidronate and lovastatin on the regression of atherosclerosis in cholesterol-fed 
rabbits.  Cardiology  1994; 85: 370-377. 
Reference List 
 193
 281.  Zigmond SH. Signal transduction and actin filament organization.  Curr Opin Cell Biol  1996; 8: 
66-73. 
 
 
 
 
 
 
 
 
 
Study: 3.1.  The effect of simvastatin 20mg/Kg/day administered for 8 weeks, on bone mineral density and quantitative bone histomorphometry, in sham-operated and ovariectomised female Sprague-
Dawley rats. 
Appendix A 3.1         Page 193 
 Appendix A 3.1 
Study 3.1: Hard data, Descriptive statistics, Statistical analyses. 
 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Bone Mineral Density: Descriptive statistics ......................................................................................................................195 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Bone Mineral Density: Statistical analyses - Mann Whitney U-test ...................................................................................195 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Bone Mineral Density: Statistical analyses - ANOVA; All effects ......................................................................................196 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Bone Mineral Density: Statistical analyses - ANOVA; Differences between groups .........................................................196 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Descriptive statistics.................................................................................................................................................197 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Descriptive statistics.................................................................................................................................................198 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Descriptive statistics.................................................................................................................................................199 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Descriptive statistics.................................................................................................................................................200 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH:. Statistical analyses - Mann Whitney U-test.............................................................................................................201 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Statistical analyses - Mann Whitney U-test..............................................................................................................202 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Statistical analyses - Mann Whitney U-test..............................................................................................................203 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Statistical analyses - ANOVA; All effects .................................................................................................................204 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Statistical analyses - ANOVA; Between group analysis ..........................................................................................205 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Statistical analyses - ANOVA; Between group analysis ..........................................................................................206 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Statistical analyses - ANOVA; Between group analysis ..........................................................................................207 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Statistical analyses - ANOVA; Between group analysis ..........................................................................................208 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: BMD delta values. Descriptive statistics ............................................................................................................................209 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: BMD delta values. Statistical analyses - ANOVA; All effects ............................................................................................209 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: BMD delta values. Statistical analyses - ANOVA; Between group analysis......................................................................209 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Rat Weights. Descriptive statistics.....................................................................................................................................210 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Rat Weights. Descriptive statistics.....................................................................................................................................211 
 
 
Study: 3.1.  The effect of simvastatin 20mg/Kg/day administered for 8 weeks, on bone mineral density and quantitative bone histomorphometry, in sham-operated and ovariectomised female Sprague-
Dawley rats. 
Appendix A 3.1         Page 194 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Rat Weights. Statistical analyses - Mann Whitney U-test..................................................................................................212 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Rat Weights. Statistical analyses - Mann Whitney U-test..................................................................................................213 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Rat Weights. Statistical analyses - Mann Whitney U-test..................................................................................................214 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Rat Weights. Statistical analyses - Mann Whitney U-test..................................................................................................215 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Rat Weights. Statistical analyses - Mann Whitney U-test..................................................................................................216 
 
 
Study: 3.1.  The effect of simvastatin 20mg/Kg/day administered for 8 weeks, on bone mineral density and quantitative bone histomorphometry, in sham-operated and ovariectomised female Sprague-
Dawley rats. 
Appendix A 3.1         Page 195 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Bone Mineral Density: Descriptive statistics 
Descriptive Statistics : BMD Study 3.1        
   Confid. Confid.      Standard   
Group Valid N Mean -95.000% +95.000% Median Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis 
Sh 10 0.10367 0.099197 0.108143 0.10380 0.0927 0.1103 0.000039 0.006253 0.001977 -0.779627 -0.431294
Sh-S 10 0.09935 0.094234 0.104466 0.10135 0.0899 0.1111 0.000051 0.007152 0.002262 0.068319 -1.299149
OVX 10 0.09380 0.089380 0.098220 0.09230 0.0855 0.1044 0.000038 0.006178 0.001954 0.646418 -0.374060
OVX-S 10 0.09374 0.088947 0.098533 0.09365 0.0844 0.1045 0.000045 0.006701 0.002119 0.127230 -1.112783
 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Bone Mineral Density: Statistical analyses - Mann Whitney U-test 
 
Mann-Whitney U Test: BMD Study 3.1  
By variable GROUPS  
Group 1: 100-Sh Group 2: 102-OVX  
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Sh OVX U Z p-level adjusted p-level Sham OVX exact p 
BMD Study 3.1 141 69 14 2.7213 0.0065 2.7224 0.0065 10 10 0.0052 
           
Mann-Whitney U Test: BMD Study 3.1  
By variable GROUPS  
Group 1: 100-Sh Group 2: 101-Sh-S  
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Sh Sh-S U Z p-level adjusted p-level Sham Sham-sta exact p 
BMD Study 3.1 122 88 33 1.2851 0.1988 1.2856 0.1986 10 10 0.2176 
 
Mann-Whitney U Test: BMD Study 3.1  
By variable GROUPS  
Group 1: 102-OVX Group 2: 103-OVX-S  
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 OVX OVX-S U Z p-level adjusted p-level OVX OVX Stat exact p 
BMD Study 3.1 105 105 50 0.0000 1.0000 0.0000 1.0000 10 10 1.0295 
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Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Bone Mineral Density: Statistical analyses - ANOVA; All effects 
 
Study 3.1: LS Means (anova)  
Current effect: F(3, 36)=5.3264, p=.00385  
Effective hypothesis decomposition  
  BMD BMD BMD BMD  
 Group Mean Std.Err. -95.00% +95.00% N 
1 Sh 0.10367 0.002082 0.099448 0.107892 10 
2 Sh-S 0.09935 0.002082 0.095128 0.103572 10 
3 OVX 0.0938 0.002082 0.089578 0.098022 10 
4 OVX-S 0.09374 0.002082 0.089518 0.097962 10 
 
 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Bone Mineral Density: Statistical analyses - ANOVA; Differences 
between groups 
 
Fisher's LSD test; variable BMD 
Probabilities for Post Hoc Tests  
Error: Between MS = .00004, df = 36.000 
 {1} {2} {3} {4} 
Group .10367 .09935 .09380 .09374 
1 Sh  0.150935 0.001893 0.00179 
2 Sh-S 0.150935  0.067484 0.064705
3 OVX 0.001893 0.067484  0.983852
4 OVX-S 0.00179 0.064705 0.983852  
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Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Descriptive statistics 
 
Descriptive Statistics             
Sh   Confid. Confid.      Standard   
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis 
Bone Volume (BV/TV)(%) 9 18.015 15.605 20.425 18.028 13.083 23.528 9.830 3.135 1.045 0.223 0.005 
Osteoid volume OV/BV (%) 9 0.801 0.204 1.398 0.547 0.154 2.760 0.603 0.777 0.259 2.429 6.448 
Osteoid volume OV/TV (%) 9 0.130 0.057 0.204 0.089 0.028 0.361 0.009 0.096 0.032 1.960 4.673 
Osteoid Surface OS/BS (%) 9 4.408 1.824 6.992 3.507 1.847 12.806 11.298 3.361 1.120 2.344 6.061 
Osteoblast surface Ob.S/BS (%) 9 0.492 0.239 0.744 0.379 0.107 1.048 0.108 0.329 0.110 0.753 -0.836 
Osteoid thickness O.Th (mcm) 9 7.660 5.407 9.914 7.556 3.778 13.600 8.597 2.932 0.977 0.730 1.304 
Eroded surface ES/BS (%) 9 6.055 3.880 8.230 5.348 3.325 12.272 8.008 2.830 0.943 1.498 2.275 
Osteoclast surface Oc.S/BS (%) 9 0.736 0.448 1.024 0.616 0.369 1.567 0.140 0.374 0.125 1.537 2.480 
Osteoclast number N.Oc/T.A. (/mm2) 9 0.057 0.035 0.079 0.045 0.033 0.121 0.001 0.028 0.009 1.735 2.809 
Mineralising surface MS/BS (%) 9 5.105 3.300 6.909 5.337 2.323 9.922 5.512 2.348 0.783 0.896 1.158 
Osteoid apposition rate OAR       xi 9 0.855 0.623 1.087 0.798 0.603 1.595 0.091 0.302 0.101 2.172 5.418 
Mineralisation lag time Mlt (days) 9 0.593 0.319 0.867 0.524 0.250 1.385 0.127 0.356 0.119 1.575 2.646 
Bone formation rate BFR/BS (mcm3/mcm2/yr) 9 15.450 9.632 21.267 14.932 5.260 32.099 57.283 7.569 2.523 1.212 2.743 
Rel mineral Vol 9 99.199 98.602 99.796 99.453 97.240 99.846 0.603 0.777 0.259 -2.429 6.448 
Surface Density 9 5.140 4.635 5.644 5.299 4.398 6.425 0.431 0.656 0.219 0.686 0.395 
Resting Surface 9 89.537 85.731 93.344 91.133 78.696 94.704 24.523 4.952 1.651 -1.629 2.326 
Surf dens ost seams 9 0.220 0.108 0.331 0.192 0.083 0.572 0.021 0.145 0.048 2.026 5.077 
Surf dens ostoid osteoblast interface 9 0.025 0.012 0.039 0.021 0.005 0.059 0.000 0.018 0.006 1.029 0.203 
Ostoid thickness index 9 17.231 12.342 22.120 18.383 8.004 29.156 40.455 6.360 2.120 0.470 0.226 
Surface density of Howship's lacunae 9 0.322 0.174 0.469 0.260 0.146 0.788 0.037 0.192 0.064 2.073 5.167 
Surface density of bone ostoclast interface 9 0.039 0.020 0.059 0.031 0.017 0.101 0.001 0.025 0.008 2.119 5.219 
Total osteoclasts (v) 9 0.302 0.155 0.449 0.240 0.180 0.775 0.037 0.191 0.064 2.280 5.598 
Bone osteoclasts (TRS) 9 0.972 0.757 1.188 0.949 0.670 1.415 0.079 0.280 0.093 0.461 -1.425 
Fractional labeled surfaces 9 8.820 5.689 11.951 8.989 4.156 17.493 16.589 4.073 1.358 1.094 1.810 
Fractional double labeled surfaces 9 1.389 0.761 2.017 1.493 0.253 2.614 0.667 0.817 0.272 0.004 -1.023 
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Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Descriptive statistics 
 
Descriptive Statistics             
Sh-St   Confid. Confid.      Standard   
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis 
Bone Volume (BV/TV)(%) 10 17.286 14.374 20.198 17.887 10.667 23.778 16.567 4.070 1.287 -0.364 -0.275 
Osteoid volume OV/BV (%) 10 1.554 0.884 2.223 1.351 0.306 3.359 0.876 0.936 0.296 0.865 0.324 
Osteoid volume OV/TV (%) 10 0.265 0.141 0.388 0.210 0.056 0.556 0.030 0.172 0.055 0.952 -0.350 
Osteoid Surface OS/BS (%) 10 9.534 6.418 12.649 9.171 2.798 16.406 18.968 4.355 1.377 -0.049 -0.730 
Osteoblast surface Ob.S/BS (%) 10 1.117 0.748 1.486 1.152 0.000 1.995 0.266 0.516 0.163 -0.693 2.352 
Osteoid thickness O.Th (mcm) 10 7.053 5.680 8.426 7.212 4.000 10.524 3.684 1.919 0.607 0.214 0.096 
Eroded surface ES/BS (%) 10 8.110 6.566 9.653 8.259 4.297 12.718 4.657 2.158 0.682 0.512 2.448 
Osteoclast surface Oc.S/BS (%) 10 1.205 0.898 1.512 1.217 0.427 1.869 0.184 0.429 0.136 -0.308 -0.145 
Osteoclast number N.Oc/T.A. (/mm2) 10 0.109 0.084 0.134 0.109 0.049 0.170 0.001 0.035 0.011 0.015 -0.024 
Mineralising surface MS/BS (%) 10 5.183 3.541 6.825 5.228 2.451 9.669 5.269 2.295 0.726 0.668 0.128 
Osteoid apposition rate OAR       xi 10 0.825 0.696 0.953 0.792 0.576 1.197 0.032 0.180 0.057 0.887 0.829 
Mineralisation lag time Mlt (days) 10 0.541 0.357 0.726 0.475 0.241 0.981 0.067 0.258 0.082 0.621 -0.947 
Bone formation rate BFR/BS (mcm3/mcm2/yr) 10 15.650 10.637 20.663 17.092 5.246 25.612 49.104 7.007 2.216 -0.222 -1.431 
Rel mineral Vol 10 98.446 97.777 99.116 98.649 96.641 99.694 0.876 0.936 0.296 -0.865 0.324 
Surface Density 10 4.915 4.120 5.709 4.756 3.424 6.318 1.233 1.110 0.351 0.073 -1.796 
Resting Surface 10 82.357 79.068 85.646 82.290 74.896 89.218 21.137 4.598 1.454 -0.083 -0.500 
Surf dens ost seams 10 0.445 0.303 0.587 0.397 0.177 0.775 0.039 0.199 0.063 0.549 -0.849 
Surf dens ostoid osteoblast interface 10 0.054 0.031 0.076 0.052 0.000 0.125 0.001 0.031 0.010 0.910 3.543 
Ostoid thickness index 10 15.651 12.978 18.325 14.790 10.945 22.807 13.965 3.737 1.182 0.774 0.126 
Surface density of Howship's lacunae 10 0.410 0.283 0.536 0.397 0.173 0.796 0.031 0.177 0.056 0.951 1.739 
Surface density of bone ostoclast interface 10 0.061 0.040 0.081 0.054 0.018 0.099 0.001 0.028 0.009 0.029 -1.521 
Total osteoclasts (v) 10 0.549 0.378 0.719 0.496 0.202 0.901 0.057 0.238 0.075 0.095 -1.401 
Bone osteoclasts (TRS) 10 1.476 0.990 1.963 1.547 0.559 2.625 0.462 0.680 0.215 0.278 -0.552 
Fractional labeled surfaces 10 8.180 5.530 10.829 7.701 3.905 14.758 13.719 3.704 1.171 0.659 -0.609 
Fractional double labeled surfaces 10 2.186 1.364 3.008 2.175 0.735 4.580 1.321 1.149 0.363 0.719 0.948 
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Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Descriptive statistics 
 
Descriptive Statistics    
OVX   Confid. Confid.      Standard   
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis 
Bone Volume (BV/TV)(%) 9 10.540 8.507 12.574 9.917 7.850 15.342 6.998 2.645 0.882 1.096 -0.031 
Osteoid volume OV/BV (%) 9 2.324 1.377 3.271 1.931 0.836 4.878 1.518 1.232 0.411 1.134 1.206 
Osteoid volume OV/TV (%) 9 0.229 0.151 0.307 0.217 0.128 0.444 0.010 0.102 0.034 1.318 1.667 
Osteoid Surface OS/BS (%) 9 11.535 7.620 15.450 10.795 5.986 18.904 25.938 5.093 1.698 0.501 -1.582 
Osteoblast surface Ob.S/BS (%) 9 0.773 0.329 1.217 1.100 0.000 1.408 0.333 0.577 0.192 -0.472 -1.817 
Osteoid thickness O.Th (mcm) 9 9.608 6.885 12.330 9.951 5.368 13.949 12.546 3.542 1.181 -0.062 -2.006 
Eroded surface ES/BS (%) 9 7.939 5.114 10.764 7.386 2.215 15.493 13.507 3.675 1.225 0.774 1.964 
Osteoclast surface Oc.S/BS (%) 9 1.665 0.957 2.374 1.475 0.316 2.895 0.849 0.922 0.307 0.075 -1.397 
Osteoclast number N.Oc/T.A. (/mm2) 9 0.158 0.092 0.224 0.136 0.037 0.295 0.007 0.086 0.029 0.279 -1.076 
Mineralising surface MS/BS (%) 9 9.288 7.367 11.210 9.434 5.495 13.667 6.248 2.500 0.833 0.231 0.072 
Osteoid apposition rate OAR       xi 9 0.961 0.799 1.124 0.975 0.665 1.268 0.045 0.212 0.071 -0.049 -1.324 
Mineralisation lag time Mlt (days) 9 0.323 0.223 0.422 0.372 0.096 0.459 0.017 0.129 0.043 -0.696 -0.837 
Bone formation rate BFR/BS (mcm3/mcm2/yr) 9 33.369 23.063 43.675 32.429 13.332 57.037 179.765 13.408 4.469 0.334 -0.204 
Rel mineral Vol 9 97.676 96.729 98.623 98.069 95.122 99.164 1.518 1.232 0.411 -1.134 1.206 
Surface Density 9 2.901 2.365 3.437 2.635 2.186 4.544 0.486 0.697 0.232 1.925 4.109 
Resting Surface 9 80.525 75.661 85.390 81.121 70.411 89.873 40.054 6.329 2.110 -0.066 -0.841 
Surf dens ost seams 9 0.314 0.237 0.391 0.298 0.203 0.478 0.010 0.100 0.033 0.563 -1.142 
Surf dens ostoid osteoblast interface 9 0.024 0.008 0.041 0.031 0.000 0.064 0.000 0.021 0.007 0.491 -0.059 
Ostoid thickness index 9 20.278 15.804 24.752 22.341 13.490 28.499 33.879 5.821 1.940 -0.046 -1.849 
Surface density of Howship's lacunae 9 0.247 0.105 0.389 0.208 0.057 0.704 0.034 0.185 0.062 2.207 5.854 
Surface density of bone ostoclast interface 9 0.046 0.029 0.064 0.049 0.008 0.076 0.001 0.023 0.008 -0.377 -0.645 
Total osteoclasts (v) 9 0.441 0.273 0.608 0.435 0.094 0.832 0.047 0.218 0.073 0.325 0.289 
Bone osteoclasts (TRS) 9 2.132 1.353 2.911 2.063 0.656 3.999 1.028 1.014 0.338 0.410 0.274 
Fractional labeled surfaces 9 13.611 10.530 16.693 13.962 8.791 22.000 16.074 4.009 1.336 0.933 1.670 
Fractional double labeled surfaces 9 4.965 3.426 6.504 4.906 2.198 8.155 4.009 2.002 0.667 0.194 -0.480 
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Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Descriptive statistics 
 
Descriptive Statistics              
OVX-St   Confid. Confid.      Standard   
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis 
Bone Volume (BV/TV)(%) 10 9.533 6.882 12.185 7.880 6.801 18.989 13.734 3.706 1.172 2.197 5.131 
Osteoid volume OV/BV (%) 10 2.632 1.334 3.931 1.971 0.480 6.280 3.295 1.815 0.574 0.905 0.175 
Osteoid volume OV/TV (%) 10 0.225 0.127 0.322 0.204 0.074 0.481 0.019 0.136 0.043 0.679 -0.480 
Osteoid Surface OS/BS (%) 10 13.594 9.281 17.907 12.178 6.630 23.209 36.350 6.029 1.907 0.601 -1.229 
Osteoblast surface Ob.S/BS (%) 10 1.376 0.496 2.257 0.959 0.000 3.659 1.515 1.231 0.389 1.220 0.422 
Osteoid thickness O.Th (mcm) 10 8.149 5.676 10.622 7.680 2.566 14.258 11.953 3.457 1.093 0.662 0.686 
Eroded surface ES/BS (%) 10 8.145 6.279 10.012 7.686 4.673 13.189 6.807 2.609 0.825 0.515 0.053 
Osteoclast surface Oc.S/BS (%) 10 1.694 1.121 2.267 1.649 0.287 2.744 0.641 0.801 0.253 -0.388 -0.660 
Osteoclast number N.Oc/T.A. (/mm2) 10 0.158 0.110 0.206 0.181 0.065 0.247 0.005 0.068 0.021 -0.359 -1.504 
Mineralising surface MS/BS (%) 10 8.837 6.549 11.126 8.616 4.893 15.447 10.232 3.199 1.012 0.816 0.542 
Osteoid apposition rate OAR       xi 10 0.996 0.898 1.094 1.047 0.764 1.186 0.019 0.137 0.043 -0.553 -0.647 
Mineralisation lag time Mlt (days) 10 0.274 0.187 0.361 0.285 0.122 0.460 0.015 0.122 0.038 0.105 -1.635 
Bone formation rate BFR/BS (mcm3/mcm2/yr) 10 31.933 24.005 39.861 33.342 17.742 45.477 122.818 11.082 3.505 -0.106 -2.015 
Rel mineral Vol 10 97.368 96.069 98.666 98.029 93.720 99.520 3.295 1.815 0.574 -0.905 0.175 
Surface Density 10 2.685 2.023 3.346 2.395 1.961 5.106 0.854 0.924 0.292 2.324 6.136 
Resting Surface 10 78.261 73.685 82.837 79.122 67.335 88.398 40.926 6.397 2.023 -0.361 -0.359 
Surf dens ost seams 10 0.354 0.239 0.470 0.344 0.149 0.691 0.026 0.162 0.051 0.720 0.888 
Surf dens ostoid osteoblast interface 10 0.037 0.013 0.061 0.022 0.000 0.102 0.001 0.033 0.011 1.042 -0.049 
Ostoid thickness index 10 18.043 13.170 22.915 17.146 5.421 31.097 46.394 6.811 2.154 0.239 1.548 
Surface density of Howship's lacunae 10 0.232 0.114 0.351 0.162 0.125 0.673 0.027 0.166 0.052 2.504 6.742 
Surface density of bone ostoclast interface 10 0.045 0.024 0.067 0.036 0.009 0.119 0.001 0.030 0.010 1.733 4.250 
Total osteoclasts (v) 10 0.421 0.234 0.607 0.389 0.180 1.083 0.068 0.261 0.082 2.023 5.119 
Bone osteoclasts (TRS) 10 2.078 1.349 2.806 2.044 0.700 3.851 1.036 1.018 0.322 0.335 -0.570 
Fractional labeled surfaces 10 13.077 9.784 16.371 13.407 6.422 21.951 21.193 4.604 1.456 0.466 0.097 
Fractional double labeled surfaces 10 4.597 3.090 6.104 4.207 2.326 8.943 4.436 2.106 0.666 1.106 0.721 
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Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH:. Statistical analyses - Mann Whitney U-test 
Mann-Whitney U Test            
By variable: GROUPS           
Group 1: 102-OVX Group 2: 100-Sh           
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided 
OVX Sham U Z p-level adjusted p-level OVX Sham exact p 
Bone Volume (BV/TV)(%) 48 123 3 -3.3113 0.0009 -3.3113 0.0009 9 9 0.0003 
Osteoid volume OV/BV (%) 119 52 7 2.9581 0.0031 2.9581 0.0031 9 9 0.0019 
Osteoid volume OV/TV (%) 111 60 15 2.2517 0.0243 2.2575 0.0240 9 9 0.0244 
Osteoid Surface OS/BS (%) 120 51 6 3.0464 0.0023 3.0464 0.0023 9 9 0.0012 
Osteoblast surface Ob.S/BS (%) 97 74 29 1.0155 0.3099 1.0160 0.3096 9 9 0.3401 
Osteoid thickness O.Th (mcm) 97.5 73.5 28.5 1.0596 0.2893 1.0602 0.2891 9 9 0.2973 
Eroded surface ES/BS (%) 100 71 26 1.2804 0.2004 1.2804 0.2004 9 9 0.2224 
Osteoclast surface Oc.S/BS (%) 110 61 16 2.1634 0.0305 2.1634 0.0305 9 9 0.0315 
Osteoclast number N.Oc/T.A. (/mm2) 115 56 11 2.6049 0.0092 2.6063 0.0092 9 9 0.0078 
Mineralising surface MS/BS (%) 117 54 9 2.7815 0.0054 2.7815 0.0054 9 9 0.0040 
Osteoid apposition rate OAR       xi 101 70 25 1.3687 0.1711 1.3687 0.1711 9 9 0.1903 
Mineralisation lag time Mlt (days) 60 111 15 -2.2517 0.0243 -2.2517 0.0243 9 9 0.0244 
Bone formation rate BFR/BS (mcm3/mcm2/yr) 117 54 9 2.7815 0.0054 2.7815 0.0054 9 9 0.0040 
Rel mineral Vol 52 119 7 -2.9581 0.0031 -2.9581 0.0031 9 9 0.0019 
Surface Density 48 123 3 -3.3113 0.0009 -3.3113 0.0009 9 9 0.0003 
Resting Surface 53 118 8 -2.8698 0.0041 -2.8698 0.0041 9 9 0.0028 
Surf dens ost seams 108 63 18 1.9868 0.0470 1.9868 0.0470 9 9 0.0503 
Surf dens ostoid osteoblast interface 83.5 87.5 38.5 -0.1766 0.8598 -0.1769 0.8596 9 9 0.8633 
Ostoid thickness index 101 70 25 1.3687 0.1711 1.3687 0.1711 9 9 0.1903 
Surface density of Howship's lacunae 69 102 24 -1.4570 0.1451 -1.4577 0.1449 9 9 0.1615 
Surface density of bone ostoclast interface 96.5 74.5 29.5 0.9713 0.3314 0.9723 0.3309 9 9 0.3401 
Total osteoclasts (v) 104 67 22 1.6336 0.1024 1.6361 0.1018 9 9 0.1135 
Bone osteoclasts (TRS) 114 57 12 2.5166 0.0119 2.5166 0.0119 9 9 0.0106 
Fractional labeled surfaces 110 61 16 2.1634 0.0305 2.1634 0.0305 9 9 0.0315 
Fractional double labeled surfaces 123 48 3 3.3113 0.0009 3.3113 0.0009 9 9 0.0003 
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Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Statistical analyses - Mann Whitney U-test 
Mann-Whitney U Test           
By variable GROUPS           
Group 1: 100-Sham Group 2: 101-Sham Sta           
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided 
Sham Sham Sta U Z p-level adjusted p-level Sham Sham Sta exact p 
Bone Volume (BV/TV)(%) 93 97 42 0.2449 0.8065 0.2449 0.8065 9 10 0.8421 
Osteoid volume OV/BV (%) 63 127 18 -2.2045 0.0275 -2.2045 0.0275 9 10 0.0279 
Osteoid volume OV/TV (%) 62.5 127.5 17.5 -2.2454 0.0248 -2.2503 0.0244 9 10 0.0220 
Osteoid Surface OS/BS (%) 60 130 15 -2.4495 0.0143 -2.4495 0.0143 9 10 0.0133 
Osteoblast surface Ob.S/BS (%) 60 130 15 -2.4495 0.0143 -2.4495 0.0143 9 10 0.0133 
Osteoid thickness O.Th (mcm) 96.5 93.5 38.5 0.5307 0.5956 0.5310 0.5955 9 10 0.6038 
Eroded surface ES/BS (%) 65 125 20 -2.0412 0.0412 -2.0412 0.0412 9 10 0.0435 
Osteoclast surface Oc.S/BS (%) 65 125 20 -2.0412 0.0412 -2.0412 0.0412 9 10 0.0435 
Osteoclast number N.Oc/T.A. (/mm2) 55 135 10 -2.8577 0.0043 -2.8590 0.0043 9 10 0.0030 
Mineralising surface MS/BS (%) 89 101 44 -0.0816 0.9349 -0.0816 0.9349 9 10 0.9682 
Osteoid apposition rate OAR       xi 89 101 44 -0.0816 0.9349 -0.0816 0.9349 9 10 0.9682 
Mineralisation lag time Mlt (days) 92 98 43 0.1633 0.8703 0.1633 0.8703 9 10 0.9048 
Bone formation rate BFR/BS (mcm3/mcm2/yr) 86 104 41 -0.3266 0.7440 -0.3266 0.7440 9 10 0.7802 
Rel mineral Vol 117 73 18 2.2045 0.0275 2.2045 0.0275 9 10 0.0279 
Surface Density 97 93 38 0.5715 0.5676 0.5715 0.5676 9 10 0.6038 
Resting Surface 124 66 11 2.7761 0.0055 2.7761 0.0055 9 10 0.0041 
Surf dens ost seams 58 132 13 -2.6128 0.0090 -2.6128 0.0090 9 10 0.0076 
Surf dens ostoid osteoblast interface 62 128 17 -2.2862 0.0222 -2.2912 0.0220 9 10 0.0220 
Ostoid thickness index 96 94 39 0.4899 0.6242 0.4899 0.6242 9 10 0.6607 
Surface density of Howship's lacunae 71 119 26 -1.5513 0.1208 -1.5520 0.1207 9 10 0.1333 
Surface density of bone ostoclast interface 68.5 121.5 23.5 -1.7555 0.0792 -1.7570 0.0789 9 10 0.0789 
Total osteoclasts (v) 60 130 15 -2.4495 0.0143 -2.4527 0.0142 9 10 0.0133 
Bone osteoclasts (TRS) 70 120 25 -1.6330 0.1025 -1.6330 0.1025 9 10 0.1128 
Fractional labeled surfaces 95 95 40 0.4082 0.6831 0.4082 0.6831 9 10 0.7197 
Fractional double labeled surfaces 70 120 25 -1.6330 0.1025 -1.6330 0.1025 9 10 0.1128 
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Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Statistical analyses - Mann Whitney U-test 
Mann-Whitney U Test (st1 histo data corelation.sta)           
By variable GROUPS           
Group 1: 102-OVX Group 2: 103-OVX Stat           
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided 
OVX OVX Stat U Z p-level adjusted p-level OVX OVX Stat exact p 
Bone Volume (BV/TV)(%) 110 80 25 1.6330 0.1025 1.6330 0.1025 9 10 0.1128 
Osteoid volume OV/BV (%) 88 102 43 -0.1633 0.8703 -0.1633 0.8703 9 10 0.9048 
Osteoid volume OV/TV (%) 92 98 43 0.1633 0.8703 0.1635 0.8701 9 10 0.9048 
Osteoid Surface OS/BS (%) 78 112 33 -0.9798 0.3272 -0.9798 0.3272 9 10 0.3562 
Osteoblast surface Ob.S/BS (%) 81 109 36 -0.7348 0.4624 -0.7361 0.4617 9 10 0.4967 
Osteoid thickness O.Th (mcm) 96 94 39 0.4899 0.6242 0.4903 0.6239 9 10 0.6607 
Eroded surface ES/BS (%) 90 100 45 0.0000 1.0000 0.0000 1.0000 9 10 1.0318 
Osteoclast surface Oc.S/BS (%) 89 101 44 -0.0816 0.9349 -0.0816 0.9349 9 10 0.9682 
Osteoclast number N.Oc/T.A. (/mm2) 93 97 42 0.2449 0.8065 0.2449 0.8065 9 10 0.8421 
Mineralising surface MS/BS (%) 96 94 39 0.4899 0.6242 0.4899 0.6242 9 10 0.6607 
Osteoid apposition rate OAR       xi 84 106 39 -0.4899 0.6242 -0.4901 0.6241 9 10 0.6607 
Mineralisation lag time Mlt (days) 101 89 34 0.8981 0.3691 0.8981 0.3691 9 10 0.4002 
Bone formation rate BFR/BS (mcm3/mcm2/yr) 92 98 43 0.1633 0.8703 0.1633 0.8703 9 10 0.9048 
Rel mineral Vol 92 98 43 0.1633 0.8703 0.1633 0.8703 9 10 0.9048 
Surface Density 104 86 31 1.1431 0.2530 1.1431 0.2530 9 10 0.2775 
Resting Surface 97 93 38 0.5715 0.5676 0.5715 0.5676 9 10 0.6038 
Surf dens ost seams 82.5 107.5 37.5 -0.6124 0.5403 -0.6126 0.5401 9 10 0.5490 
Surf dens ostoid osteoblast interface 82.5 107.5 37.5 -0.6124 0.5403 -0.6137 0.5394 9 10 0.5490 
Ostoid thickness index 96 94 39 0.4899 0.6242 0.4899 0.6242 9 10 0.6607 
Surface density of Howship's lacunae 93.5 96.5 41.5 0.2858 0.7751 0.2859 0.7750 9 10 0.7802 
Surface density of bone ostoclast interface 100.5 89.5 34.5 0.8573 0.3913 0.8581 0.3909 9 10 0.4002 
Total osteoclasts (v) 96 94 39 0.4899 0.6242 0.4901 0.6241 9 10 0.6607 
Bone osteoclasts (TRS) 92 98 43 0.1633 0.8703 0.1633 0.8703 9 10 0.9048 
Fractional labeled surfaces 93 97 42 0.2449 0.8065 0.2449 0.8065 9 10 0.8421 
Fractional double labeled surfaces 97 93 38 0.5715 0.5676 0.5715 0.5676 9 10 0.6038 
 
 
Study: 3.1.  The effect of simvastatin 20mg/Kg/day administered for 8 weeks, on bone mineral density and quantitative bone histomorphometry, in sham-operated and ovariectomised female Sprague-
Dawley rats. 
Appendix A 3.1         Page 204 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Statistical analyses - ANOVA; All effects 
GROUPS; LS Means  
Wilks lambda=.09727, F(33, 71.412)=2.6086, p=.00037 
Effective hypothesis decomposition 
 BONE VOL BONE VOL BONE VOL BONE VOL OST VOL OST VOL OST VOL OST VOL OST VOL OST VOL OST VOL OST VOL 
GROUPS Mean Std.Err. -95.00% +95.00% Mean Std.Err. -95.00% +95.00% Mean Std.Err. -95.00% +95.00% 
Sham 18.0152 1.1537 15.6705 20.3598 0.8014 0.4221 -0.0563 1.6591 0.1305 0.0440 0.0412 0.2198 
Sham Sta 17.2859 1.0945 15.0615 19.5102 1.5537 0.4004 0.7400 2.3674 0.2646 0.0417 0.1798 0.3493 
OVX 10.5402 1.1537 8.1955 12.8849 2.3244 0.4221 1.4667 3.1821 0.2289 0.0440 0.1396 0.3182 
OVX Stat 9.5335 1.0945 7.3091 11.7578 2.6325 0.4004 1.8188 3.4462 0.2245 0.0417 0.1398 0.3093 
 OST SURF OST SURF OST SURF OST SURF OB SURF OB SURF OB SURF OB SURF EROD SURF EROD SURF EROD SURF EROD SURF 
GROUPS Mean Std.Err. -95.00% +95.00% Mean Std.Err. -95.00% +95.00% Mean Std.Err. -95.00% +95.00% 
Sham 4.4079 1.6126 1.1307 7.6851 0.4917 0.2529 -0.0222 1.0056 6.0550 0.9485 4.1274 7.9826 
Sham Sta 9.5337 1.5299 6.4247 12.6428 1.1168 0.2399 0.6293 1.6043 8.1096 0.8998 6.2809 9.9383 
OVX 11.5353 1.6126 8.2580 14.8125 0.7730 0.2529 0.2591 1.2869 7.9395 0.9485 6.0119 9.8671 
OVX Stat 13.5938 1.5299 10.4848 16.7029 1.3765 0.2399 0.8890 1.8640 8.1451 0.8998 6.3164 9.9738 
 OC SURF OC SURF OC SURF OC SURF OC NUMB OC NUMB OC NUMB OC NUMB BFR BFR BFR BFR 
GROUPS Mean Std.Err. -95.00% +95.00% Mean Std.Err. -95.00% +95.00% Mean Std.Err. -95.00% +95.00% 
Sham 0.7361 0.2239 0.2811 1.1912 0.0570 0.0196 0.0171 0.0968 15.4496 3.3547 8.6321 22.2671 
Sham Sta 1.2051 0.2124 0.7734 1.6368 0.1092 0.0186 0.0714 0.1470 15.6503 3.1825 9.1826 22.1180 
OVX 1.6651 0.2239 1.2100 2.1202 0.1584 0.0196 0.1186 0.1983 33.3692 3.3547 26.5516 40.1867 
OVX Stat 1.6937 0.2124 1.2620 2.1254 0.1581 0.0186 0.1203 0.1959 31.9327 3.1825 25.4651 38.4004 
 TOT OC TOT OC TOT OC TOT OC X_BONE_O BONE OC BONE OC BONE OC     
GROUPS Mean Std.Err. -95.00% +95.00% Mean Std.Err. -95.00% +95.00%     
Sham 0.3018 0.0766 0.1462 0.4574 0.9721 0.2702 0.4231 1.5212     
Sham Sta 0.5486 0.0726 0.4010 0.6962 1.4763 0.2563 0.9553 1.9972     
OVX 0.4407 0.0766 0.2851 0.5963 2.1320 0.2702 1.5829 2.6811     
OVX Stat 0.4205 0.0726 0.2729 0.5681 2.0777 0.2563 1.5568 2.5986     
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Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Statistical analyses - ANOVA; Between group analysis 
 
LSD test; variable BONE VOL (anova histo.sta) 
Probabilities for Post Hoc Tests  
Error: Between MS = 11.980, df = 34.000 
  {1} {2} {3} {4} 
 GROUPS 18.015 17.286 10.540 9.5335 
1 Sham  0.64945314 5.95564E-05 6.34029E-06 
2 Sham Sta 0.64945314  0.000161122 1.67577E-05 
3 OVX 5.9556E-05 0.000161122  0.530959101
4 OVX Stat 6.3403E-06 1.67577E-05 0.530959101  
 
LSD test; variable OST VOL (anova histo.sta) 
Probabilities for Post Hoc Tests  
Error: Between MS = 1.6031, df = 34.000 
  {1} {2} {3} {4} 
 GROUPS .80144 1.5537 2.3244 2.6325 
1 Sham  0.204680899 0.015392146 0.003418107
2 Sham Sta 0.2046809  0.19411176 0.06524982 
3 OVX 0.01539215 0.19411176  0.599807789
4 OVX Stat 0.00341811 0.06524982 0.599807789  
 
LSD test; variable OST VOL (anova histo.sta) 
Probabilities for Post Hoc Tests  
Error: Between MS = .01739, df = 34.000 
  {1} {2} {3} {4} 
 GROUPS .13049 .26455 .22892 .22452 
1 Sham  0.033728343 0.12256407 0.129933252
2 Sham Sta 0.03372834  0.560322421 0.501767734
3 OVX 0.12256407 0.560322421  0.942475691
4 OVX Stat 0.12993325 0.501767734 0.942475691  
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Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Statistical analyses - ANOVA; Between group analysis 
 
LSD test; variable OST SURF (anova histo.sta) 
Probabilities for Post Hoc Tests  
Error: Between MS = 23.405, df = 34.000 
  {1} {2} {3} {4} 
 GROUPS 4.4079 9.5337 11.535 13.594 
1 Sham  0.027337866 0.003624295 0.00022112 
2 Sham Sta 0.02733787  0.374222464 0.069179039
3 OVX 0.00362429 0.374222464  0.36092041 
4 OVX Stat 0.00022112 0.069179039 0.36092041  
 
LSD test; variable E_OSTEOB (anova histo.sta) 
Probabilities for Post Hoc Tests  
Error: Between MS = .57547, df = 34.000 
  {1} {2} {3} {4} 
 GROUPS .49171 1.1168 .77302 1.3765 
1 Sham  0.08181064 0.436940221 0.015881465
2 Sham Sta 0.08181064  0.330949266 0.449254162
3 OVX 0.43694022 0.330949266  0.092447917
4 OVX Stat 0.01588146 0.449254162 0.092447917  
 
LSD test; variable G_ERODED (anova histo.sta) 
Probabilities for Post Hoc Tests  
Error: Between MS = 8.0971, df = 34.000 
  {1} {2} {3} {4} 
 GROUPS 6.0550 8.1096 7.9395 8.1451 
1 Sham  0.125328797 0.169132377 0.1191582 
2 Sham Sta 0.1253288  0.897228138 0.97792925 
3 OVX 0.16913238 0.897228138  0.875970902
4 OVX Stat 0.1191582 0.97792925 0.875970902  
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Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Statistical analyses - ANOVA; Between group analysis 
 
LSD test; variable H_OSTEOC (anova histo.sta) 
Probabilities for Post Hoc Tests  
Error: Between MS = .45127, df = 34.000 
  {1} {2} {3} {4} 
 GROUPS .73614 1.2051 1.6651 1.6937 
1 Sham  0.13788824 0.005963527 0.003848783
2 Sham Sta 0.13788824  0.145381262 0.113127307
3 OVX 0.00596353 0.145381262  0.926721783
4 OVX Stat 0.00384878 0.113127307 0.926721783  
 
LSD test; variable J_OSTEOC (anova histo.sta) 
Probabilities for Post Hoc Tests  
Error: Between MS = .00346, df = 34.000 
  {1} {2} {3} {4} 
 GROUPS .05695 .10919 .15842 .15807 
1 Sham  0.061572805 0.000847199 0.000673397
2 Sham Sta 0.06157281  0.077239163 0.071762864
3 OVX 0.0008472 0.077239163  0.989588355
4 OVX Stat 0.0006734 0.071762864 0.989588355  
 
LSD test; variable N_BONE_F (anova histo.sta) 
Probabilities for Post Hoc Tests  
Error: Between MS = 101.28, df = 34.000 
  {1} {2} {3} {4} 
 GROUPS 15.450 15.650 33.369 31.933 
1 Sham  0.965635799 0.000610337 0.001105271
2 Sham Sta 0.9656358  0.000522886 0.000953901
3 OVX 0.00061034 0.000522886  0.757969564
4 OVX Stat 0.00110527 0.000953901 0.757969564  
 
 
Study: 3.1.  The effect of simvastatin 20mg/Kg/day administered for 8 weeks, on bone mineral density and quantitative bone histomorphometry, in sham-operated and ovariectomised female Sprague-
Dawley rats. 
Appendix A 3.1         Page 208 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: QBH: Statistical analyses - ANOVA; Between group analysis 
 
 
LSD test; variable W_TOTAL (anova histo.sta) 
Probabilities for Post Hoc Tests  
Error: Between MS = .05275, df = 34.000 
  {1} {2} {3} {4} 
 GROUPS .30183 .54864 .44073 .42055 
1 Sham  0.02536602 0.20819934 0.268489264
2 Sham Sta 0.02536602  0.313771367 0.220906142
3 OVX 0.20819934 0.313771367  0.849435496
4 OVX Stat 0.26848926 0.220906142 0.849435496  
 
LSD test; variable X_BONE_O (anova histo.sta) 
Probabilities for Post Hoc Tests  
Error: Between MS = .65701, df = 34.000 
  {1} {2} {3} {4} 
 GROUPS .97214 1.4763 2.1320 2.0777 
1 Sham  0.184797994 0.004583901 0.005451994
2 Sham Sta 0.18479799  0.087279328 0.106296542
3 OVX 0.0045839 0.087279328  0.884875618
4 OVX Stat 0.00545199 0.106296542 0.884875618  
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Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: BMD delta values. Descriptive statistics 
 
Descriptive Statistics (bmd 1 and 2 femur.sta)  
   Confid. Confid.      Standard   
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis 
SH_DELTA 10 -0.00432 -0.00668 -0.00196 -0.0041 -0.0098 0.0008 1.09E-05 0.003304 0.001045 -0.33443 -0.25984 
OVX_DELT 10 -6E-05 -0.00133 0.001215 -0.00065 -0.0019 0.0032 3.18E-06 0.001782 0.000564 0.919437 -0.37823 
 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: BMD delta values. Statistical analyses - ANOVA; All effects 
 
GROUP; LS Means (bmd 1 and 2 femur.sta) 
Current effect: F(1, 18)=12.879, p=.00210 
Effective hypothesis decomposition 
  DELTAS DELTAS DELTAS DELTAS  
 GROUP Mean Std.Err. -95.00% +95.00% N 
1 Sh -0.00432 0.000839 -0.00608 -0.00256 10 
2 OVX -6E-05 0.000839 -0.00182 0.001703 10 
 
Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: BMD delta values. Statistical analyses - ANOVA; Between group 
analysis 
 
LSD test; variable DELTAS (bmd 1 and 2 femur.sta) 
Probabilities for Post Hoc Tests 
Error: Between MS = .00001, df = 18.000 
  {1} {2}  
 GROUP -.0043 -.0001  
1 Sh  0.002099  
2 OVX 0.002099   
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Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Rat Weights. Descriptive statistics.  
 
 
Descriptive Statistics: Sh weights       
   Confid. Confid.       Standard
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Range Variance Std.Dev. Error 
W1 10 246.600 233.789 259.411 248.500 223.000 274.000 51.000 320.711 17.908 5.663 
W2 10 251.100 235.484 266.716 250.000 221.000 297.000 76.000 476.544 21.830 6.903 
W3 10 245.900 232.313 259.487 249.500 215.000 274.000 59.000 360.767 18.994 6.006 
W4 10 233.400 220.435 246.365 233.500 207.000 265.000 58.000 328.489 18.124 5.731 
W5 10 234.700 221.458 247.942 239.500 204.000 261.000 57.000 342.678 18.512 5.854 
W6 10 231.700 218.670 244.730 230.500 206.000 264.000 58.000 331.789 18.215 5.760 
W7 10 249.600 237.520 261.680 251.000 219.000 279.000 60.000 285.156 16.887 5.340 
W8 10 261.600 249.662 273.538 260.000 236.000 289.000 53.000 278.489 16.688 5.277 
 
Descriptive Statistics: OVX weights        
   Confid. Confid.       Standard
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Range Variance Std.Dev. Error 
W1 10 247.000 235.684 258.316 241.000 229.000 271.000 42.000 250.222 15.818 5.002 
W2 10 265.100 253.338 276.862 263.500 243.000 290.000 47.000 270.322 16.441 5.199 
W3 10 256.900 245.919 267.881 260.000 231.000 277.000 46.000 235.656 15.351 4.854 
W4 10 245.000 234.151 255.849 247.000 220.000 267.000 47.000 230.000 15.166 4.796 
W5 10 244.600 234.075 255.125 245.000 220.000 266.000 46.000 216.489 14.714 4.653 
W6 10 247.900 241.152 254.648 249.500 230.000 266.000 36.000 88.989 9.433 2.983 
W7 10 262.000 252.691 271.309 263.000 242.000 287.000 45.000 169.333 13.013 4.115 
W8 10 278.500 267.535 289.465 278.000 256.000 308.000 52.000 234.944 15.328 4.847 
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Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Rat Weights. Descriptive statistics. 
 
Descriptive Statistics: Sh-St weights.       
   Confid. Confid.       Standard
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Range Variance Std.Dev. Error 
W1 10 236.100 221.559 250.641 228.000 216.000 263.000 47.000 413.211 20.328 6.428 
W2 10 239.000 225.381 252.619 232.000 219.000 264.000 45.000 362.444 19.038 6.020 
W3 10 237.100 223.019 251.181 230.000 216.000 262.000 46.000 387.433 19.683 6.224 
W4 10 223.500 209.772 237.228 218.500 199.000 252.000 53.000 368.278 19.191 6.069 
W5 10 222.200 209.949 234.451 219.500 199.000 244.000 45.000 293.289 17.126 5.416 
W6 10 222.300 210.301 234.299 220.500 203.000 245.000 42.000 281.344 16.773 5.304 
W7 10 237.400 226.831 247.969 234.500 216.000 257.000 41.000 218.267 14.774 4.672 
W8 10 254.600 241.387 267.813 249.000 234.000 280.000 46.000 341.156 18.470 5.841 
 
Descriptive Statistics: OVX-St weights.       
   Confid. Confid.       Standard
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Range Variance Std.Dev. Error 
W1 10 255.200 241.582 268.818 255.500 229.000 285.000 56.000 362.400 19.037 6.020 
W2 10 269.700 256.744 282.656 270.500 242.000 299.000 57.000 328.011 18.111 5.727 
W3 10 266.500 252.755 280.245 265.500 236.000 296.000 60.000 369.167 19.214 6.076 
W4 10 252.900 239.084 266.716 249.500 222.000 290.000 68.000 372.989 19.313 6.107 
W5 10 250.500 234.485 266.515 241.500 219.000 290.000 71.000 501.167 22.387 7.079 
W6 10 248.100 234.301 261.899 240.500 221.000 283.000 62.000 372.100 19.290 6.100 
W7 10 263.500 248.094 278.906 257.000 228.000 301.000 73.000 463.833 21.537 6.811 
W8 10 279.000 263.896 294.104 280.000 238.000 310.000 72.000 445.778 21.113 6.677 
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Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Rat Weights. Statistical analyses - Mann Whitney U-test. 
 
Mann-Whitney U Test (statbones 1 weights1.sta)     
By variable GROUP         
Group 1: 100-Sh Group 2: 101-Sh-S        
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Sh Sh-S U Z p-level adjusted p-level Sh Sh-S exact p 
W1 121.5 88.5 33.500 1.247 0.212 1.250 0.211 10 10 0.218 
W2 120.5 89.5 34.500 1.172 0.241 1.173 0.241 10 10 0.247 
W3 114.0 96.0 41.000 0.680 0.496 0.682 0.495 10 10 0.529 
W4 117.0 93.0 38.000 0.907 0.364 0.909 0.363 10 10 0.393 
W5 125.5 84.5 29.500 1.550 0.121 1.551 0.121 10 10 0.123 
W6 120.5 89.5 34.500 1.172 0.241 1.173 0.241 10 10 0.247 
W7 124.0 86.0 31.000 1.436 0.151 1.437 0.151 10 10 0.165 
W8 117.0 93.0 38.000 0.907 0.364 0.908 0.364 10 10 0.393 
           
Mann-Whitney U Test (statbones 1 weights1.sta)      
By variable GROUP         
Group 1: 100-Sh Group 2: 102-OVX        
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Sh OVX U Z p-level adjusted p-level Sh OVX exact p 
W1 104.5 105.5 49.500 -0.038 0.970 -0.038 0.970 10 10 0.971 
W2 84.0 126.0 29.000 -1.587 0.112 -1.589 0.112 10 10 0.123 
W3 87.5 122.5 32.500 -1.323 0.186 -1.323 0.186 10 10 0.190 
W4 87.0 123.0 32.000 -1.361 0.174 -1.362 0.173 10 10 0.190 
W5 89.5 120.5 34.500 -1.172 0.241 -1.173 0.241 10 10 0.247 
W6 74.0 136.0 19.000 -2.343 0.019 -2.344 0.019 10 10 0.019 
W7 84.0 126.0 29.000 -1.587 0.112 -1.589 0.112 10 10 0.123 
W8 78.0 132.0 23.000 -2.041 0.041 -2.043 0.041 10 10 0.043 
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Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Rat Weights. Statistical analyses - Mann Whitney U-test. 
 
          
Mann-Whitney U Test (statbones 1 weights1.sta)      
By variable GROUP         
Group 1: 100-Sh Group 2: 103-OVX-S       
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Sh OVX-S U Z p-level adjusted p-level Sh OVX-S exact p 
W1 91.0 119.0 36.000 -1.058 0.290 -1.060 0.289 10 10 0.315 
W2 79.5 130.5 24.500 -1.928 0.054 -1.928 0.054 10 10 0.052 
W3 77.0 133.0 22.000 -2.117 0.034 -2.117 0.034 10 10 0.035 
W4 78.0 132.0 23.000 -2.041 0.041 -2.042 0.041 10 10 0.043 
W5 88.5 121.5 33.500 -1.247 0.212 -1.250 0.211 10 10 0.218 
W6 85.0 125.0 30.000 -1.512 0.131 -1.514 0.130 10 10 0.143 
W7 83.5 126.5 28.500 -1.625 0.104 -1.628 0.103 10 10 0.105 
W8 81.0 129.0 26.000 -1.814 0.070 -1.816 0.069 10 10 0.075 
          
Mann-Whitney U Test (statbones 1 weights1.sta)      
By variable GROUP         
Group 1: 101-Sh-S Group 2: 102-OVX       
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Sh-S OVX U Z p-level adjusted p-level Sh-S OVX exact p 
W1 85.5 124.5 30.500 -1.474 0.140 -1.476 0.140 10 10 0.143 
W2 71.0 139.0 16.000 -2.570 0.010 -2.573 0.010 10 10 0.009 
W3 75.0 135.0 20.000 -2.268 0.023 -2.269 0.023 10 10 0.023 
W4 73.5 136.5 18.500 -2.381 0.017 -2.383 0.017 10 10 0.015 
W5 70.0 140.0 15.000 -2.646 0.008 -2.648 0.008 10 10 0.007 
W6 63.5 146.5 8.500 -3.137 0.002 -3.139 0.002 10 10 0.001 
W7 65.0 145.0 10.000 -3.024 0.002 -3.024 0.002 10 10 0.002 
W8 71.5 138.5 16.500 -2.532 0.011 -2.534 0.011 10 10 0.009 
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Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Rat Weights. Statistical analyses - Mann Whitney U-test. 
 
          
Mann-Whitney U Test (statbones 1 weights1.sta)      
By variable GROUP         
Group 1: 101-Sh-S Group 2: 103-OVX-S       
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Sh-S OVX-S U Z p-level adjusted p-level Sh-S OVX-S exact p 
W1 77.0 133.0 22.000 -2.117 0.034 -2.121 0.034 10 10 0.035 
W2 68.5 141.5 13.500 -2.759 0.006 -2.762 0.006 10 10 0.004 
W3 70.0 140.0 15.000 -2.646 0.008 -2.648 0.008 10 10 0.007 
W4 69.5 140.5 14.500 -2.684 0.007 -2.686 0.007 10 10 0.005 
W5 75.0 135.0 20.000 -2.268 0.023 -2.269 0.023 10 10 0.023 
W6 75.5 134.5 20.500 -2.230 0.026 -2.233 0.026 10 10 0.023 
W7 71.5 138.5 16.500 -2.532 0.011 -2.537 0.011 10 10 0.009 
W8 73.5 136.5 18.500 -2.381 0.017 -2.387 0.017 10 10 0.015 
          
Mann-Whitney U Test (statbones 1 weights1.sta)      
By variable GROUP         
Group 1: 102-OVX Group 2: 103-OVX-S       
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
OVX OVX-S U Z p-level adjusted p-level OVX OVX-S exact p 
W1 95.0 115.0 40.000 -0.756 0.450 -0.759 0.448 10 10 0.481 
W2 98.0 112.0 43.000 -0.529 0.597 -0.530 0.596 10 10 0.631 
W3 91.5 118.5 36.500 -1.021 0.307 -1.022 0.307 10 10 0.315 
W4 97.0 113.0 42.000 -0.605 0.545 -0.605 0.545 10 10 0.579 
W5 101.5 108.5 46.500 -0.265 0.791 -0.265 0.791 10 10 0.796 
W6 116.0 94.0 39.000 0.832 0.406 0.833 0.405 10 10 0.436 
W7 105.5 104.5 49.500 0.038 0.970 0.038 0.970 10 10 0.971 
W8 101.0 109.0 46.000 -0.302 0.762 -0.302 0.762 10 10 0.796 
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Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Rat Weights. Statistical analyses - Mann Whitney U-test. 
 
Mann-Whitney U Test (delta.sta)        
By variable GROUP          
Group 1: 100-Sham Group 2: 103-OVX-St       
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Sham OVX-St U Z p-level adjusted p-level Sham OVX-St exact p 
DELTA 96 114 41 -0.680 0.496 -0.682 0.495 10 10 0.529 
           
Mann-Whitney U Test (delta.sta)         
By variable GROUP          
Group 1: 101-OVX Group 2: 102-Sh-St        
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 OVX Sh-St U Z p-level adjusted p-level OVX Sh-St exact p 
DELTA 126 84 29 1.587 0.112 1.589 0.112 10 10 0.123 
           
Mann-Whitney U Test (delta.sta)         
By variable GROUP          
Group 1: 100-Sham Group 2: 101-OVX        
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Sham OVX U Z p-level adjusted p-level Sham OVX exact p 
DELTA 84.5 125.5 29.5 -1.550 0.121 -1.552 0.121 10 10 0.123 
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Study 3.1: Groups Sh, Sh-S, OVX, OVX-S: Rat Weights. Statistical analyses - Mann Whitney U-test. 
 
           
Mann-Whitney U Test (delta.sta)         
By variable GROUP          
Group 1: 101-OVX Group 2: 103-OVX-St       
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 OVX OVX-St U Z p-level adjusted p-level OVX OVX-St exact p 
DELTA 116 94 39 0.832 0.406 0.833 0.405 10 10 0.436 
           
Mann-Whitney U Test (delta.sta)         
By variable GROUP          
Group 1: 100-Sham Group 2: 102-Sh-St        
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Sham Sh-St U Z p-level adjusted p-level Sham Sh-St exact p 
DELTA 103 107 48 -0.151 0.880 -0.151 0.880 10 10 0.912 
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Study 3.2. The effect of simvastatin 20mg/Kg/day administered for 12 weeks, on bone mineral density and quantitative bone histomorphometry, in intact female Sprague-Dawley rats. 
Study 3.2: Groups S20, C: Bone Mineral Density: Descriptive statistics 
 
 
 
 
 
Descriptive Statistics (bmd 1 and 2 femur.sta)        
   Confid. Confid.      Standard   
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis
CONTROL 10 0.1053 0.1012 0.1093 0.1039 0.0979 0.1161 0.0000 0.0057 0.0018 0.7839 -0.0845 
S20 10 0.1031 0.0991 0.1071 0.1023 0.0941 0.1138 0.0000 0.0056 0.0018 0.5187 0.4303 
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Study 3.2. The effect of simvastatin 20mg/Kg/day administered for 12 weeks, on bone mineral density and quantitative bone histomorphometry, in intact female Sprague-Dawley rats. 
Study 3.2: Groups S20, C: QBH: Descriptive statistics 
Descriptive Statistics (data histo for graphs.sta)             
S20   Confid. Confid.      Standard   
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis 
A Bone Volume (BV/TV)(%) 10 22.660 20.361 24.959 22.030 18.889 28.781 10.327 3.214 1.016 0.651 -0.479 
B Osteoid volume OV/BV (%) 10 0.923 0.374 1.472 0.820 0.267 2.457 0.588 0.767 0.243 1.317 0.740 
C Osteoid volume OV/TV (%) 10 0.202 0.093 0.312 0.187 0.051 0.483 0.024 0.154 0.049 1.013 -0.033 
D Osteoid Surface OS/BS (%) 10 6.905 3.531 10.280 5.388 1.959 18.428 22.252 4.717 1.492 1.845 3.882 
E Osteoblast surface Ob.S/BS (%) 10 1.755 0.797 2.712 1.486 0.309 4.072 1.792 1.339 0.423 1.079 0.067 
F Osteoid thickness O.Th (mcm) 10 6.572 4.766 8.377 6.776 3.091 10.990 6.372 2.524 0.798 0.181 -0.528 
G Eroded surface ES/BS (%) 10 9.351 7.851 10.850 9.361 5.740 12.263 4.394 2.096 0.663 -0.304 -0.849 
H Osteoclast surface Oc.S/BS (%) 10 1.360 1.012 1.707 1.495 0.717 1.994 0.236 0.486 0.154 -0.060 -1.682 
J Osteoclast number N.Oc/T.A. (/mm2) 10 0.114 0.084 0.145 0.118 0.052 0.173 0.002 0.043 0.014 -0.127 -1.426 
K Mineralising surface MS/BS (%) 10 7.923 6.837 9.009 7.465 5.877 10.554 2.304 1.518 0.480 0.483 -0.961 
L Osteoid apposition rate OAR       xi 10 0.712 0.661 0.763 0.702 0.607 0.843 0.005 0.071 0.023 0.399 -0.347 
M Mineralisation lag time Mlt (days) 10 0.334 0.230 0.438 0.332 0.139 0.526 0.021 0.146 0.046 -0.013 -1.888 
N Bone formation rate BFR/BS (mcm3/mcm2/yr) 10 20.560 17.367 23.754 18.748 15.476 29.409 19.927 4.464 1.412 1.032 0.195 
O Rel mineral Vol 10 99.077 98.528 99.626 99.180 97.543 99.733 0.588 0.767 0.243 -1.317 0.740 
P Surface Density 10 5.612 5.032 6.192 5.461 4.586 7.244 0.658 0.811 0.257 0.790 0.310 
Q Resting Surface 10 83.744 79.629 87.860 85.121 71.003 89.691 33.094 5.753 1.819 -1.342 1.654 
R Surf dens ost seams 10 0.377 0.216 0.539 0.327 0.090 0.922 0.051 0.226 0.071 1.598 3.827 
S Surf dens ostoid osteoblast interface 10 0.097 0.048 0.146 0.088 0.014 0.217 0.005 0.069 0.022 0.827 -0.350 
T Ostoid thickness index 10 12.676 9.463 15.890 13.320 5.929 19.576 20.176 4.492 1.420 -0.116 -0.691 
U Surface density of Howship's lacunae 10 0.525 0.415 0.636 0.534 0.333 0.888 0.024 0.154 0.049 1.395 3.089 
V Surface density of bone ostoclast interface 10 0.077 0.053 0.101 0.078 0.038 0.144 0.001 0.034 0.011 0.714 0.184 
W Total osteoclasts (v) 10 0.648 0.440 0.855 0.640 0.300 1.252 0.084 0.291 0.092 0.819 0.737 
X Bone osteoclasts (TRS) 10 1.193 0.999 1.387 1.219 0.856 1.604 0.073 0.271 0.086 0.169 -1.496 
Y Fractional labeled surfaces 10 13.194 11.438 14.951 12.623 9.634 17.647 6.030 2.456 0.777 0.391 -0.571 
Z Fractional double labeled surfaces 10 2.652 2.062 3.243 2.297 1.765 4.035 0.681 0.826 0.261 0.875 -0.915 
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Study 3.2. The effect of simvastatin 20mg/Kg/day administered for 12 weeks, on bone mineral density and quantitative bone histomorphometry, in intact female Sprague-Dawley rats. 
Study 3.2: Groups S20, C: QBH: Descriptive statistics 
Descriptive Statistics (data histo for graphs.sta)             
C     Confid. Confid.      Standard   
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis 
A Bone Volume (BV/TV)(%) 10 23.971 20.618 27.325 24.343 16.000 29.851 21.977 4.688 1.482 -0.447 -0.794 
B Osteoid volume OV/BV (%) 10 0.557 0.426 0.688 0.649 0.240 0.714 0.033 0.183 0.058 -0.991 -0.764 
C Osteoid volume OV/TV (%) 10 0.131 0.097 0.166 0.128 0.061 0.202 0.002 0.048 0.015 0.007 -0.681 
D Osteoid Surface OS/BS (%) 10 4.657 3.729 5.585 4.684 2.582 7.285 1.682 1.297 0.410 0.610 1.110 
E Osteoblast surface Ob.S/BS (%) 10 0.836 0.483 1.189 0.749 0.221 1.716 0.244 0.494 0.156 0.875 -0.079 
F Osteoid thickness O.Th (mcm) 10 6.060 4.750 7.371 5.740 3.643 9.067 3.358 1.833 0.580 0.747 -0.330 
G Eroded surface ES/BS (%) 10 7.388 6.617 8.160 7.334 5.978 9.379 1.164 1.079 0.341 0.471 -0.299 
H Osteoclast surface Oc.S/BS (%) 10 0.799 0.646 0.952 0.816 0.516 1.188 0.046 0.213 0.068 0.414 -0.379 
J Osteoclast number N.Oc/T.A. (/mm2) 10 0.065 0.052 0.079 0.068 0.041 0.098 0.000 0.019 0.006 0.198 -1.078 
K Mineralising surface MS/BS (%) 10 7.053 5.921 8.185 7.296 4.421 8.811 2.503 1.582 0.500 -0.584 -1.021 
L Osteoid apposition rate OAR       xi 10 0.670 0.615 0.725 0.666 0.544 0.821 0.006 0.077 0.024 0.417 1.038 
M Mineralisation lag time Mlt (days) 10 0.370 0.262 0.479 0.339 0.227 0.752 0.023 0.152 0.048 1.958 4.802 
N Bone formation rate BFR/BS (mcm3/mcm2/yr) 10 17.279 14.015 20.542 16.816 10.752 24.655 20.814 4.562 1.443 0.045 -1.045 
O Rel mineral Vol 10 99.443 99.312 99.574 99.351 99.286 99.760 0.033 0.183 0.058 0.991 -0.764 
P Surface Density 10 6.085 5.173 6.996 5.853 3.926 8.065 1.624 1.274 0.403 0.290 -0.018 
Q Resting Surface 10 87.955 86.591 89.319 88.498 84.674 89.945 3.634 1.906 0.603 -0.526 -1.260 
R Surf dens ost seams 10 0.279 0.222 0.337 0.280 0.156 0.400 0.007 0.081 0.026 -0.016 -0.690 
S Surf dens ostoid osteoblast interface 10 0.050 0.029 0.071 0.048 0.013 0.104 0.001 0.029 0.009 0.723 -0.148 
T Ostoid thickness index 10 11.920 9.817 14.023 11.560 7.768 17.477 8.642 2.940 0.930 0.491 -0.236 
U Surface density of Howship's lacunae 10 0.453 0.358 0.547 0.451 0.255 0.756 0.017 0.132 0.042 1.135 2.963 
V Surface density of bone ostoclast interface 10 0.048 0.038 0.057 0.046 0.030 0.066 0.000 0.013 0.004 0.014 -1.516 
W Total osteoclasts (v) 10 0.395 0.301 0.488 0.388 0.240 0.592 0.017 0.131 0.041 0.142 -1.777 
X Bone osteoclasts (TRS) 10 0.921 0.665 1.177 0.856 0.544 1.426 0.128 0.358 0.113 0.284 -1.839 
Y Fractional labeled surfaces 10 11.961 10.188 13.734 11.949 7.878 15.010 6.142 2.478 0.784 -0.402 -1.108 
Z Fractional double labeled surfaces 10 2.144 1.545 2.744 2.314 0.965 3.524 0.702 0.838 0.265 -0.196 -0.637 
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Study 3.2. The effect of simvastatin 20mg/Kg/day administered for 12 weeks, on bone mineral density and quantitative bone histomorphometry, in intact female Sprague-Dawley rats. 
Study 3.2: Groups S20, C: Bone mineral density: Statistical analysis - Mann Whitney U-test 
 
 
 
 
 
 
Mann-Whitney U Test (bmd 1 and 2 femur.sta)      
By variable GR_ST2          
Group 1: 100-Control Group 2: 20mg        
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Control Group 2 U Z p-level adjusted p-level Control Group 2 exact p 
BMD_ST_2 117 93 38 0.9071 0.3644 0.9071 0.3644 10 10 0.3930 
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Study 3.2. The effect of simvastatin 20mg/Kg/day administered for 12 weeks, on bone mineral density and quantitative bone histomorphometry, in intact female Sprague-Dawley rats. 
Study 3.2: Groups S20, C: QBH: Statistical analysis- Mann Whitney U-test 
Mann-Whitney U Test (data histo for graphs.sta)           
Group 1: 100-Control Group 2: 101-Simva20           
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Control Simva20 U Z p-level adjusted p-level Control Simva20 exact p 
A Bone Volume (BV/TV)(%) 116 94 39 0.8315 0.4057 0.8315 0.4057 10 10 0.436 
B Osteoid volume OV/BV (%) 89 121 34 -1.2095 0.2265 -1.2095 0.2265 10 10 0.247 
C Osteoid volume OV/TV (%) 92 118 37 -0.9827 0.3258 -0.9831 0.3256 10 10 0.353 
D Osteoid Surface OS/BS (%) 87 123 32 -1.3607 0.1736 -1.3607 0.1736 10 10 0.190 
E Osteoblast surface Ob.S/BS (%) 81 129 26 -1.8142 0.0697 -1.8142 0.0697 10 10 0.075 
F Osteoid thickness O.Th (mcm) 107.5 102.5 47.5 0.1890 0.8501 0.1891 0.8500 10 10 0.853 
G Eroded surface ES/BS (%) 124 86 31 1.4363 0.1509 1.4363 0.1509 10 10 0.165 
H Osteoclast surface Oc.S/BS (%) 129 81 26 1.8142 0.0697 1.8142 0.0697 10 10 0.075 
J Osteoclast number N.Oc/T.A. (/mm2) 115 95 40 0.7559 0.4497 0.7559 0.4497 10 10 0.481 
K Mineralising surface MS/BS (%) 136 74 19 2.3434 0.0191 2.3434 0.0191 10 10 0.019 
L Osteoid apposition rate OAR       xi 115 95 40 0.7559 0.4497 0.7562 0.4495 10 10 0.481 
M Mineralisation lag time Mlt (days) 92 118 37 -0.9827 0.3258 -0.9827 0.3258 10 10 0.353 
N Bone formation rate BFR/BS (mcm3/mcm2/yr) 138 72 17 2.4946 0.0126 2.4946 0.0126 10 10 0.011 
O Rel mineral Vol 84 126 29 -1.5875 0.1124 -1.5875 0.1124 10 10 0.123 
 
Mann-Whitney U Test (data histo desc stats.sta)          
Group 1: 100-Sham Sta Group 2: 101-Simva20           
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Sham Sta Simva20 U Z p-level adjusted p-level Sham Sta Simva20 exact p 
B Osteoid volume OV/BV (%) 131 79 24 1.965 0.049 1.965 0.049 10 10 0.052 
C Osteoid volume OV/TV (%) 131.5 78.5 23.5 2.003 0.045 2.005 0.045 10 10 0.043 
D Osteoid Surface OS/BS (%) 138 72 17 2.495 0.013 2.495 0.013 10 10 0.011 
E Osteoblast surface Ob.S/BS (%) 109 101 46 0.302 0.762 0.302 0.762 10 10 0.796 
G Eroded surface ES/BS (%) 117 93 38 0.907 0.364 0.907 0.364 10 10 0.393 
H Osteoclast surface Oc.S/BS (%) 93 117 38 -0.907 0.364 -0.907 0.364 10 10 0.393 
J Osteoclast number N.Oc/T.A. (/mm2) 110 100 45 0.378 0.705 0.378 0.705 10 10 0.739 
V Surface density of bone ostoclast interface 101 109 46 -0.302 0.762 -0.302 0.762 10 10 0.796 
W Total osteoclasts (v) 109 101 46 0.302 0.762 0.302 0.762 10 10 0.796 
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Study 3.2. The effect of simvastatin 20mg/Kg/day administered for 12 weeks, on bone mineral density and quantitative bone histomorphometry, in intact female Sprague-Dawley rats. 
Study 3.2: Groups S20, C: Rat Weights: Descriptive statistics 
 
 
 
 
 
 
Descriptive Statistics (statbone 2 weights1.sta)        
by GROUP: Control Control          
   Confid. Confid.      Standard   
 Valid N Mean -95.000% 95.000 Minimum Maximum Range Variance Std.Dev. Error Skewness Kurtosis
W1 10 247.1 240.17 254.03 230.00 260.00 30.00 93.88 9.69 3.06 -0.70 -0.31 
             
Descriptive Statistics (statbone 2 weights1.sta)        
by GROUP: S20 S20           
   Confid. Confid.      Standard   
 Valid N Mean -95.000% 95.000 Minimum Maximum Range Variance Std.Dev. Error Skewness Kurtosis
W1 10 241.7 232.22 251.18 220.00 255.00 35.00 175.79 13.26 4.19 -0.63 -0.96 
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Study 3.2. The effect of simvastatin 20mg/Kg/day administered for 12 weeks, on bone mineral density and quantitative bone histomorphometry, in intact female Sprague-Dawley rats. 
Study 3.2: Groups S20, C: Rat Weights: Statistical analysis - Mann Whitney U-test. 
 
 
 
 
 
 
Mann-Whitney U Test (statbone 2 weights1.sta)      
By variable GROUP          
Group 1: 100-S20 Group 2: 101-Control        
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
S20 Control U Z p-level adjusted p-level S20 Control exact p 
W1 94 116 39.00 -0.83 0.41 -0.84 0.40 10.00 10.00 0.44 
          
Mann-Whitney U Test (statbone 2 weights1.sta)       
By variable GROUP          
Group 1: 100-S20 Group 2: 101-Control        
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
S20 Control U Z p-level adjusted p-level S20 Control exact p 
WT_GAIN 91.5 118.5 36.50 -1.02 0.31 -1.03 0.31 10.00 10.00 0.31 
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Study 3.3 The effect of different dosages of simvastatin (20mg/Kg/day, 10mg/Kg/day, 5mg/Kg/day and 1mg/Kg/day) administered for 12 weeks, on bone mineral density and quantitative bone 
histomorphometry in intact female Sprague-Dawley rats. 
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Study 3.3: Groups S20, S10,S5, S1, C: Bone Mineral Density: Descriptive statistics 
 
 
Descriptive Statistics (bmd 1 and 2 femur.sta)        
   Confid. Confid.      Standard   
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis
CONTROL 10 0.1053 0.1012 0.1093 0.1039 0.0979 0.1161 0.0000 0.0057 0.0018 0.7839 -0.0845 
S20 10 0.1031 0.0991 0.1071 0.1023 0.0941 0.1138 0.0000 0.0056 0.0018 0.5187 0.4303 
S10 10 0.1001 0.0952 0.1050 0.0990 0.0890 0.1092 0.0000 0.0069 0.0022 -0.0638 -1.1106 
S5 10 0.1024 0.0971 0.1076 0.0986 0.0925 0.1118 0.0001 0.0074 0.0023 0.2722 -1.8984 
S1 9 0.0991 0.0943 0.1039 0.0989 0.0897 0.1081 0.0000 0.0063 0.0021 -0.4247 -0.6052 
 
 
Study 3.3 The effect of different dosages of simvastatin (20mg/Kg/day, 10mg/Kg/day, 5mg/Kg/day and 1mg/Kg/day) administered for 12 weeks, on bone mineral density and quantitative bone 
histomorphometry in intact female Sprague-Dawley rats. 
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Study 3.3: Groups S20, S10,S5, S1, C: Bone Mineral Density: Statistical analyses - Mann Whitney U-test 
 
 
Mann-Whitney U Test (bmd 1 and 2 femur.sta)      
By variable GR_ST2          
Group 1: 100-Control Group 2: 1mg         
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Control Group 2 U Z p-level adjusted p-level Control Group 2 exact p 
BMD_ST_2 121.0000 69.0000 24.0000 1.7146 0.0864 1.7146 0.0864 10 9 0.0947 
          
Mann-Whitney U Test (bmd 1 and 2 femur.sta)       
By variable GR_ST2          
Group 1: 100-Control Group 2: 5mg         
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Control Group 2 U Z p-level adjusted p-level Control Group 2 exact p 
BMD_ST_2 119.5000 90.5000 35.5000 1.0961 0.2730 1.0965 0.2729 10 10 0.2799 
          
Mann-Whitney U Test (bmd 1 and 2 femur.sta)       
By variable GR_ST2          
Group 1: 100-Control Group 2: 10mg        
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Control Group 2 U Z p-level adjusted p-level Control Group 2 exact p 
BMD_ST_2 125.5000 84.5000 29.5000 1.5497 0.1212 1.5502 0.1211 10 10 0.1230 
          
Mann-Whitney U Test (bmd 1 and 2 femur.sta)       
By variable GR_ST2          
Group 1: 100-Control Group 2: 20mg        
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Control Group 2 U Z p-level adjusted p-level Control Group 2 exact p 
BMD_ST_2 117.0000 93.0000 38.0000 0.9071 0.3644 0.9071 0.3644 10 10 0.3930 
 
Study 3.3 The effect of different dosages of simvastatin (20mg/Kg/day, 10mg/Kg/day, 5mg/Kg/day and 1mg/Kg/day) administered for 12 weeks, on bone mineral density and quantitative bone 
histomorphometry in intact female Sprague-Dawley rats. 
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Study 3.3: Groups S20, S10,S5, S1, C: QBH: Descriptive statistics 
 
Descriptive Statistics (data histo for graphs.sta)             
S20   Confid. Confid.      Standard   
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis 
A Bone Volume (BV/TV)(%) 10 22.66 20.36 24.96 22.03 18.89 28.78 10.33 3.21 1.02 0.65 -0.48 
B Osteoid volume OV/BV (%) 10 0.92 0.37 1.47 0.82 0.27 2.46 0.59 0.77 0.24 1.32 0.74 
C Osteoid volume OV/TV (%) 10 0.20 0.09 0.31 0.19 0.05 0.48 0.02 0.15 0.05 1.01 -0.03 
D Osteoid Surface OS/BS (%) 10 6.91 3.53 10.28 5.39 1.96 18.43 22.25 4.72 1.49 1.84 3.88 
E Osteoblast surface Ob.S/BS (%) 10 1.75 0.80 2.71 1.49 0.31 4.07 1.79 1.34 0.42 1.08 0.07 
F Osteoid thickness O.Th (mcm) 10 6.57 4.77 8.38 6.78 3.09 10.99 6.37 2.52 0.80 0.18 -0.53 
G Eroded surface ES/BS (%) 10 9.35 7.85 10.85 9.36 5.74 12.26 4.39 2.10 0.66 -0.30 -0.85 
H Osteoclast surface Oc.S/BS (%) 10 1.36 1.01 1.71 1.49 0.72 1.99 0.24 0.49 0.15 -0.06 -1.68 
J Osteoclast number N.Oc/T.A. (/mm2) 10 0.11 0.08 0.14 0.12 0.05 0.17 0.00 0.04 0.01 -0.13 -1.43 
K Mineralising surface MS/BS (%) 10 7.92 6.84 9.01 7.46 5.88 10.55 2.30 1.52 0.48 0.48 -0.96 
L Osteoid apposition rate OAR       xi 10 0.71 0.66 0.76 0.70 0.61 0.84 0.01 0.07 0.02 0.40 -0.35 
M Mineralisation lag time Mlt (days) 10 0.33 0.23 0.44 0.33 0.14 0.53 0.02 0.15 0.05 -0.01 -1.89 
N Bone formation rate BFR/BS (mcm3/mcm2/yr) 10 20.56 17.37 23.75 18.75 15.48 29.41 19.93 4.46 1.41 1.03 0.20 
O Rel mineral Vol 10 99.08 98.53 99.63 99.18 97.54 99.73 0.59 0.77 0.24 -1.32 0.74 
P Surface Density 10 5.61 5.03 6.19 5.46 4.59 7.24 0.66 0.81 0.26 0.79 0.31 
Q Resting Surface 10 83.74 79.63 87.86 85.12 71.00 89.69 33.09 5.75 1.82 -1.34 1.65 
R Surf dens ost seams 10 0.38 0.22 0.54 0.33 0.09 0.92 0.05 0.23 0.07 1.60 3.83 
S Surf dens ostoid osteoblast interface 10 0.10 0.05 0.15 0.09 0.01 0.22 0.00 0.07 0.02 0.83 -0.35 
T Ostoid thickness index 10 12.68 9.46 15.89 13.32 5.93 19.58 20.18 4.49 1.42 -0.12 -0.69 
U Surface density of Howship's lacunae 10 0.53 0.41 0.64 0.53 0.33 0.89 0.02 0.15 0.05 1.39 3.09 
V Surface density of bone ostoclast interface 10 0.08 0.05 0.10 0.08 0.04 0.14 0.00 0.03 0.01 0.71 0.18 
W Total osteoclasts (v) 10 0.65 0.44 0.86 0.64 0.30 1.25 0.08 0.29 0.09 0.82 0.74 
X Bone osteoclasts (TRS) 10 1.19 1.00 1.39 1.22 0.86 1.60 0.07 0.27 0.09 0.17 -1.50 
Y Fractional labeled surfaces 10 13.19 11.44 14.95 12.62 9.63 17.65 6.03 2.46 0.78 0.39 -0.57 
Z Fractional double labeled surfaces 10 2.65 2.06 3.24 2.30 1.76 4.04 0.68 0.83 0.26 0.87 -0.91 
 
Study 3.3 The effect of different dosages of simvastatin (20mg/Kg/day, 10mg/Kg/day, 5mg/Kg/day and 1mg/Kg/day) administered for 12 weeks, on bone mineral density and quantitative bone 
histomorphometry in intact female Sprague-Dawley rats. 
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Study 3.3: Groups S20, S10,S5, S1, C: QBH: Descriptive statistics 
 
Descriptive Statistics (data histo for graphs.sta)             
S10   Confid. Confid.      Standard   
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis 
A Bone Volume (BV/TV)(%) 10 20.41 17.53 23.30 20.85 12.32 27.00 16.27 4.03 1.28 -0.50 1.02 
B Osteoid volume OV/BV (%) 10 0.48 0.13 0.84 0.28 0.11 1.72 0.25 0.50 0.16 2.02 4.04 
C Osteoid volume OV/TV (%) 10 0.09 0.03 0.15 0.06 0.02 0.26 0.01 0.08 0.03 1.30 0.62 
D Osteoid Surface OS/BS (%) 10 3.96 1.29 6.63 2.77 0.85 13.79 13.98 3.74 1.18 2.39 6.28 
E Osteoblast surface Ob.S/BS (%) 10 0.44 0.04 0.84 0.27 0.00 1.95 0.32 0.56 0.18 2.53 7.08 
F Osteoid thickness O.Th (mcm) 10 6.55 3.51 9.59 5.49 1.48 15.11 18.07 4.25 1.34 0.79 0.25 
G Eroded surface ES/BS (%) 10 6.95 4.18 9.73 5.13 3.85 15.32 15.06 3.88 1.23 1.44 1.15 
H Osteoclast surface Oc.S/BS (%) 10 0.74 0.25 1.22 0.46 0.20 2.37 0.46 0.68 0.21 1.95 3.43 
J Osteoclast number N.Oc/T.A. (/mm2) 10 0.07 0.03 0.12 0.05 0.02 0.23 0.00 0.06 0.02 1.90 3.46 
K Mineralising surface MS/BS (%) 10 5.42 2.65 8.20 4.52 2.46 15.88 15.09 3.88 1.23 2.57 7.26 
L Osteoid apposition rate OAR       xi 10 0.63 0.53 0.73 0.63 0.39 0.80 0.02 0.14 0.04 -0.44 -0.93 
M Mineralisation lag time Mlt (days) 10 0.73 0.31 1.15 0.53 0.12 1.76 0.35 0.59 0.19 0.64 -1.08 
N Bone formation rate BFR/BS (mcm3/mcm2/yr) 10 12.14 6.15 18.14 10.34 3.51 34.71 70.25 8.38 2.65 2.52 7.41 
O Rel mineral Vol 10 99.52 99.16 99.87 99.72 98.28 99.89 0.25 0.50 0.16 -2.02 4.04 
P Surface Density 10 5.50 4.96 6.03 5.61 4.06 6.46 0.57 0.75 0.24 -0.62 -0.26 
Q Resting Surface 10 89.09 84.15 94.02 92.20 70.89 93.77 47.60 6.90 2.18 -2.42 6.36 
R Surf dens ost seams 10 0.20 0.09 0.31 0.16 0.05 0.56 0.02 0.16 0.05 1.65 2.43 
S Surf dens ostoid osteoblast interface 10 0.02 0.01 0.04 0.01 0.00 0.08 0.00 0.02 0.01 1.84 3.93 
T Ostoid thickness index 10 13.81 7.35 20.27 13.17 3.10 34.26 81.53 9.03 2.86 1.22 2.19 
U Surface density of Howship's lacunae 10 0.37 0.25 0.49 0.29 0.18 0.68 0.03 0.17 0.05 0.91 -0.50 
V Surface density of bone ostoclast interface 10 0.04 0.02 0.06 0.02 0.01 0.10 0.00 0.03 0.01 1.46 0.98 
W Total osteoclasts (v) 10 0.38 0.19 0.57 0.29 0.14 0.91 0.07 0.26 0.08 1.31 0.82 
X Bone osteoclasts (TRS) 10 1.01 0.71 1.32 1.07 0.50 1.58 0.19 0.43 0.14 0.05 -1.79 
Y Fractional labeled surfaces 10 9.15 4.44 13.86 7.41 4.43 27.02 43.39 6.59 2.08 2.64 7.61 
Z Fractional double labeled surfaces 10 1.70 0.82 2.58 1.33 0.49 4.74 1.52 1.23 0.39 1.93 4.12 
 
Study 3.3 The effect of different dosages of simvastatin (20mg/Kg/day, 10mg/Kg/day, 5mg/Kg/day and 1mg/Kg/day) administered for 12 weeks, on bone mineral density and quantitative bone 
histomorphometry in intact female Sprague-Dawley rats. 
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Study 3.3: Groups S20, S10,S5, S1, C: QBH: Descriptive statistics 
 
Descriptive Statistics (data histo for graphs.sta)             
S5   Confid. Confid.      Standard   
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis 
A Bone Volume (BV/TV)(%) 10 22.97 20.99 24.95 22.75 19.58 26.57 7.65 2.77 0.87 0.03 -1.76 
B Osteoid volume OV/BV (%) 10 0.42 0.29 0.56 0.40 0.18 0.72 0.04 0.19 0.06 0.33 -1.03 
C Osteoid volume OV/TV (%) 10 0.10 0.07 0.13 0.10 0.04 0.18 0.00 0.04 0.01 0.32 0.02 
D Osteoid Surface OS/BS (%) 10 3.68 2.54 4.81 3.06 1.86 6.74 2.54 1.59 0.50 1.18 0.41 
E Osteoblast surface Ob.S/BS (%) 10 0.67 0.42 0.92 0.55 0.23 1.39 0.12 0.35 0.11 0.91 0.72 
F Osteoid thickness O.Th (mcm) 10 6.46 4.06 8.86 5.37 2.34 11.33 11.23 3.35 1.06 0.32 -1.75 
G Eroded surface ES/BS (%) 10 5.30 4.47 6.12 5.23 3.91 7.26 1.34 1.16 0.37 0.59 -0.52 
H Osteoclast surface Oc.S/BS (%) 10 0.56 0.28 0.84 0.53 0.10 1.48 0.15 0.39 0.12 1.40 3.01 
J Osteoclast number N.Oc/T.A. (/mm2) 10 0.06 0.03 0.08 0.05 0.01 0.14 0.00 0.04 0.01 1.18 2.10 
K Mineralising surface MS/BS (%) 10 4.54 3.96 5.12 4.67 3.10 5.91 0.66 0.81 0.26 -0.13 -0.08 
L Osteoid apposition rate OAR       xi 10 1.00 0.91 1.09 0.98 0.78 1.17 0.01 0.12 0.04 -0.40 -0.22 
M Mineralisation lag time Mlt (days) 10 0.40 0.24 0.56 0.34 0.11 0.82 0.05 0.22 0.07 0.83 -0.11 
N Bone formation rate BFR/BS (mcm3/mcm2/yr) 10 16.71 13.51 19.91 15.69 11.03 25.22 20.05 4.48 1.42 0.55 -0.17 
O Rel mineral Vol 10 99.58 99.44 99.71 99.60 99.28 99.82 0.04 0.19 0.06 -0.33 -1.03 
P Surface Density 10 5.78 5.25 6.31 5.65 4.85 6.96 0.55 0.74 0.23 0.39 -1.22 
Q Resting Surface 10 91.37 90.28 92.46 91.50 88.67 93.61 2.30 1.52 0.48 -0.39 -0.36 
R Surf dens ost seams 10 0.21 0.14 0.28 0.18 0.13 0.41 0.01 0.10 0.03 1.34 0.83 
S Surf dens ostoid osteoblast interface 10 0.04 0.02 0.05 0.04 0.01 0.09 0.00 0.02 0.01 1.18 2.23 
T Ostoid thickness index 10 12.87 7.85 17.89 10.11 4.67 25.57 49.28 7.02 2.22 0.58 -0.91 
U Surface density of Howship's lacunae 10 0.31 0.25 0.36 0.28 0.20 0.40 0.01 0.07 0.02 0.24 -1.64 
V Surface density of bone ostoclast interface 10 0.03 0.02 0.05 0.03 0.00 0.08 0.00 0.02 0.01 1.01 1.02 
W Total osteoclasts (v) 10 0.32 0.18 0.47 0.27 0.06 0.73 0.04 0.20 0.06 0.87 0.53 
X Bone osteoclasts (TRS) 10 1.01 0.65 1.37 0.96 0.28 1.89 0.25 0.50 0.16 0.30 -0.53 
Y Fractional labeled surfaces 10 7.88 6.88 8.87 7.72 5.86 10.24 1.93 1.39 0.44 0.30 -0.79 
Z Fractional double labeled surfaces 10 1.20 0.88 1.53 1.20 0.34 2.02 0.20 0.45 0.14 -0.16 1.23 
 
Study 3.3 The effect of different dosages of simvastatin (20mg/Kg/day, 10mg/Kg/day, 5mg/Kg/day and 1mg/Kg/day) administered for 12 weeks, on bone mineral density and quantitative bone 
histomorphometry in intact female Sprague-Dawley rats. 
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Study 3.3: Groups S20, S10,S5, S1, C: QBH: Descriptive statistics 
 
Descriptive Statistics (data histo for graphs.sta)             
S1   Confid. Confid.      Standard   
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis 
A Bone Volume (BV/TV)(%) 9 21.04 17.29 24.79 20.56 14.20 28.32 23.78 4.88 1.63 0.25 -0.99 
B Osteoid volume OV/BV (%) 9 0.43 0.10 0.76 0.24 0.09 1.47 0.19 0.43 0.14 2.11 4.81 
C Osteoid volume OV/TV (%) 9 0.08 0.03 0.12 0.07 0.02 0.21 0.00 0.06 0.02 1.45 2.41 
D Osteoid Surface OS/BS (%) 9 2.86 0.23 5.48 1.71 0.76 11.61 11.66 3.41 1.14 2.59 7.07 
E Osteoblast surface Ob.S/BS (%) 9 0.53 0.10 0.96 0.46 0.00 1.75 0.32 0.56 0.19 1.41 2.02 
F Osteoid thickness O.Th (mcm) 9 8.51 5.60 11.41 8.24 1.74 13.60 14.33 3.79 1.26 -0.23 0.05 
G Eroded surface ES/BS (%) 9 6.78 5.09 8.47 6.05 3.98 10.02 4.84 2.20 0.73 0.31 -1.31 
H Osteoclast surface Oc.S/BS (%) 9 0.97 0.64 1.31 0.90 0.42 1.75 0.19 0.44 0.15 0.60 -0.16 
J Osteoclast number N.Oc/T.A. (/mm2) 9 0.10 0.06 0.13 0.09 0.04 0.18 0.00 0.05 0.02 0.52 -0.40 
K Mineralising surface MS/BS (%) 9 5.04 2.70 7.38 4.33 2.38 12.42 9.30 3.05 1.02 2.05 4.95 
L Osteoid apposition rate OAR       xi 9 0.51 0.36 0.66 0.55 0.22 0.80 0.04 0.19 0.06 -0.05 -1.00 
M Mineralisation lag time Mlt (days) 9 1.22 0.58 1.87 0.97 0.23 2.51 0.70 0.84 0.28 0.67 -1.18 
N Bone formation rate BFR/BS (mcm3/mcm2/yr) 9 9.69 4.16 15.23 7.07 2.88 24.80 51.87 7.20 2.40 1.37 1.35 
O Rel mineral Vol 9 99.57 99.24 99.90 99.76 98.53 99.91 0.19 0.43 0.14 -2.11 4.81 
P Surface Density 9 5.52 4.84 6.19 5.56 4.09 7.22 0.77 0.88 0.29 0.44 1.35 
Q Resting Surface 9 90.36 86.43 94.29 92.15 78.38 95.25 26.16 5.11 1.70 -1.86 3.88 
R Surf dens ost seams 9 0.14 0.04 0.24 0.10 0.04 0.47 0.02 0.13 0.04 2.31 5.91 
S Surf dens ostoid osteoblast interface 9 0.03 0.01 0.04 0.02 0.00 0.07 0.00 0.02 0.01 0.78 0.01 
T Ostoid thickness index 9 17.81 11.68 23.93 19.03 3.62 28.22 63.48 7.97 2.66 -0.37 -0.48 
U Surface density of Howship's lacunae 9 0.36 0.29 0.43 0.40 0.20 0.46 0.01 0.09 0.03 -0.74 -0.49 
V Surface density of bone ostoclast interface 9 0.05 0.04 0.07 0.05 0.02 0.08 0.00 0.02 0.01 -0.28 -1.04 
W Total osteoclasts (v) 9 0.52 0.34 0.70 0.54 0.20 0.88 0.05 0.23 0.08 0.06 -1.10 
X Bone osteoclasts (TRS) 9 1.38 1.08 1.69 1.20 0.93 2.07 0.15 0.39 0.13 0.65 -0.80 
Y Fractional labeled surfaces 9 8.48 4.98 11.98 7.51 4.09 18.79 20.73 4.55 1.52 1.57 2.98 
Z Fractional double labeled surfaces 9 1.60 0.28 2.92 1.00 0.40 6.05 2.96 1.72 0.57 2.67 7.54 
 
Study 3.3 The effect of different dosages of simvastatin (20mg/Kg/day, 10mg/Kg/day, 5mg/Kg/day and 1mg/Kg/day) administered for 12 weeks, on bone mineral density and quantitative bone 
histomorphometry in intact female Sprague-Dawley rats. 
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Study 3.3: Groups S20, S10,S5, S1, C: QBH: Descriptive statistics 
 
Descriptive Statistics (data histo for graphs.sta)             
C     Confid. Confid.      Standard   
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis 
A Bone Volume (BV/TV)(%) 10 23.97 20.62 27.32 24.34 16.00 29.85 21.98 4.69 1.48 -0.45 -0.79 
B Osteoid volume OV/BV (%) 10 0.56 0.43 0.69 0.65 0.24 0.71 0.03 0.18 0.06 -0.99 -0.76 
C Osteoid volume OV/TV (%) 10 0.13 0.10 0.17 0.13 0.06 0.20 0.00 0.05 0.02 0.01 -0.68 
D Osteoid Surface OS/BS (%) 10 4.66 3.73 5.58 4.68 2.58 7.28 1.68 1.30 0.41 0.61 1.11 
E Osteoblast surface Ob.S/BS (%) 10 0.84 0.48 1.19 0.75 0.22 1.72 0.24 0.49 0.16 0.88 -0.08 
F Osteoid thickness O.Th (mcm) 10 6.06 4.75 7.37 5.74 3.64 9.07 3.36 1.83 0.58 0.75 -0.33 
G Eroded surface ES/BS (%) 10 7.39 6.62 8.16 7.33 5.98 9.38 1.16 1.08 0.34 0.47 -0.30 
H Osteoclast surface Oc.S/BS (%) 10 0.80 0.65 0.95 0.82 0.52 1.19 0.05 0.21 0.07 0.41 -0.38 
J Osteoclast number N.Oc/T.A. (/mm2) 10 0.07 0.05 0.08 0.07 0.04 0.10 0.00 0.02 0.01 0.20 -1.08 
K Mineralising surface MS/BS (%) 10 7.05 5.92 8.18 7.30 4.42 8.81 2.50 1.58 0.50 -0.58 -1.02 
L Osteoid apposition rate OAR       xi 10 0.67 0.61 0.73 0.67 0.54 0.82 0.01 0.08 0.02 0.42 1.04 
M Mineralisation lag time Mlt (days) 10 0.37 0.26 0.48 0.34 0.23 0.75 0.02 0.15 0.05 1.96 4.80 
N Bone formation rate BFR/BS (mcm3/mcm2/yr) 10 17.28 14.01 20.54 16.82 10.75 24.65 20.81 4.56 1.44 0.04 -1.05 
O Rel mineral Vol 10 99.44 99.31 99.57 99.35 99.29 99.76 0.03 0.18 0.06 0.99 -0.76 
P Surface Density 10 6.08 5.17 7.00 5.85 3.93 8.06 1.62 1.27 0.40 0.29 -0.02 
Q Resting Surface 10 87.95 86.59 89.32 88.50 84.67 89.95 3.63 1.91 0.60 -0.53 -1.26 
R Surf dens ost seams 10 0.28 0.22 0.34 0.28 0.16 0.40 0.01 0.08 0.03 -0.02 -0.69 
S Surf dens ostoid osteoblast interface 10 0.05 0.03 0.07 0.05 0.01 0.10 0.00 0.03 0.01 0.72 -0.15 
T Ostoid thickness index 10 11.92 9.82 14.02 11.56 7.77 17.48 8.64 2.94 0.93 0.49 -0.24 
U Surface density of Howship's lacunae 10 0.45 0.36 0.55 0.45 0.25 0.76 0.02 0.13 0.04 1.13 2.96 
V Surface density of bone ostoclast interface 10 0.05 0.04 0.06 0.05 0.03 0.07 0.00 0.01 0.00 0.01 -1.52 
W Total osteoclasts (v) 10 0.39 0.30 0.49 0.39 0.24 0.59 0.02 0.13 0.04 0.14 -1.78 
X Bone osteoclasts (TRS) 10 0.92 0.67 1.18 0.86 0.54 1.43 0.13 0.36 0.11 0.28 -1.84 
Y Fractional labeled surfaces 10 11.96 10.19 13.73 11.95 7.88 15.01 6.14 2.48 0.78 -0.40 -1.11 
Z Fractional double labeled surfaces 10 2.14 1.55 2.74 2.31 0.96 3.52 0.70 0.84 0.26 -0.20 -0.64 
 
Study 3.3 The effect of different dosages of simvastatin (20mg/Kg/day, 10mg/Kg/day, 5mg/Kg/day and 1mg/Kg/day) administered for 12 weeks, on bone mineral density and quantitative bone 
histomorphometry in intact female Sprague-Dawley rats. 
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Study 3.3: Groups S20, S10,S5, S1, C: QBH: Statistical analyses - Mann Whitney U-test 
 
Mann-Whitney U Test (st2 histo data corelation)           
By variable GROUPS           
Group 1: 100-Control Group 2: 101-Simva20           
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided 
Control Simva20 U Z p-level adjusted p-level Control Simva20 exact p 
A Bone Volume (BV/TV)(%) 116 94 39 0.832 0.406 0.832 0.406 10 10 0.436 
B Osteoid volume OV/BV (%) 89 121 34 -1.209 0.226 -1.209 0.226 10 10 0.247 
C Osteoid volume OV/TV (%) 92 118 37 -0.983 0.326 -0.983 0.326 10 10 0.353 
D Osteoid Surface OS/BS (%) 87 123 32 -1.361 0.174 -1.361 0.174 10 10 0.190 
E Osteoblast surface Ob.S/BS (%) 81 129 26 -1.814 0.070 -1.814 0.070 10 10 0.075 
F Osteoid thickness O.Th (mcm) 97 113 42 -0.605 0.545 -0.605 0.545 10 10 0.579 
G Eroded surface ES/BS (%) 78 132 23 -2.041 0.041 -2.041 0.041 10 10 0.043 
H Osteoclast surface Oc.S/BS (%) 70 140 15 -2.646 0.008 -2.646 0.008 10 10 0.007 
J Osteoclast number N.Oc/T.A. (/mm2) 73 137 18 -2.419 0.016 -2.419 0.016 10 10 0.015 
K Mineralising surface MS/BS (%) 91 119 36 -1.058 0.290 -1.058 0.290 10 10 0.315 
L Osteoid apposition rate OAR       xi 89.5 120.5 34.5 -1.172 0.241 -1.173 0.241 10 10 0.247 
M Mineralisation lag time Mlt (days) 110 100 45 0.378 0.705 0.378 0.705 10 10 0.739 
N Bone formation rate BFR/BS (mcm3/mcm2/yr) 86 124 31 -1.436 0.151 -1.436 0.151 10 10 0.165 
O Rel mineral Vol 121 89 34 1.209 0.226 1.209 0.226 10 10 0.247 
P Surface Density 119 91 36 1.058 0.290 1.058 0.290 10 10 0.315 
Q Resting Surface 132 78 23 2.041 0.041 2.041 0.041 10 10 0.043 
R Surf dens ost seams 86.5 123.5 31.5 -1.398 0.162 -1.399 0.162 10 10 0.165 
S Surf dens ostoid osteoblast interface 85 125 30 -1.512 0.131 -1.512 0.131 10 10 0.143 
T Ostoid thickness index 100 110 45 -0.378 0.705 -0.378 0.705 10 10 0.739 
U Surface density of Howship's lacunae 88 122 33 -1.285 0.199 -1.285 0.199 10 10 0.218 
V Surface density of bone ostoclast interface 77 133 22 -2.117 0.034 -2.117 0.034 10 10 0.035 
W Total osteoclasts (v) 75.5 134.5 20.5 -2.230 0.026 -2.231 0.026 10 10 0.023 
X Bone osteoclasts (TRS) 84 126 29 -1.587 0.112 -1.587 0.112 10 10 0.123 
Y Fractional labeled surfaces 90 120 35 -1.134 0.257 -1.134 0.257 10 10 0.280 
Z Fractional double labeled surfaces 97 113 42 -0.605 0.545 -0.605 0.545 10 10 0.579 
 
Study 3.3 The effect of different dosages of simvastatin (20mg/Kg/day, 10mg/Kg/day, 5mg/Kg/day and 1mg/Kg/day) administered for 12 weeks, on bone mineral density and quantitative bone 
histomorphometry in intact female Sprague-Dawley rats. 
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Study 3.3: Groups S20, S10,S5, S1, C: QBH: Statistical analyses - Mann Whitney U-test 
 
Mann-Whitney U Test (st2 histo data corelation)           
By variable GROUPS           
Group 1: 100-Control Group 2: 102-simva10           
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Control simva10 U Z p-level adjusted p-level Control simva10 exact p 
A Bone Volume (BV/TV)(%) 129 81 26 1.814 0.070 1.814 0.070 10 10 0.075 
B Osteoid volume OV/BV (%) 126 84 29 1.587 0.112 1.587 0.112 10 10 0.123 
C Osteoid volume OV/TV (%) 127 83 28 1.663 0.096 1.664 0.096 10 10 0.105 
D Osteoid Surface OS/BS (%) 129 81 26 1.814 0.070 1.814 0.070 10 10 0.075 
E Osteoblast surface Ob.S/BS (%) 137 73 18 2.419 0.016 2.419 0.016 10 10 0.015 
F Osteoid thickness O.Th (mcm) 107.5 102.5 47.5 0.189 0.850 0.189 0.850 10 10 0.853 
G Eroded surface ES/BS (%) 124 86 31 1.436 0.151 1.436 0.151 10 10 0.165 
H Osteoclast surface Oc.S/BS (%) 129 81 26 1.814 0.070 1.814 0.070 10 10 0.075 
J Osteoclast number N.Oc/T.A. (/mm2) 115 95 40 0.756 0.450 0.756 0.450 10 10 0.481 
K Mineralising surface MS/BS (%) 136 74 19 2.343 0.019 2.343 0.019 10 10 0.019 
L Osteoid apposition rate OAR       xi 115 95 40 0.756 0.450 0.756 0.450 10 10 0.481 
M Mineralisation lag time Mlt (days) 92 118 37 -0.983 0.326 -0.983 0.326 10 10 0.353 
N Bone formation rate BFR/BS (mcm3/mcm2/yr) 138 72 17 2.495 0.013 2.495 0.013 10 10 0.011 
O Rel mineral Vol 84 126 29 -1.587 0.112 -1.587 0.112 10 10 0.123 
P Surface Density 117 93 38 0.907 0.364 0.907 0.364 10 10 0.393 
Q Resting Surface 83 127 28 -1.663 0.096 -1.663 0.096 10 10 0.105 
R Surf dens ost seams 130 80 25 1.890 0.059 1.890 0.059 10 10 0.063 
S Surf dens ostoid osteoblast interface 136 74 19 2.343 0.019 2.343 0.019 10 10 0.019 
T Ostoid thickness index 103 107 48 -0.151 0.880 -0.151 0.880 10 10 0.912 
U Surface density of Howship's lacunae 122 88 33 1.285 0.199 1.285 0.199 10 10 0.218 
V Surface density of bone ostoclast interface 129 81 26 1.814 0.070 1.814 0.070 10 10 0.075 
W Total osteoclasts (v) 118 92 37 0.983 0.326 0.983 0.326 10 10 0.353 
X Bone osteoclasts (TRS) 100.5 109.5 45.5 -0.340 0.734 -0.340 0.734 10 10 0.739 
Y Fractional labeled surfaces 138 72 17 2.495 0.013 2.495 0.013 10 10 0.011 
Z Fractional double labeled surfaces 122 88 33 1.285 0.199 1.285 0.199 10 10 0.218 
 
Study 3.3 The effect of different dosages of simvastatin (20mg/Kg/day, 10mg/Kg/day, 5mg/Kg/day and 1mg/Kg/day) administered for 12 weeks, on bone mineral density and quantitative bone 
histomorphometry in intact female Sprague-Dawley rats. 
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Study 3.3: Groups S20, S10,S5, S1, C: QBH: Statistical analyses - Mann Whitney U-test 
 
Mann-Whitney U Test (st2 histo data corelation)           
By variable GROUPS           
Group 1: 100-Control Group 2: 103-simva 5           
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Control simva 5 U Z p-level adjusted p-level Control simva 5 exact p 
A Bone Volume (BV/TV)(%) 115 95 40 0.756 0.450 0.756 0.450 10 10 0.481 
B Osteoid volume OV/BV (%) 124 86 31 1.436 0.151 1.436 0.151 10 10 0.165 
C Osteoid volume OV/TV (%) 127.5 82.5 27.5 1.701 0.089 1.702 0.089 10 10 0.089 
D Osteoid Surface OS/BS (%) 127 83 28 1.663 0.096 1.663 0.096 10 10 0.105 
E Osteoblast surface Ob.S/BS (%) 114 96 41 0.680 0.496 0.680 0.496 10 10 0.529 
F Osteoid thickness O.Th (mcm) 105 105 50 0.000 1.000 0.000 1.000 10 10 1.029 
G Eroded surface ES/BS (%) 147 63 8 3.175 0.002 3.175 0.002 10 10 0.001 
H Osteoclast surface Oc.S/BS (%) 133 77 22 2.117 0.034 2.117 0.034 10 10 0.035 
J Osteoclast number N.Oc/T.A. (/mm2) 120 90 35 1.134 0.257 1.134 0.257 10 10 0.280 
K Mineralising surface MS/BS (%) 145 65 10 3.024 0.002 3.024 0.002 10 10 0.002 
L Osteoid apposition rate OAR       xi 56 154 1 -3.704 0.000 -3.711 0.000 10 10 0.000 
M Mineralisation lag time Mlt (days) 106 104 49 0.076 0.940 0.076 0.940 10 10 0.971 
N Bone formation rate BFR/BS (mcm3/mcm2/yr) 110 100 45 0.378 0.705 0.378 0.705 10 10 0.739 
O Rel mineral Vol 86 124 31 -1.436 0.151 -1.436 0.151 10 10 0.165 
P Surface Density 113 97 42 0.605 0.545 0.605 0.545 10 10 0.579 
Q Resting Surface 62 148 7 -3.250 0.001 -3.250 0.001 10 10 0.000 
R Surf dens ost seams 128 82 27 1.739 0.082 1.739 0.082 10 10 0.089 
S Surf dens ostoid osteoblast interface 116 94 39 0.832 0.406 0.832 0.406 10 10 0.436 
T Ostoid thickness index 104 106 49 -0.076 0.940 -0.076 0.940 10 10 0.971 
U Surface density of Howship's lacunae 141 69 14 2.721 0.007 2.721 0.007 10 10 0.005 
V Surface density of bone ostoclast interface 131 79 24 1.965 0.049 1.965 0.049 10 10 0.052 
W Total osteoclasts (v) 122.5 87.5 32.5 1.323 0.186 1.323 0.186 10 10 0.190 
X Bone osteoclasts (TRS) 101.5 108.5 46.5 -0.265 0.791 -0.265 0.791 10 10 0.796 
Y Fractional labeled surfaces 148 62 7 3.250 0.001 3.250 0.001 10 10 0.000 
Z Fractional double labeled surfaces 135 75 20 2.268 0.023 2.268 0.023 10 10 0.023 
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Study 3.3: Groups S20, S10,S5, S1, C: QBH: Statistical analyses - Mann Whitney U-test 
 
Mann-Whitney U Test (st2 histo data corelation)           
By variable GROUPS           
Group 1: 100-Control Group 2: 104-simva 1           
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided 
Control simva 1 U Z p-level adjusted p-level Control simva 1 exact p 
A Bone Volume (BV/TV)(%) 116 74 29 1.306 0.191 1.306 0.191 10 9 0.211 
B Osteoid volume OV/BV (%) 123 67 22 1.878 0.060 1.878 0.060 10 9 0.065 
C Osteoid volume OV/TV (%) 126 64 19 2.123 0.034 2.127 0.033 10 9 0.035 
D Osteoid Surface OS/BS (%) 133 57 12 2.694 0.007 2.694 0.007 10 9 0.006 
E Osteoblast surface Ob.S/BS (%) 118 72 27 1.470 0.142 1.470 0.142 10 9 0.156 
F Osteoid thickness O.Th (mcm) 78.5 111.5 23.5 -1.755 0.079 -1.759 0.079 10 9 0.079 
G Eroded surface ES/BS (%) 112 78 33 0.980 0.327 0.980 0.327 10 9 0.356 
H Osteoclast surface Oc.S/BS (%) 89 101 34 -0.898 0.369 -0.898 0.369 10 9 0.400 
J Osteoclast number N.Oc/T.A. (/mm2) 83 107 28 -1.388 0.165 -1.388 0.165 10 9 0.182 
K Mineralising surface MS/BS (%) 130 60 15 2.449 0.014 2.449 0.014 10 9 0.013 
L Osteoid apposition rate OAR       xi 124 66 21 1.960 0.050 1.960 0.050 10 9 0.053 
M Mineralisation lag time Mlt (days) 67 123 12 -2.694 0.007 -2.694 0.007 10 9 0.006 
N Bone formation rate BFR/BS (mcm3/mcm2/yr) 128 62 17 2.286 0.022 2.286 0.022 10 9 0.022 
O Rel mineral Vol 77 113 22 -1.878 0.060 -1.878 0.060 10 9 0.065 
P Surface Density 113 77 32 1.061 0.288 1.061 0.288 10 9 0.315 
Q Resting Surface 72 118 17 -2.286 0.022 -2.286 0.022 10 9 0.022 
R Surf dens ost seams 133 57 12 2.694 0.007 2.696 0.007 10 9 0.006 
S Surf dens ostoid osteoblast interface 122.5 67.5 22.5 1.837 0.066 1.838 0.066 10 9 0.065 
T Ostoid thickness index 75 115 20 -2.041 0.041 -2.041 0.041 10 9 0.043 
U Surface density of Howship's lacunae 120 70 25 1.633 0.102 1.633 0.102 10 9 0.113 
V Surface density of bone ostoclast interface 94 96 39 -0.490 0.624 -0.490 0.624 10 9 0.661 
W Total osteoclasts (v) 85.5 104.5 30.5 -1.184 0.236 -1.184 0.236 10 9 0.243 
X Bone osteoclasts (TRS) 75 115 20 -2.041 0.041 -2.041 0.041 10 9 0.043 
Y Fractional labeled surfaces 129 61 16 2.368 0.018 2.368 0.018 10 9 0.017 
Z Fractional double labeled surfaces 125 65 20 2.041 0.041 2.041 0.041 10 9 0.043 
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Study 3.3: Groups S20, S10,S5, S1, C: QBH: Statistical analyses - ANOVA; All effects 
 
GROUPS; LS Means (anova histo.sta)  
Wilks lambda=.11347, F(44, 132.03)=2.2992, 
p=.00015 
 
Effective hypothesis 
decomposition 
 
  A_BONE_V A_BONE_V A_BONE_V A_BONE_V B_OSTEOI B_OSTEOI B_OSTEOI B_OSTEOI
 GROUPS Mean Std.Err. -95.00% +95.00% Mean Std.Err. -95.00% +95.00% 
1 Control 23.971129 1.25795577 21.43588573 26.50637227 0.5566112 0.1481202 0.2580946 0.8551278 
2 Simva20 22.66002484 1.25795577 20.12478157 25.19526811 0.9229872 0.1481202 0.6244705 1.2215038 
3 simva10 20.41238032 1.25795577 17.87713705 22.94762359 0.4837381 0.1481202 0.1852215 0.7822547 
4 simva 5 22.97275915 1.25795577 20.43751589 25.50800242 0.4204743 0.1481202 0.1219577 0.7189909 
5 simva 1 21.03659905 1.32600181 18.364218 23.7089801 0.4263382 0.1561324 0.1116741 0.7410023 
            
C_OSTEOI C_OSTEOI C_OSTEOI C_OSTEOI D_OSTEOI D_OSTEOI D_OSTEOI D_OSTEOI E_OSTEOB E_OSTEOB E_OSTEOB E_OSTEOB
Mean Std.Err. -95.00% +95.00% Mean Std.Err. -95.00% +95.00% Mean Std.Err. -95.00% +95.00% 
0.1314057 0.0277156 0.0755485 0.1872629 4.6567381 1.0194953 2.6020804 6.7113958 0.8361509 0.237416 0.3576704 1.3146315 
0.2024754 0.0277156 0.1466182 0.2583326 6.9052518 1.0194953 4.8505941 8.9599095 1.754879 0.237416 1.2763984 2.2333595 
0.0935893 0.0277156 0.0377322 0.1494465 3.9595466 1.0194953 1.9048889 6.0142043 0.4390165 0.237416 -0.039464 0.9174971 
0.0963887 0.0277156 0.0405315 0.1522459 3.6750944 1.0194953 1.6204367 5.7297521 0.6664853 0.237416 0.1880047 1.1449658 
0.0784112 0.0292148 0.0195325 0.1372898 2.8583533 1.0746424 0.6925539 5.0241527 0.526879 0.2502585 0.0225162 1.0312418 
            
G_ERODED G_ERODED G_ERODED G_ERODED H_OSTEOC H_OSTEOC H_OSTEOC H_OSTEOC J_OSTEOC J_OSTEOC J_OSTEOC J_OSTEOC
Mean Std.Err. -95.00% +95.00% Mean Std.Err. -95.00% +95.00% Mean Std.Err. -95.00% +95.00% 
7.388349 0.7329027 5.9112806 8.8654174 0.798863 0.1476738 0.5012459 1.0964801 0.0654654 0.0139785 0.0372937 0.0936371 
9.350524 0.7329027 7.8734556 10.827592 1.3597289 0.1476738 1.0621119 1.657346 0.1143167 0.0139785 0.0861449 0.1424884 
6.9547904 0.7329027 5.477722 8.4318588 0.7390997 0.1476738 0.4414826 1.0367168 0.0738179 0.0139785 0.0456461 0.1019896 
5.2974791 0.7329027 3.8204107 6.7745475 0.5574757 0.1476738 0.2598586 0.8550927 0.0560027 0.0139785 0.0278309 0.0841744 
6.7821358 0.7725473 5.225169 8.3391027 0.9736851 0.1556619 0.6599692 1.2874011 0.0975526 0.0147346 0.067857 0.1272482 
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N_BONE_F N_BONE_F N_BONE_F N_BONE_F W_TOTAL W_TOTAL W_TOTAL W_TOTAL X_BONE_O X_BONE_O X_BONE_O X_BONE_O  
Mean Std.Err. -95.00% +95.00% Mean Std.Err. -95.00% +95.00% Mean Std.Err. -95.00% +95.00% N 
17.278585 1.9035316 13.442269 21.114901 0.3947829 0.0728067 0.2480506 0.5415151 0.9212775 0.1260861 0.6671677 1.1753874 10 
20.560469 1.9035316 16.724153 24.396784 0.6475376 0.0728067 0.5008053 0.7942698 1.1927945 0.1260861 0.9386846 1.4469043 10 
12.141993 1.9035316 8.3056768 15.978308 0.3785835 0.0728067 0.2318512 0.5253157 1.0129474 0.1260861 0.7588376 1.2670573 10 
16.710413 1.9035316 12.874097 20.546728 0.3224792 0.0728067 0.175747 0.4692115 1.0060964 0.1260861 0.7519865 1.2602062 10 
9.6947419 2.0064984 5.65091 13.738574 0.5232589 0.076745 0.3685895 0.6779283 1.384589 0.1329064 1.1167337 1.6524442 9 
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Study 3.3: Groups S20, S10,S5, S1, C: QBH: Statistical analyses - ANOVA; Differences between groups 
 
LSD test; variable A_BONE_V (anova histo.sta)  
Probabilities for Post Hoc Tests 
Error: Between MS = 15.825, df = 44.000  
  {1} {2} {3} {4} {5} 
 GROUPS 23.971 22.660 20.412 22.973 21.037 
1 Control  0.46504517 0.051651751 0.577514127 0.115532
2 Simva20 0.46504517  0.213092341 0.861265161 0.379262
3 simva10 0.05165175 0.21309234  0.157167888 0.734338
4 simva 5 0.57751413 0.86126516 0.157167888  0.295242
5 simva 1 0.11553215 0.37926225 0.734338006 0.295242367  
LSD test; variable B_OSTEOI (anova histo.sta)  
Probabilities for Post Hoc Tests 
Error: Between MS = .21940, df = 44.000  
  {1} {2} {3} {4} {5} 
 GROUPS .55661 .92299 .48374 .42047 .42634 
1 Control  0.08725887 0.729584124 0.519135745 0.548076
2 Simva20 0.08725887  0.041782097 0.020746647 0.025779
3 simva10 0.72958412 0.0417821  0.764064997 0.790938
4 simva 5 0.51913575 0.02074665 0.764064997  0.978386
5 simva 1 0.54807647 0.02577865 0.790937524 0.978386106  
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LSD test; variable C_OSTEOI (anova histo.sta)  
Probabilities for Post Hoc Tests 
Error: Between MS = .00768, df = 44.000  
  {1} {2} {3} {4} {5} 
 GROUPS .13141 .20248 .09359 .09639 .07841 
1 Control  0.07662632 0.339915057 0.376511019 0.194995
2 Simva20 0.07662632  0.008009853 0.009638998 0.003553
3 simva10 0.33991506 0.00800985  0.943387262 0.708051
4 simva 5 0.37651102 0.009639 0.943387262  0.657479
5 simva 1 0.19499453 0.00355321 0.708051261 0.657478835  
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Study 3.3: Groups S20, S10,S5, S1, C: QBH: Statistical analyses - ANOVA; Differences between groups 
 
LSD test; variable D_OSTEOI (anova histo.sta)  
Probabilities for Post Hoc Tests 
Error: Between MS = 10.394, df = 44.000  
  {1} {2} {3} {4} {5} 
 GROUPS 4.6567 6.9053 3.9595 3.6751 2.8584 
1 Control  0.12603417 0.631094842 0.499531762 0.231199
2 Simva20 0.12603417  0.047060528 0.030164381 0.009027
3 simva10 0.63109484 0.04706053  0.844507761 0.461191
4 simva 5 0.49953176 0.03016438 0.844507761  0.584169
5 simva 1 0.23119928 0.00902693 0.461190527 0.584168958  
LSD test; variable E_OSTEOB (anova histo.sta)  
Probabilities for Post Hoc Tests 
Error: Between MS = .56366, df = 44.000  
  {1} {2} {3} {4} {5} 
 GROUPS .83615 1.7549 .43902 .66649 .52688 
1 Control  0.00892741 0.24323918 0.615854114 0.374838
2 Simva20 0.00892741  0.000306653 0.002268606 0.000905
3 simva10 0.24323918 0.00030665  0.501648172 0.800137
4 simva 5 0.61585411 0.00226861 0.501648172  0.687655
5 simva 1 0.37483787 0.00090461 0.800137477 0.687654631  
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LSD test; variable G_ERODED (anova histo.sta)  
Probabilities for Post Hoc Tests 
Error: Between MS = 5.3715, df = 44.000  
  {1} {2} {3} {4} {5} 
 GROUPS 7.3883 9.3505 6.9548 5.2975 6.7821 
1 Control  0.06493148 0.67776341 0.04979253 0.572063
2 Simva20 0.06493148  0.025554459 0.00031495 0.020108
3 simva10 0.67776341 0.02555446  0.116982489 0.871942
4 simva 5 0.04979253 0.00031495 0.116982489  0.170259
5 simva 1 0.5720632 0.02010833 0.871942022 0.170258959  
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Study 3.3: Groups S20, S10,S5, S1, C: QBH: Statistical analyses - ANOVA; Differences between groups 
 
LSD test; variable H_OSTEOC (anova histo.sta)  
Probabilities for Post Hoc Tests 
Error: Between MS = .21808, df = 44.000  
  {1} {2} {3} {4} {5} 
 GROUPS .79886 1.3597 .73910 .55748 .97369 
1 Control  0.0101729 0.776095089 0.253986418 0.41959 
2 Simva20 0.0101729  0.004785597 0.000388834 0.078849
3 simva10 0.77609509 0.0047856  0.389200205 0.280209
4 simva 5 0.25398642 0.00038883 0.389200205  0.058833
5 simva 1 0.41958981 0.07884893 0.280208972 0.058833285  
LSD test; variable J_OSTEOC (anova histo.sta)  
Probabilities for Post Hoc Tests 
Error: Between MS = .00195, df = 44.000  
  {1} {2} {3} {4} {5} 
 GROUPS .06547 .11432 .07382 .05600 .09755 
1 Control  0.0174105 0.674707662 0.634538064 0.121304
2 Simva20 0.0174105  0.046490395 0.00507733 0.413597
3 simva10 0.67470766 0.04649039  0.372392993 0.248854
4 simva 5 0.63453806 0.00507733 0.372392993  0.046786
5 simva 1 0.12130351 0.41359698 0.248854223 0.046785974  
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LSD test; variable N_BONE_F (anova histo.sta)  
Probabilities for Post Hoc Tests 
Error: Between MS = 36.234, df = 44.000  
  {1} {2} {3} {4} {5} 
 GROUPS 17.279 20.560 12.142 16.710 9.6947 
1 Control  0.2292925 0.062917376 0.83381519 0.008795
2 Simva20 0.2292925  0.00312532 0.159727408 0.000298
3 simva10 0.06291738 0.00312532  0.096753993 0.381055
4 simva 5 0.83381519 0.15972741 0.096753993  0.014816
5 simva 1 0.00879539 0.00029779 0.381055001 0.014816113  
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Study 3.3: Groups S20, S10,S5, S1, C: QBH: Statistical analyses - ANOVA; Differences between groups 
 
LSD test; variable W_TOTAL (anova histo.sta)  
Probabilities for Post Hoc Tests 
Error: Between MS = .05301, df = 44.000  
  {1} {2} {3} {4} {5} 
 GROUPS .39478 .64754 .37858 .32248 .52326 
1 Control  0.01812132 0.875704117 0.486239619 0.231037
2 Simva20 0.01812132  0.012263802 0.00287677 0.246387
3 simva10 0.87570412 0.0122638  0.588580082 0.178374
4 simva 5 0.48623962 0.00287677 0.588580082  0.06427 
5 simva 1 0.23103714 0.2463873 0.178373887 0.064270408  
LSD test; variable X_BONE_O (anova histo.sta)  
Probabilities for Post Hoc Tests 
Error: Between MS = .15898, df = 44.000  
  {1} {2} {3} {4} {5} 
 GROUPS .92128 1.1928 1.0129 1.0061 1.3846 
1 Control  0.13498878 0.609757114 0.636659339 0.015098
2 Simva20 0.13498878  0.318678727 0.300805053 0.300854
3 simva10 0.60975711 0.31867873  0.969525346 0.048575
4 simva 5 0.63665934 0.30080505 0.969525346  0.044745
5 simva 1 0.01509822 0.30085386 0.048575488 0.04474526  
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Study 3.3: Groups S20, S10, S5, S1, C: Rat Weights. Descriptive statistics.  
 
 
Descriptive Statistics (statbone 2 weights1.sta)      
by GROUPS: Simva 1m Simva 1mg        
   Confid. Confid.     Standard   
 Valid N Mean -95.000% 95.000 Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis
W1 10 239.5 231.74 247.26 222.00 255.00 117.61 10.84 3.43 -0.14 -1 
            
Descriptive Statistics (statbone 2 weights1.sta)       
by GROUPS: Simva 5m Simva 5mg        
   Confid. Confid.     Standard   
 Valid N Mean -95.000% 95.000 Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis
W1 10 240.3 231.51 249.09 224.00 255.00 150.90 12.28 3.88 -0.05 -2 
            
Descriptive Statistics (statbone 2 weights1.sta)       
by GROUPS: Simva 10 Simva 10mg        
   Confid. Confid.     Standard   
 Valid N Mean -95.000% 95.000 Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis
W1 10 239.9 230.54 249.26 219.00 264.00 171.21 13.08 4.14 0.54 0 
            
Descriptive Statistics (statbone 2 weights1.sta)       
by GROUPS: Simva 20 Simva 20mg        
   Confid. Confid.     Standard   
 Valid N Mean -95.000% 95.000 Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis
W1 10 241.7 232.22 251.18 220.00 255.00 175.79 13.26 4.19 -0.63 -1 
            
Descriptive Statistics (statbone 2 weights1.sta)       
by GROUPS: Control Control         
   Confid. Confid.     Standard   
 Valid N Mean -95.000% 95.000 Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis
W1 10 247.1 240.17 254.03 230.00 260.00 93.88 9.69 3.06 -0.70 0 
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Study 3.3: Groups S20, S10, S5, S1, C: Rat Weights. Statistical analyses - Mann Whitney U-test 
 
 
Mann-Whitney U Test (statbone 2 weights1.sta)     
By variable GROUPS         
Group 1: 100-Simva 1m Group 2: 101-Simva 5m      
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Simva 1m Simva 5m U Z p-level adjusted p-level Simva 1m Simva 5m exact p 
W1 99.00 111.00 44.00 -0.45 0.65 -0.45 0.65 10.00 10.00 0.68 
           
Mann-Whitney U Test (statbone 2 weights1.sta)      
By variable GROUPS         
Group 1: 100-Simva 1m Group 2: 102-Simva 10      
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Simva 1m Simva 10 U Z p-level adjusted p-level Simva 1m Simva 10 exact p 
W1 103.00 107.00 48.00 -0.15 0.88 -0.15 0.88 10.00 10.00 0.91 
           
Mann-Whitney U Test (statbone 2 weights1.sta)      
By variable GROUPS         
Group 1: 100-Simva 1m Group 2: 103-Simva 20      
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Simva 1m Simva 20 U Z p-level adjusted p-level Simva 1m Simva 20 exact p 
W1 98.50 111.50 43.50 -0.49 0.62 -0.49 0.62 10.00 10.00 0.63 
           
Mann-Whitney U Test (statbone 2 weights1.sta)      
By variable GROUPS         
Group 1: 100-Simva 1m Group 2: 104-Control      
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Simva 1m Control U Z p-level adjusted p-level Simva 1m Control exact p 
W1 82.50 127.50 27.50 -1.70 0.09 -1.70 0.09 10.00 10.00 0.09 
 
 
Study 3.3 The effect of different dosages of simvastatin (20mg/Kg/day, 10mg/Kg/day, 5mg/Kg/day and 1mg/Kg/day) administered for 12 weeks, on bone mineral density and quantitative bone 
histomorphometry in intact female Sprague-Dawley rats. 
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Study 3.3: Groups S20, S10, S5, S1, C: Rat Weights. Statistical analyses - Mann Whitney U-test 
 
 
Mann-Whitney U Test (statbone 2 weights1.sta)      
By variable GROUPS         
Group 1: 101-Simva 5m Group 2: 102-Simva 10      
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Simva 5m Simva 10 U Z p-level adjusted p-level Simva 5m Simva 10 exact p 
W1 105.00 105.00 50.00 0.00 1.00 0.00 1.00 10.00 10.00 1.03 
           
Mann-Whitney U Test (statbone 2 weights1.sta)      
By variable GROUPS         
Group 1: 101-Simva 5m Group 2: 103-Simva 20      
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Simva 5m Simva 20 U Z p-level adjusted p-level Simva 5m Simva 20 exact p 
W1 103.50 106.50 48.50 -0.11 0.91 -0.11 0.91 10.00 10.00 0.91 
           
Mann-Whitney U Test (statbone 2 weights1.sta)      
By variable GROUPS         
Group 1: 101-Simva 5m Group 2: 104-Control      
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Simva 5m Control U Z p-level adjusted p-level Simva 5m Control exact p 
W1 89.50 120.50 34.50 -1.17 0.24 -1.17 0.24 10.00 10.00 0.25 
           
Mann-Whitney U Test (statbone 2 weights1.sta)      
By variable GROUPS         
Group 1: 102-Simva 10 Group 2: 103-Simva 20      
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Simva 10 Simva 20 U Z p-level adjusted p-level Simva 10 Simva 20 exact p 
W1 98.50 111.50 43.50 -0.49 0.62 -0.49 0.62 10.00 10.00 0.63 
 
Study 3.3 The effect of different dosages of simvastatin (20mg/Kg/day, 10mg/Kg/day, 5mg/Kg/day and 1mg/Kg/day) administered for 12 weeks, on bone mineral density and quantitative bone 
histomorphometry in intact female Sprague-Dawley rats. 
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Study 3.3: Groups S20, S10, S5, S1, C: Rat Weights. Statistical analyses - Mann Whitney U-test 
Mann-Whitney U Test (statbone 2 weights1.sta)      
By variable GROUPS         
Group 1: 102-Simva 10 Group 2: 104-Control      
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Simva 10 Control U Z p-level adjusted p-level Simva 10 Control exact p 
W1 87.50 122.50 32.50 -1.32 0.19 -1.33 0.19 10.00 10.00 0.19 
           
Mann-Whitney U Test (statbone 2 weights1.sta)      
By variable GROUPS         
Group 1: 103-Simva 20 Group 2: 104-Control      
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Simva 20 Control U Z p-level adjusted p-level Simva 20 Control exact p 
W1 94.00 116.00 39.00 -0.83 0.41 -0.84 0.40 10.00 10.00 0.44 
 
Mann-Whitney U Test (statbone 2 weights1.sta)      
By variable GROUPS          
Group 1: 100-Simva 1m Group 2: 101-Simva 5m       
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Simva 1m Simva 5m U Z p-level adjusted p-level Simva 1m Simva 5m exact p 
WT_GAIN 98.00 112.00 43.00 -0.53 0.60 -0.53 0.60 10.00 10.00 0.63 
          
Mann-Whitney U Test (statbone 2 weights1.sta)       
By variable GROUPS          
Group 1: 100-Simva 1m Group 2: 102-Simva 10       
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Simva 1m Simva 10 U Z p-level adjusted p-level Simva 1m Simva 10 exact p 
WT_GAIN 82.00 128.00 27.00 -1.74 0.08 -1.74 0.08 10.00 10.00 0.09 
 
Study 3.3 The effect of different dosages of simvastatin (20mg/Kg/day, 10mg/Kg/day, 5mg/Kg/day and 1mg/Kg/day) administered for 12 weeks, on bone mineral density and quantitative bone 
histomorphometry in intact female Sprague-Dawley rats. 
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Study 3.3: Groups S20, S10, S5, S1, C: Rat Weights. Statistical analyses - Mann Whitney U-test 
 
 
Mann-Whitney U Test (statbone 2 weights1.sta)       
By variable GROUPS          
Group 1: 100-Simva 1m Group 2: 103-Simva 20       
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Simva 1m Simva 20 U Z p-level adjusted p-level Simva 1m Simva 20 exact p 
WT_GAIN 90.00 120.00 35.00 -1.13 0.26 -1.14 0.25 10.00 10.00 0.28 
          
Mann-Whitney U Test (statbone 2 weights1.sta)       
By variable GROUPS          
Group 1: 100-Simva 1m Group 2: 104-Control       
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Simva 1m Control U Z p-level adjusted p-level Simva 1m Control exact p 
WT_GAIN 77.50 132.50 22.50 -2.08 0.04 -2.08 0.04 10.00 10.00 0.04 
          
Mann-Whitney U Test (statbone 2 weights1.sta)       
By variable GROUPS          
Group 1: 101-Simva 5m Group 2: 102-Simva 10       
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Simva 5m Simva 10 U Z p-level adjusted p-level Simva 5m Simva 10 exact p 
WT_GAIN 94.50 115.50 39.50 -0.79 0.43 -0.79 0.43 10.00 10.00 0.44 
          
Mann-Whitney U Test (statbone 2 weights1.sta)       
By variable GROUPS          
Group 1: 101-Simva 5m Group 2: 103-Simva 20       
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Simva 5m Simva 20 U Z p-level adjusted p-level Simva 5m Simva 20 exact p 
WT_GAIN 102.00 108.00 47.00 -0.23 0.82 -0.23 0.82 10.00 10.00 0.85 
 
Study 3.3 The effect of different dosages of simvastatin (20mg/Kg/day, 10mg/Kg/day, 5mg/Kg/day and 1mg/Kg/day) administered for 12 weeks, on bone mineral density and quantitative bone 
histomorphometry in intact female Sprague-Dawley rats. 
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Study 3.3: Groups S20, S10, S5, S1, C: Rat Weights. Statistical analyses - Mann Whitney U-test 
 
 
Mann-Whitney U Test (statbone 2 weights1.sta)       
By variable GROUPS          
Group 1: 101-Simva 5m Group 2: 104-Control       
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Simva 5m Control U Z p-level adjusted p-level Simva 5m Control exact p 
WT_GAIN 94.00 116.00 39.00 -0.83 0.41 -0.83 0.41 10.00 10.00 0.44 
          
Mann-Whitney U Test (statbone 2 weights1.sta)       
By variable GROUPS          
Group 1: 102-Simva 10 Group 2: 103-Simva 20       
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Simva 10 Simva 20 U Z p-level adjusted p-level Simva 10 Simva 20 exact p 
WT_GAIN 114.50 95.50 40.50 0.72 0.47 0.72 0.47 10.00 10.00 0.48 
          
Mann-Whitney U Test (statbone 2 weights1.sta)       
By variable GROUPS          
Group 1: 102-Simva 10 Group 2: 104-Control       
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Simva 10 Control U Z p-level adjusted p-level Simva 10 Control exact p 
WT_GAIN 104.50 105.50 49.50 -0.04 0.97 -0.04 0.97 10.00 10.00 0.97 
          
Mann-Whitney U Test (statbone 2 weights1.sta)       
By variable GROUPS          
Group 1: 103-Simva 20 Group 2: 104-Control       
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Simva 20 Control U Z p-level adjusted p-level Simva 20 Control exact p 
WT_GAIN 91.50 118.50 36.50 -1.02 0.31 -1.03 0.31 10.00 10.00 0.31 
 
 
Study 3.4 The effect atorvastatin 2.5mg/Kg/day and pravastatin, administered for 12 weeks, on bone mineral density in intact female Sprague-Dawley rats. 
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Study 3.4 The effect atorvastatin 2.5mg/Kg/day and pravastatin, administered for 12 weeks, on bone mineral density in intact female Sprague-Dawley rats. 
 
Study 3.4: Groups A, C: Bone Mineral Density: Descriptive statistics 
 
 
Descriptive Statistics (bmd 1 and 2 femur.sta)        
   Confid. Confid.      Standard   
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis
CONTROL 10 0.1053 0.1012 0.1093 0.1039 0.0979 0.1161 0.0000 0.0057 0.0018 0.7839 -0.0845 
A 10 0.0942 0.0909 0.0975 0.0940 0.0852 0.1014 0.0000 0.0046 0.0015 -0.2180 0.7944 
 
 
 
 
 
Study 3.4: Groups A, C: Bone Mineral Density: Statistical analyses - Mann Whitney U-test 
 
 
 
Mann-Whitney U Test (bmd 1 and 2 femur.sta)       
By variable GR_ST2          
Group 1: 100-Control Group 2: 101-
Atorva 
       
Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
Control Atorva U Z p-level adjusted p-level Control Atorva exact p 
BMD_ST_2 150.5 59.5 4.5 3.4395 0.0006 3.4408 0.0006 10 10 0.0001 
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Study 3.4 The effect atorvastatin 2.5mg/Kg/day and pravastatin, administered for 12 weeks, on bone mineral density in intact female Sprague-Dawley rats. 
 
Study 3.4: Groups A, C: Rat Weights: Descriptive statistics 
 
 
Descriptive Statistics (statbone 2 weights1.sta)       
   Confid. Confid.     Standard   
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Std.Dev. Error Skewness Kurtosis
WT_GAIN 20 25.05 17.59 32.51 21 -1 55 15.95 3.57 0.34 -1.05 
W1CONTR 10 247.1 240.17 254.03 249 230 260 9.69 3.06 -0.70 -0.31 
WT_GN_C 10 21.5 10.75 32.25 18.5 -1 47 15.03 4.75 0.59 -0.19 
W1AT 10 212.4 203.24 221.56 210 195 230 12.80 4.05 0.10 -1.58 
WT_GN_A 10 28.6 16.56 40.64 28 7 55 16.83 5.32 0.11 -1.46 
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Study 3.4 The effect atorvastatin 2.5mg/Kg/day and pravastatin, administered for 12 weeks, on bone mineral density in intact female Sprague-Dawley rats. 
Study 3.4: Groups P, C: Bone Mineral Density: Descriptive statistics 
 
 
Descriptive Statistics (bmd 1 and 2 femur.sta)        
   Confid. Confid.      Standard   
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis
CONTROL 10 0.1053 0.1012 0.1093 0.1039 0.0979 0.1161 0.0000 0.0057 0.0018 0.7839 -0.0845 
P 10 0.0965 0.0918 0.1012 0.0980 0.0802 0.1022 0.0000 0.0065 0.0021 -1.9472 4.4711 
 
 
 
 
Study 3.4: Groups P, C: Bone Mineral Density: Statistical analyses - Mann Whitney U-test 
 
 
 
Mann-Whitney U Test (bmd 1 and 2 femur.sta)  
By variable GR_ST2  
Group 1: 100-Control Group 2: 102-Prava  
 Rank Sum Rank Sum    Z  Valid N Valid N 2*1sided
 Control Prava U Z p-level adjusted p-level Control Prava exact p 
BMD_ST_2 142.5 67.5 12.5 2.8347 0.0046 2.8358 0.0046 10 10 0.0029 
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Study 3.4 The effect atorvastatin 2.5mg/Kg/day and pravastatin, administered for 12 weeks, on bone mineral density in intact female Sprague-Dawley rats. 
Study 3.4: Groups P, C: Rat Weights: Descriptive statistics 
 
 
Descriptive Statistics (statbone 2 weights1.sta)        
   Confid. Confid.      Standard   
 Valid N Mean -95.000% +95.000% Median Minimum Maximum Variance Std.Dev. Error Skewness Kurtosis
WT_GAIN 20 25.95 16.23 35.67 21 -9 70 431.21 20.77 4.64 0.54 0.01 
W1CONTR 10 247.1 240.17 254.03 249 230 260 93.88 9.69 3.06 -0.70 -0.31 
WT_GN_C 10 21.5 10.75 32.25 18.5 -1 47 225.83 15.03 4.75 0.59 -0.19 
W1PR 10 226.4 208.04 244.76 228.5 181 263 658.93 25.67 8.12 -0.44 -0.46 
WT_GN_PR 10 30.4 12.30 48.50 27 -9 70 640.49 25.31 8.00 0.16 -0.53 
 
 
Appendix D 3.4         Page 254 
